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Abstract: 
 
The human myocardium is a metabolic omnivore and utilises fatty acids, glucose, ketones, amino 
acids and lactate to produce energy. Altered metabolism results in cardiac muscle dysfunction 
and can play a potentially significant role in development of heart failure. Metabolic modulators 
like Perhexiline are potentially significant new treatments in the management of heart failure and 
coronary artery disease. 
Diabetes is a metabolic disorder that results in altered high energy phosphate kinetics in the 
myocardium. We demonstrate that microvascular disease plays little role in the development of 
impaired cardiac energetics in young patients with uncomplicated type 1 diabetes. We have 
shown an increase in left ventricular torsion in these patients with normal ejection fraction. 
Coronary microvascular disease and rotational deformation delay play a significant role in the 
development of increased torsion in these individuals which counteracts the early diastolic 
dysfunction. Furthermore the left atrial contribution to left ventricular filling is increased in these 
individuals. 
We demonstrate that Perhexiline has a differential action on insulin sensitivity in subjects with 
and without diabetes. It also increased plasma ketones and triglycerides in these patients. Finally 
we demonstrate that Perhexiline can be safely used and provides good relief of symptoms when 
used clinically in subjects with refractory angina and heart failure. 
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Burden of ischaemic heart disease and heart failure 
The global burden of coronary artery disease (CAD) is ever increasing.  Around 18 million 
people die worldwide every year from cardiovascular disease (CVD) 97, of which 4.3 million 
are from Europe, accounting for nearly half of all deaths in Europe 10. It is the main cause of 
disease burden in the western world. Diabetes is an important risk factor for the development 
of CVD and the global burden of diabetes is increasing 59;266;282. Approximately 80% of 
deaths in patients with diabetes are secondary to cardiovascular complications 64;83. The 
economic costs are alarming: CVD cost the European Union around 192 billion Euro in 2006 
and this figure is increasing every year 10. The prevalence of heart failure has dramatically 
increased throughout the western world. The incidence and prevalence of heart failure 
increases with increasing age 19;73 and ageing of the population accounts in part for the 
increasing prevalence of heart failure. Increased survival rates in patients suffering acute 
myocardial infarction 24 (due to reperfusion therapies) has also been proposed to contribute.  It 
has been estimated that there are currently 6.5 million chronic heart failure (CHF) patients in 
Europe and 5 million in the USA 260.  CHF has a poor prognosis with nearly 50% of the 
patients dying in the first four years of diagnosis and nearly half of those with severe heart 
failure dying  within 1 year 155;249;256. These dismal figures are in spite of the dramatic 
improvements in the treatment of CHF over the past 20 years or so. These have focused 
mainly on the blockade  of maladaptive neuro-hormonal activation66;69. Recently, there has 
been increasing interest in metabolic agents (which alter the fuel usage of the heart) as 
treatment for both CAD and CHF 5;6. Understanding myocardial metabolism and its various 
adaptive and maladaptive features in conditions like CAD and CHF is key to further 
developments in this field. Studying changes in myocardial metabolism in diabetes can 
provide further insights into the patho-physiology of development of CHF in diabetes. Heart 
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failure occurs more frequently in diabetes 109 and is commonly due to epicardial CAD and/or 
hypertension 101;126;250. However in some patients left ventricular (LV) dysfunction occurs in 
the absence of significant epicardial CAD or hypertension 214. This indicates that diabetes 
may have a direct effect on the heart, which can contribute to the development of LV 
dysfunction. This condition is sometimes termed ‘diabetic cardiomyopathy’. Hence further 
insights into myocardial metabolism and its alteration may play a significant role in 
improving outcomes in patients with CAD and CHF. 
 
Myocardial metabolism in normal hearts 
The human heart is a relentless pump that never stops working during life. It beats for 
approximately 100,000 times a day and requires a vast amount of energy to fulfil its function. 
Therefore it would not be a surprise that impaired cardiac energetics may play a key role in 
the pathogenesis and progression of diabetes to CHF. Cardiac energetic impairment has been 
shown to be an adverse  prognostic feature in patients with CHF 176. The myocardium is a 
metabolic omnivore and is able to metabolise glucose, free fatty acids (FFAs), amino acids, 
ketones and lactate for energy production. In normal circumstances 60-90% of the acetyl Co-
A which enters the Krebs cycle comes from beta-oxidation of FFAs and 10-40% from 
oxidation of pyruvate derived from glycolysis 242;243 [Fig (1.1)]. Glucose metabolism consists 
of two important components, glycolysis and carbohydrate oxidation. Glycolysis which 
occurs in the cytosol involves conversion of glucose to pyruvate, while carbohydrate 
oxidation involves the subsequent mitochondrial oxidation of pyruvate. Pyruvate derived from 
glucose and lactate enters the Krebs cycle via the pyruvate dehydrogenase complex (PDC) 
that catalyses the conversion of pyruvate to acetyl Co-A 53;147. Glycolysis only contributes 
approximately 5% of the total adenosine tri-phosphate (ATP) generated by the heart during 
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aerobic conditions. During ischaemia, glycolysis is increased. However, this may result in 
accumulation of protons and lactate if carbohydrate oxidation does not increase in parallel. 
Ischaemia inhibits the PDC and results in anaerobic glycolysis189;201.  Therefore, accelerated 
glycolysis during ischaemia can have detrimental consequences. Unlike glucose metabolism, 
fatty acid metabolism produces all of the ATP that it generates in the mitochondria via beta 
oxidation. Fatty acid oxidation consumes more oxygen to produce the same amount of ATP as 
compared with glucose oxidation. Also increased fatty acid metabolism results in a 
concomitant decrease in glucose oxidation due to Co-A mediated inhibition of PDC. This can 
lead to an uncoupling of glycolysis from carbohydrate oxidation with a resultant increase in 
proton and lactate production 183. 
 
The myocardium normally works at 15-20% of its maximal oxidative capacity at rest 65;244. It 
is able to adapt its substrate utilisation according to its needs. At low to moderate intensity 
exercise there is a net increase in glucose and lactate utilisation with no change in FFA 
utilisation 72. At high intensity exercise, glucose uptake falls compared to lower intensity 
exercise 113. There is a concomitant 10 fold increase in lactate uptake which serves as the 
main substrate during high intensity exercise. 
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Figure 1.1 
 
Myocardial metabolism.  
 
CPT-carnitine-palmitoyl-transferase; IMM-inner mitochondrial membrane; OMM-outer mitochondrial 
membrane; PDH-pyruvate dehydrogenase; GLUT-1- Glucose transporter-1; FATP-1- fatty acid transporter 
protein-1;  PFK- phosphofructokinase  ; AMPK- AMP-activated protein kinase.  Reproduced from Abozguia et 
al Future Cardiology. (2007)  3(5), 525-535(11) with permission of Future Medicine Ltd  6 
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Substrate Utilisation and Myocardial Oxygen Utilisation 
 
Simple stoichiometry suggests that utilisation of fatty acids should cost approximately 10-
12% more oxygen per unit of ATP generated than glucose. In practice, the increased oxygen 
requirement when plasma FFAs are increased compared with dominant glucose utilisation 
appears to be substantially greater (up to 40 %) 98;120;162, implying the presence of an ‘oxygen 
wasting’ phenomenon with increased FFA usage. In the isolated perfused rat heart, increasing 
the palmitate and octanoate in the perfusate disproportionately increased oxygen utilisation 
and this was only partially abolished by administration of an inhibitor of fatty acid beta 
oxidation, suggesting that a component of the oxygen ‘wasting effect’ of increased FFAs is 
not related to mitochondrial long chain fatty acid oxidation 100.  It is possible that it may be 
due to the up-regulation of uncoupling protein expression in the mitochondria via FFA 
activation of peroxisome proliferators-activated receptor alpha (PPAR ) 23. Normally the 
electron transport chain generates a net proton gradient across the inner mitochondrial 
membrane and this drives the phosphorylation of adenosine di-phosphate (ADP) to ATP. 
However, when mitochondria are ‘uncoupled’ there is proton leakage and the electrochemical 
gradient is dissipated as heat 226. Emerging evidence suggests that the primary role of 
uncoupling proteins (UCP) is the export of lipid peroxides and long chain fatty acids out from 
the mitochondrion which helps prevent oxidative damage to mitochondrial DNA 74. This 
occurs when fatty acid delivery exceeds oxidative capacity and when there is an accumulation 
of lipid peroxides. PPAR α activation by fatty acids increases the expression of UCP 23 and 
furthermore, the activity of UCP is increased by lipid peroxides 217. Heart failure is associated 
with elevated free fatty acid concentrations 139 which might increase uncoupling.  Further, 
Murray et al showed that mitochondrial uncoupling protein expression in human cardiac 
muscle correlated positively with plasma FFA concentration in patients undergoing elective 
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coronary artery bypass surgery 166. This relationship was noted in patients with heart failure as 
well. Furthermore, high levels of FFA may trigger intracellular futile metabolic cycles such as 
intra-myocardial lipolysis and re-esterification 21;120;161.  
 
Metabolic changes in ischaemic heart disease 
 
All metabolic adaptive mechanisms during ischaemia, whether physiological or 
pharmacological, aim at improving the oxygen efficiency of the myocardium by shifting 
substrate use towards glucose metabolism. This shift can be beneficial as it can result in up to 
30-40% reduction in oxygen usage as compared to FFA 98;120;162. As the myocardium works at 
only 15-20% of oxidative capacity under normal conditions, even during subtotal ischaemia, 
the myocardium continues to derive a large proportion of its energy from oxidative 
metabolism. During more marked ischaemia, there is a shift towards greater use of glucose as 
a substrate for energy production 118. Despite this shift, the predominant source of ATP in the 
ischaemic heart continues to be FFA oxidation 134. During myocardial ischaemia, FFA 
oxidation is not only more oxygen demanding, it also suppresses glucose oxidation by directly 
inhibiting PDC 110;134;143. The consequence of this is the accumulation of lactate and hydrogen 
ions in ischaemic cells and associated wastage of ATP in restoring intracellular ionic 
homeostasis 144. Phosphocreatine (PCr) also begins to deplete at this point because it is used 
to generate ATP. This not only generates inefficiency but may also have detrimental effects 
on myocardial contractile function.  Low intracellular pH and increased intracellular lactate 
are associated with reduced contractile function of myocardial segments 89.  Diastolic function 
and rhythm stability may be adversely affected by the accumulation of metabolic 
intermediates generated by the beta oxidation of fatty acids during ischaemia 114;165. Ischaemia 
also results in opening of the late inward sodium current leading to intracellular sodium 
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increase and secondary increases in calcium, in turn causing a marked slowing of LV active 
relaxation 18. 
 
Myocardial stunning and hibernation 
Myocardial stunning is a phenomenon which results from brief ischaemic injury followed by 
reperfusion 273. It is seen in many clinical circumstances including spontaneous episodes of 
ischaemia following percutaneous coronary intervention (PCI), thrombolysis and /or coronary 
artery bypass surgery. The pathogenesis of stunning is via production of oxygen free radicals, 
alterations in calcium homeostasis and oxidative metabolism and possible changes in muscle 
protein structure 156;289. Gerber et al demonstrated normal oxygen consumption in the 
dysfunctional myocardium following reperfusion by PCI 71. This indicated a marked 
reduction in the regional mechanical efficiency (work done divided by oxygen consumption). 
McNulty et al demonstrated increased glucose uptake with decreased glycogen synthesis in 
post-ischaemic myocardial stunning models of rats 24hrs after ischaemic insult 156. This 
suggests an important role of enhanced glycolysis in the recovery from myocardial stunning 
156. Based on this, glucose-insulin-potassium (GIK) infusion therapy which drives glucose 
uptake was noted to be beneficial in one study of diabetic patients with acute myocardial 
infarction 63. Although insulin drives glucose uptake and glycolysis, the inhibition of PDC 
that occurs in ischaemia results in uncoupling of glycolysis and glucose oxidation 144. This 
leads to accumulation of protons and lactate which can further enhance cell damage. Another 
recent study of diabetic patients with acute myocardial infarction did not show any benefit of 
GIK followed by intensive glucose control 158. 
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Myocardial stunning is an acute phenomenon and potentially reversible. However when the 
myocardium receives repeated insults of ischaemic injury these result in a phenomenon called 
myocardial hibernation. The hibernating myocardium is still viable but not contracting, and 
timely revascularisation will restore contractile function. Hibernating myocardium exhibits 
reduced oxidative metabolism and FFA utilization 229;258. Ischaemia-induced increased 
glucose utilization is also supported by studies of preconditioning which demonstrated 
markedly increased glucose uptake 102. Following revascularisation improvement of 
contractile function is associated with an increase in FFA metabolism. It has been suggested 
that recovery of myocardial function  may be related to the improvement in FFA metabolism 
235. However, increases in FFA metabolism may be a consequence of improved oxygen 
availability due to revascularisation rather than the cause of myocardial contractile restoration. 
This is supported by the fact that metabolic modulating agents that putatively shift 
metabolism from FFA towards glucose also result in improvement in systolic function in 
patients with chronic ischaemic LV dysfunction 132;210;276. 
 
For patients experiencing myocardial ischaemia, any agent that shifts substrate utilisation 
towards glucose might be anticipated to offer considerable benefit. A shift towards increased 
utilisation of glucose by the myocardium can be induced by any intervention that suppresses 
FFA uptake and/or oxidation. Currently available metabolic agents achieve increased glucose 
utilisation by inhibiting FFA uptake into the mitochondria, or by inhibiting beta oxidation 
(Table 1.1). However, it is important to note that modulating FFA metabolism may not be 
without risk. Inherited disorders of fatty acid metabolism, particularly involving Acyl-CoA 
dehydrogenase, have been associated with dilated cardiomyopathy and arrhythmogenesis in 
infants, possibly secondary to accumulation of free-fatty acid metabolites 25;151.  
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Table 1.1 
Classification of metabolic agents* 
 FFA uptake inhibitors 
Perhexiline 
Oxfenicine 
Etmoxir 
? Beta-Blockers 
? Amiodarone 
 
 FFA β-Oxidation inhibitors 
Trimetazidine 
? Ranolazine 
 
 Others 
D-Ribose 
Proprionyl-L-Carnitine 
Glucagon-like Peptide-1 
 
* Mechanism of action not confirmed in vivo 
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Metabolic changes in Heart Failure  
In animal models of left ventricular hypertrophy (LVH) and heart failure a relative switch 
towards increased glucose uptake and reduced fatty acid oxidation has been demonstrated. In 
the canine rapid pacing model of heart failure, there was a relatively normal substrate 
utilisation in the early stages of heart failure. A shift towards relatively greater glucose uptake 
was however noted in the end stages of heart failure 203. This shift in metabolism was 
attributed to reduced expression and activity of retinoid X receptor Alpha (RXR-alpha), a 
receptor known to stimulate expression of Medium Chain acyl CoA Dehydrogenase (MCAD) 
and enzymes involved in FFA oxidation. Studies of canine microembolisation-induced heart 
failure indicate that substrate change to glucose is a late phenomenon 38. Various other 
complex mechanisms may be responsible for the shift to this foetal phenotype. Increased 
adenosine mono-phosphate (AMP) and AMP kinase activity has been reported in 
hypertrophied rat hearts undergoing transition to heart failure 263. Increased AMP kinase 
activity increases glucose uptake via GLUT-1 transporters and increased glycolysis via 
phosphorylation of 6-phosphofructo-2-kinase.  Chronic activation of AMP kinase also 
decreases FFA utilisation via decreased expression of carnitine palmitoyl transferase-1 (CPT-
1) and MCAD enzymes 148;263.  
 
There remains a controversy as to whether the shift towards increased glucose uptake in 
animal models of LVH and heart failure is adaptive or maladaptive. Human genetic disorders 
of fatty acid beta oxidation may be associated with the development of heart failure 25;151. 
Furthermore, in animal models of both LVH and heart failure, whilst glucose uptake and 
glycolysis are increased, glucose oxidation is reduced because of reduced activity of the PDC. 
Therefore pyruvate conversion to acetyl coenzyme A is reduced and anaplerotic reactions fail 
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to compensate 241. Unlike the above animal experimental models that undergo transition from 
LVH to heart failure and in which there is a shift to a ‘fetal’ pattern, the available evidence 
suggests that human heart failure may not be associated with a shift towards predominant 
glucose utilisation; indeed the converse may be true. Using Positron Emission Tomography  
(PET) technique, Taylor et al demonstrated increased myocardial FFA uptake and reduced 
glucose uptake in human heart failure 259. There are several potential explanations for this. 
Firstly, insulin resistance is commonly present in CHF. Indeed, Nikolaidis et al demonstrated 
a progressive increase in cardiac insulin resistance during disease progression in the canine 
rapid pacing heart failure model 180. There was a reduced cardiac basal and insulin stimulated 
glucose uptake (associated with reduced insulin stimulated GLUT-4 translocation). Secondly, 
increased plasma FFAs are characteristically found in CHF due to sympathetic activation 186 
and contribute to insulin resistance. Despite the uncertainty of whether the shift towards 
glucose metabolism in experimental models of heart failure is adaptive or maladaptive in 
nature, our observations with Perhexiline (over 2 months) 132and those with Trimetazidine (up 
to 18 months) 56 in patients with CHF suggest that pharmacologically-induced inhibition of 
fatty acid metabolism has beneficial effects on cardiac performance, exercise capacity and 
symptoms. Interestingly however, acute reduction of FFA uptake/oxidation may not be 
beneficial in heart failure. For, in a recent study using acipimox, patients with heart failure 
developed acute deterioration of LV function 268; Acipimox significantly reduces plasma 
concentrations of FFA and consequently FFA uptake by the myocardium. One plausible 
explanation for the deterioration in LV function is that the reduced FFA uptake was not  
associated with concomitant increase glucose oxidation due to the presence of insulin 
resistance in heart failure patients. In other words, depriving the heart of an important source 
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of fuel (FFA) may result in deterioration of LV function. It would be interesting to assess the 
effects of chronic acipimox use in CHF patients. 
Myocardial energetics in heart failure 
There is now strong evidence indicating impaired cardiac energetics playing a significant part 
in the pathogenesis of heart failure even in patients without CAD. Animal models have shown 
that there is a global loss of the total adenine nucleotide (TAN) pool 136;234. The energetic 
abnormality may in turn exacerbate the loss of TAN in that  increased AMP activates 
cytosolic 5’AMP –specific 5’nucleotidase, the primary enzyme responsible for the conversion 
of AMP to adenosine in muscle cells. In a study by Shen and colleagues, a canine rapid 
pacing model was used to investigate the changes of cardiac energetics during the evolution 
of heart failure. They showed a progressive monotonic decay in total adenine nucleotides and 
creatine from the onset of pacing. Interestingly, the onset of the decline in energetic status 
preceded objective evidence of cardiac contractile dysfunction 234. The cardiac creatine 
content is determined primarily by the activity of the creatine transporter which is responsible 
for creatine uptake into the myocytes against a concentration gradient 177. Two thirds of the 
creatine in the heart is phosphorylated via the creatine kinase (CK) reaction to form PCr. PCr 
is a vital energy buffer molecule that provides precious phosphoryl groups to ADP to generate 
ATP rapidly during periods of physiological stress e.g. exercise. This reaction is also 
mediated via CK and can generate ATP 10 times faster than that occurs via oxidative 
phosphorylation. Interestingly, heart failure studies in animals and humans have shown a 
progressive reduction in the creatine pool, as much as 60% loss, and  the level of reduction is 
related to heart failure severity 171;262;288.  This reduction in the total creatine pool 
consequently causes a reduction in PCr and in PCr/ATP ratios, as measured by phosphorus 
(31P) Nuclear Magnetic Resonance (NMR) spectroscopy 45;82.  Evidence originating from 
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Cardiac Magnetic Resonance Spectroscopy (MRS) studies have shown reduced myocardial 
energetic status in patients with systolic heart failure 81, insulin resistance 167;221 and ischaemic 
heart disease284. Similarly, patients with hypertrophic cardiomyopathy (HCM) also have 
impaired cardiac energetics as shown by a diminished resting PCr/ATP ratio 107. Data from 
vivo 31P NMR spectroscopy studies and human biopsy specimens indicates a 25-30% 
reduction of ATP in the failing human heart. The magnitude of the fall in PCr/ATP ratio 
predicts mortality 176. The reduction in PCr in heart failure is further compounded by a 
decreased number of creatine transporters 177 and a reduction in CK isoenzyme expression, 
particularly mitochondrial CK which leads to a reduced [PCr]/[Total Creatine] 51.There is 
some evidence to suggest that iNOS-derived nitric oxide may also play a role in the reduction 
of mitochondrial CK activity 77. Some studies have shown that short term oral creatine 
supplementation in CHF increases skeletal muscle function, however LV ejection fraction (EF) 
remains unchanged 13;75. Competitive athletes have been known to take creatine supplements 
to increase their performances but this has little benefit because myocyte levels of creatine is 
limited by membrane transporters 103;164.   
 
Studies with Trimetazidine, a beta-oxidation inhibitor have demonstrated improvement in 
cardiac energetics associated with improvements in New York Heart association (NYHA) 
class and LV function when given to patients with heart failure 68. Therefore, the impaired 
cardiac energetics in heart failure could be secondary to increased FFA uptake and 
metabolism. However, the metabolic changes that occur in ischaemic heart disease i.e. shifts 
towards glucose metabolism may be at least partially beneficial to restore the cardiac energy 
reserve. In summary, in the myocardium of a failing heart even in the absence of CAD (or of 
myocardial hypoxia) there is now strong evidence indicating a reduction of cardiac energy 
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reserve. This appears to be related to the degree of heart failure but it nevertheless appears to 
begin early in the evolution of heart failure even before the development of overt signs and 
symptoms of heart failure 274. 
 
 
Metabolic therapies in ischaemia and heart failure 
 
It appears that shifting the metabolism towards glucose is beneficial in both ischaemic heart 
disease and heart failure. In a study in the late 1990’s intracoronary pyruvate was shown to 
acutely increase stroke volume (SV) and reduce pulmonary capillary wedge pressure, 
implying acute beneficial effects of a shift away from fatty acid metabolism  87.  This has 
driven interest in the potential beneficial effects of modifying substrate utilisation in CHF.  A 
number of pharmacological agents have been shown to inhibit FFA utilisation in the heart, 
either by inhibiting FFA uptake into the mitochondrion or by inhibiting beta oxidation (Table 
1.1 and Figure 1.2). Some of these agents have been used as antianginal agents because of 
their ‘oxygen sparing’ actions. A summary of clinical trials of metabolic agents is shown in 
table 1.2. 
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Figure 1.2 
 
Effects of metabolic agents on myocardial metabolism in cardiomyocyte mitochondria.  
 
FFA uptake inhibitors such as perhexiline, oxfenicine, and etomoxir prevent uptake of free 
fatty acids via inhibition of carnitine palmitoyltransferase I, which is a key enzyme in this 
process in mitochondria. FFA β-oxidation inhibitors such as Trimetazidine inhibit β-oxidation 
of free fatty acids.  These actions shift myocardial substrate use from free fatty acids to 
glucose, which is more efficient in terms of energy production, leading to an oxygen-sparing 
effect.  
 
Abbreviations: CoA, coenzyme A; CPT, carnitine palmitoyltransferase; FA-CoA, fatty acid coenzyme A; 
FATP1, fatty acid transporter protein 1; FFA, free fatty acid; G6P, glucose-6-phosphate; IMM, inner 
mitochondrial membrane; OMM, outer mitochondrial membrane; PDH, pyruvate dehydrogenase. Reproduced 
from Abozguia et al Future Cardiology. (2007)  3(5), 525-535(11) with permission of Future Medicine Ltd 6 
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Table 1.2 
 
Metabolic 
Agents 
 
Study 
(Ref) 
 
Study 
design 
 
No 
Patie
nts 
 
Patient Characteristics 
 
Study 
duration 
 
Outcome 
 
Perhexiline 
 
Lee et al 
2005132 
 
RC PCT* 
Double 
blind 
 
56 
 EF≤ 45 
Non-ischaemic and  ischaemic CHF 
NYHA II-IV 
 
2 months 
       LVEF 
 
       Vo2 max 
 
Improved quality of 
life (QOL) 
Trimetazidine Vitale C 
et al 
2004276 
RC PCT 47 EF< 50% 
Chronic stable angina 
NYHA I-III 
6 months 
  LVEF 
Better QOL 
 
Trimetazidine Di Napoli 
et al 
200556 
Open label 61 LVEF <40% 
Ischaemic LV dysfunction 
NYHA II-IV 
18 months 
  LVEF 
Improved -NYHA 
 
Trimetazidine Fragasso 
G et al 
200667 
Open label 55 LVEF<45% 
Ischaemic and non-ishchaemic 
CHF 
NYHA II-III 
13 months 
  LVEF 
Improved -NYHA 
 
Etomoxir Schmidt-
Schweda 
et al 
2000222 
Open label 10 LVEF<40% 
Dilated Cardiomyopathy 
NYHAII-III 
3 months 
  LVEF 
Increased Stroke 
volume during 
exercise 
Etomoxir Holubarsc
h CJ et al 
200792 
RC PCT 350 LVEF<40% 
Ischaemic and non-ischaemic 
moderate CHF 
NYHA II-III 
6 months Study stopped 
prematurely 
because of 
hepatotoxicity. 
D-Ribose Omran  
et al 
2003181 
RC PCT 
Cross over 
15 Ischaemic Cardiomyopathy 
NYHA II-III 
3 weeks Improved 
functional capacity 
and diastolic 
function 
L-Carnitine Anand  
et al 
199812 
RC PCT 
Single blind 
30 LVEF<40% 
NYHA II-III 
Ischaemic and non-ischaemic 
cardiomyopathy 
4 weeks 
  VO2 max 
No change in 
LVEF 
 
L-Carnitine Eur Heart 
journal 
19992 
RC PCT 
Double 
Blind 
537 LVEF <40% 
NYHA II-III 
Ischaemic and non-ischaemic 
cardiomyopathy 
6 months No increase in 
exercise capacity 
 
Glucagon-like 
Peptide 1 
Sokos  
et al 
2006239 
 Open label  12 NYHA III-IV 5 weeks      LVEF 
 
Improved QOL 
* RC PCT: Randomized Placebo Controlled Trial 
Summary of human clinical trials of metabolic agents for treatment of CHF 
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FFA Uptake Inhibitors 
Perhexiline 
Perhexiline is a metabolic modulator which causes a shift in cardiac substrate use from fatty 
acids to carbohydrates.  It is a reversible inhibitor of both CPT1 and CPT2 which are key 
enzymes involved in the transport of FFA into the mitochondria 114;115. Perhexiline was 
frequently used as an antianginal agent in the 1970s and is an effective monotherapy for 
relieving symptoms of angina 95;277;281, improving exercise tolerance, and increasing the 
workload needed to induce ischaemia 44;93. Its use however declined dramatically in the late 
1970s and early 1980s following reports of hepatotoxic effects and peripheral neuropathy 
28;192;208. These effects were later demonstrated to occur in patients in whom hydroxylation 
was slow because they possesed a genetic variant of the cytochrome P450 enzyme, which 
metabolizes the drug, resulting in drug accumulation and, consequently, accumulation of 
phospholipids in the liver and nerves 163. However, the risk of toxic effects is virtually 
eliminated by maintaining plasma concentrations at between 150 and 600 ng/ml, at this level 
the drug also remains efficacious 44;96.  As a result, in countries such as Australia, the use of 
perhexiline was re-introduced as an adjunctive therapy for refractory angina, with good 
results.  At therapeutic concentrations, perhexiline has no effects on systemic vascular 
resistance and is not negatively inotropic 121;190;191. In a double-blind, randomized, placebo-
controlled trial, our group have shown short-term beneficial effects of perhexiline in patients 
with ischaemic or non-ischaemic heart failure 132. Patients taking optimal conventional 
medical therapy were randomized to perhexiline or placebo for 8 weeks, with dummy dose 
adjustment in the placebo group.  We noted a large increase in the combined primary endpoint 
of peak oxygen uptake (≈ 3 ml kg–1 min–1) and LVEF (≈ 10 percentage points), and 
improvement in symptoms as assessed by the Minnesota Living with Heart Failure 
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Questionnaire. The study design involved separate randomization of the ischaemic and non 
ischaemic groups, permitting separate analysis of the primary endpoint in each group.  Peak 
oxygen uptake was significantly increased in both the ischaemic and non-ischaemic groups; 
therefore suggesting the mechanism of benefit is not primarily anti-ischaemic.  The study was 
however of short duration (8 weeks) and therefore, further work is required to show whether 
the clinical benefits of perhexiline are prolonged and whether it reduces hospitalization and 
mortality.  
 
Oxfenicine 
Oxfenicine is an irreversible inhibitor of carnitine palmitoyltransferase I (CPT1).  Oxfenicine 
has been shown to delay development of terminal heart failure in animal models, attenuate 
adverse haemodynamic changes, prevent wall thinning, prevent the activation of matrix 
metalloproteinases, and result in the transcriptional downregulation of CPT1 and of key 
enzymes involved in cardiac energy metabolism in animal models of heart failure 137.  
However a dose-related increase in cardiac weight due to uniform myocardial fiber 
hypertrophy of all cardiac chambers was noted in animal studies 76.  There was an increase in 
liver and kidney weights as well 16. No human studies have been reported with use of 
Oxfenicine in heart failure. 
 
Etomoxir 
Etomoxir, an irreversible inhibitor of CPT1, was initially introduced as a therapy for diabetes 
due to its hypoglycemic properties 4;202. It has been shown to favourably modify ventricular 
mass, geometry and function in pressure-overloaded rats 267, and reduce the occurrence of 
ventricular failure in diabetic rat hearts 142. In humans, a 3-month, open-label, uncontrolled 
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trial in 10 patients with NYHA class II–III heart failure, etomoxir treatment in addition to 
standard therapy significantly improved LVEF, cardiac output at peak exercise, and clinical 
status 222. However, recently a large randomized placebo controlled study was terminated 
prematurely because of the development of significant hepatotoxicity in four subjects 92.  
Therefore etomoxir may not be a suitable metabolic modulator for use in heart failure. 
 
Beta Blockers 
β-adrenoreceptor blockade improves LV function and prognosis in patients with ischaemic or 
nonischaemic cardiomyopathy 31;185.  Interestingly, Wallhaus et al. demonstrated that in 
patients with heart failure carvedilol caused a 57% reduction in myocardial free fatty acid 
uptake 278. However, neither mean myocardial uptake of labelled glucose tracers, nor the rates 
of glucose use were significantly increased.  This could be because of a type II error, since a 
marked fall in the ratio of myocardial free fatty acid to glucose use does suggest a so-called 
metabolic shift. This effect may be due to CPT1 inhibition. In another study, Al-Hesayen and 
colleagues showed that after 4 months of carvedilol therapy, myocardial lactate consumption 
was increased and myocardial uptake of FFA in patients with CHF was reduced 9.  This 
suggests that carvedilol therapy may cause a significant shift in myocardial substrate use from 
FFA towards carbohydrates.  
 
FFA β-Oxidation inhibitors 
Trimetazidine 
Trimetazidine reduces the oxidation of FFA via inhibition of the enzyme long-chain 3-
ketoacyl coenzyme A thiolase, which is crucial in the β-oxidation pathway 111. It is an 
effective anti-anginal agent with no significant vasodilator properties at rest or during 
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dynamic exercise 257.  In a double-blind, placebo-controlled trial involving 47 patients with 
CAD and a reduced LV function, limited by angina but not by heart failure, trimetazidine 
therapy improved LV systolic and diastolic function and quality of life 276.  A number of other 
studies have also demonstrated benefits with Trimetazidine.  Di Napoli et al demonstrated in 
an 18 months, open-label study a significant improvement in LV function in patients with 
ischaemic cardiomyopathy with reduced LVEF 56.  Patients were excluded if they had 
experienced acute myocardial infarction less than 3 months previously, or had acute heart 
failure.  Many patients however were taking suboptimal conventional therapy. Rosano and 
colleagues also demonstrated improvements in LVEF among patients with diabetes and 
coronary heart disease and LV systolic dysfunction, but without frank heart failure, following 
6 months of trimetazidine therapy 210.  Recently, Fragasso et al demonstrated in patients with 
either ischaemic or non-ischaemic cardiomyopathy, an increase in LVEF and decrease in 
NYHA class with the use of Trimetazidine 67. However, in another study, which assessed the 
effects of trimetazidine in patients with heart failure who were diabetic, revealed no 
significant improvement on exercise capacity and only minor effects on LV systolic function 
in both resting and exercise states 261.  
 
Ronalazine 
Ranolazine has been shown to be a partial inhibitor of fatty acid β oxidation 43;152, but this has 
not been reliably replicated in large experimental or human studies.  Ranolazine also reduces 
late sodium entry into ischaemic myocardial cells and, therefore, is thought to indirectly 
reduce calcium uptake via the sodium–calcium exchanger, so preserving ionic homeostasis, 
and  reversing ischaemia-induced contractile dysfunction 153. The drug has anti-anginal 
properties. In a study of a canine microembolization model of heart failure, intravenous 
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ranolazine increased myocardial work without increasing myocardial oxygen use, which 
implies an increase in cardiac efficiency 39. Acute intravenous administration of ranolazine 
also improved LV systolic function in dogs with heart failure 215. So far there have been no 
studies looking at the effects of ranolazine in humans with CHF.  There have been reports that 
the drug slightly prolongs the QT interval on electrocardiograms (ECGs). This effect raises 
concerns about possible complications such as torsade de pointes, polymorphic ventricular 
tachycardia and sudden cardiac death 133.  However, in the MERLIN TIMI 36 study on >6000 
patients, ronalazine decreased the incidence of ventricular and supraventricular arrhythmias 
providing support for its safety 230. 
 
Glucagon-Like Peptide 1 
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and 
insulinomimetic properties with resultant increases in myocardial glucose uptake.  In a dog 
model of heart failure, GLP-1  improved LV function and systemic haemodynamics 179.  In a 
small open label study, chronic infusion of GLP-1 significantly improved LV function, 
functional status, and quality of life in patients with severe heart failure 239.  However, in a 
recent study involving patients with heart failure, infusion of GLP-1 for 48 hours had no 
effects on LV ejection fraction or cardiac index 80. GLP-1 is administered subcutaneously 
because of breakdown in the gut and it is given as an analogue because it is broken down by 
DPP IV intravascularly. However, there are now DPP IV inhibitors available that inhibit the 
breakdown of endogenous GLP-1 which are used to treat diabetes 169;198;211. 
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D-Ribose 
D-Ribose is a pentose sugar which enhances ATP production by entering the pentose 
phosphate pathway and bypassing rate limiting steps of glycolysis. Omran et al studied the 
effect of ribose supplementation on cardiac haemodynamics and quality of life in patients 
with ischaemic cardiomyopathy.  This was a prospective, double blind, randomised, cross 
over design study which showed improved quality of life and improved diastolic function 
with ribose supplementation 181. However this has not been confirmed in large scale studies. 
 
Proprionyl-L-Carnitine 
Previous studies have demonstrated carnitine deficiency in heart failure patients 204;205;255.  
Carnitine is an important co-factor in intermediary metabolism of the myocardium which 
improves utilisation of pyruvate in Krebs cycle. Studies with carnitine supplementation have 
shown mixed results.  A small study by Anand et al showed improvement in maximal oxygen 
consumption at peak exercise (VO2 max) but no change in EF 12. However a larger study in 
1999 with 537 patients showed no improvement in exercise capacity 2. 
 
Conclusion 
 
Myocardial metabolism is altered in ischaemia and heart failure and plays a key role in the 
pathogenesis and progression of these diseases.  Acute and chronic ischaemia causes a shift 
towards increased glucose utilization which could partially compensate the oxygen deficiency. 
However, myocardial metabolism in heart failure appears to be complicated and depends on 
aetiology, duration and whether associated comorbid disorders are present. Nevertheless, 
medications that can augment myocardial metabolism would seem to have a potential role in 
the management of these heart diseases. 
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Diabetes and the heart 
Diabetes is a metabolic disorder characterised by hyperglycaemia, insulin resistance and/or 
deficiency and dyslipidaemia. Its prevalence is rapidly increasing throughout the western 
world 117. It is associated with hypertension, microvascular disease 1;122;173;206 and premature 
atherosclerosis in the large and medium sized arteries. Heart failure occurs more frequently in 
diabetes patients 109 and is commonly due to epicardial CAD 101;126;250 and/or hypertension. 
However in some patients LV dysfunction occurs in the absence of significant epicardial 
CAD or hypertension 214. The term ‘diabetic cardiomyopathy’ has been applied to this 
syndrome. The Framingham study demonstrated increased incidence of heart failure in both 
diabetic males (2.4:1) and females (5:1) 109. Diabetes patients also have a far greater risk of 
developing heart failure and have poorer prognosis following myocardial infarction than 
patients without diabetes101;250. Diabetic cardiac consequences initially involve diastolic 
dysfunction but ultimately this may progress to systolic dysfunction, which may be severe. 
Cardiac fibrosis 112;207 and myocyte hypertrophy are prominent histological features 138. 
Previous rodent studies in type 1 diabetes (T1DM) (streptozotocin-induced or genetic 
nonobese diabetic mice) and type 2 diabetes (T2DM) (Zucker diabetic fatty rats and ob/ob or 
db/db mice) have demonstrated systolic and diastolic dysfunction 3;253;265. In vivo studies have 
shown elevated diastolic pressure with decreased systolic pressure and altered dP/dt (change 
in pressure over time) 108. Rodents are resistant to atherosclerosis and hence all the changes 
can be attributed directly to diabetes 11. However it is important to note that experimental 
diabetes does not precisely mimic either type 1 or type 2 diabetes and hence the 
pathophysiology of diabetic cardiomyopathy may be different in humans. 
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Metabolic changes in the myocardium in diabetes 
The metabolic changes in the myocardium in patients with diabetes potentially play a 
significant role in the development and progression of CAD and CHF. Both type 1 and type 2 
diabetes result in significant changes to cardiac energy metabolism which may contribute to 
the development of contractile dysfunction and increases the potential for ischaemia induced 
injury. Diabetes results in alteration of plasma substrates. Decreased glucose utilisation 
(because of insulin deficiency and/or resistance) and increased hepatic glucose production 
results in hyperglycaemia. Enhanced lipolysis and increased production of lipoprotein lipases 
by the liver results in increased plasma FFA. Diabetes is associated with decreased glucose 
transport, glycolysis and oxidation 141. The reduced uptake of glucose via GLUT4 receptors 
which is insulin-dependent decreases the availability of glucose in the myocardium 243. 
However FFA entry into the myocardium is not hormone dependent and high levels of 
circulating FFA result in their accumulation in the myocardium. In normal hearts, 60-90% of 
the energy is derived from fatty acid oxidation. In diabetes this can increase to 90-100% 140. 
The increased utilization of FFA to generate energy has been demonstrated in PET studies on 
patients with T1DM 88. Increased FFA usage has a greater oxygen cost, in part explicable by 
stoichiometry but also possibly due to increased mitochondrial uncoupling 225 and wasteful 
cycling of FFAs through intramyocardial lipolysis and esterification 91;209. In T1DM, a recent 
PET study demonstrated reduced cardiac glucose uptake and utilisation and markedly 
increased FFA uptake and utilisation 88. The increased FFA uptake results in lipid 
accumulation in the form of triglycerides and ceramides in spite of the increased FFA 
oxidation 29. Lipid accumulation can worsen the myocardial insulin resistance which in turn 
worsens glucose uptake 188. Also increased FFA oxidation produces more reactive oxygen 
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species (ROS) which can oxidize lipids and proteins resulting in cell damage. ROS impairs 
mitochondrial coupling resulting in decrease in ATP production. 
 
There is a direct relationship between altered energy metabolism and cardiac muscle 
dysfunction. Systolic and diastolic dysfunction has been demonstrated by echocardiography in 
streptozotocin-induced type 1 diabetic rats 106 and elevated LV end diastolic pressure and 
reduced systolic pressure has been demonstrated by invasive measurements 108. An increase in 
FFA metabolism with decrease in uptake and utilisation of glucose has also been 
demonstrated in this animal model and directly implicated in contractile dysfunction 232;243. 
Cardiac dysfunction begins with diastolic abnormalities and finally leads to systolic 
dysfunction. However, it has been shown that altering cardiac metabolism reverses the 
contractile abnormalities 40;178. Similarly systolic and diastolic dysfunction has been detected 
by echocardiography in type 2 diabetic mice associated with abnormal metabolism 231.  
 
The impact of diabetes on the heart can occur via several other mechanisms including: 
 
Unrecognised hypertension - Patients presenting in heart failure may be viewed as 
normotensive but have prior, unrecognised hypertension. Furthermore, increased large artery 
stiffness 48;223;237 is a prominent feature in diabetes patients and in these circumstances central 
aortic systolic pressure may be considerably higher than brachial pressures. 
 
Microvascular disease – This occurs frequently in both type1 and type2 diabetes and is 
related to  duration of diabetes 122;173 and to glycaemic control 1;206. One of the important 
consequences of diabetic micro-angiopathy is the development of thickened basement 
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membrane. The thickened basement membrane results in increased permeability via 
compromised tight junctions and vesicular transport213. Microvascular disease causes 
ischaemia which along with increased capillary permeability may be involved in the 
pathogenesis of diabetic heart failure 149. Previous studies have demonstrated a reduced 
coronary flow reserve 55;119;128;130;170;195 in asymptomatic (type 1 and 2) diabetes patients as 
compared to healthy controls (HC), which is a measure of microvascular dysfunction in the 
heart (in the absence of epicardial CAD). 
 
Energetic impairment – Asymptomatic type 2 diabetes patients have impaired cardiac 
energetic status as reflected in a reduced PCr/ATP ratio on MRS and also  have impaired 
skeletal muscle energetics (as reflected by a prolonged PCr recovery half time following 
exercise) 221. Whilst microvascular ischaemia may potentially be contributory, a primary 
disturbance of energetic status unrelated to ischaemia is also likely. The potential role of 
altered cardiac substrate utilisation and of uncoupling in this energetic impairment is 
discussed below. 
 
Oxidant stress – Diabetes is characterised by increased oxidant stress. Multiple sources may 
contribute to increased production of ROS, but a substantial body of evidence suggests an 
important role for nicotinamide adenine dinucleotide phosphate (NADPH) oxidase derived 
ROS and uncoupled nitric oxide synthase (NOS) 135. ROS (particularly NADPH derived) have 
been implicated as major factors in the development of LVH and cardiac fibrosis and in the 
transition of LVH to heart failure 90;146. Ventricular myocytes of streptozotocin-induced 
diabetic rats develop a slow diastolic decay of calcium transients and require longer times for 
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maximum cell shortening and re-lengthening 125. In this model, angiotensin II mediated 
NADPH oxidase activation is involved in cardiomyocyte dysfunction 199;285. 
 
Cardiac autonomic neuropathy (CAN) – Autonomic dysfunction potentially plays a 
significant role in development and progression of cardiomyopathy. It also predisposes to life 
threatening arrhythmias. Previous studies by our group have demonstrated that CAN is 
associated with impaired myocardial blood flow using PET 197;246. The sympathetic 
dysinnervation of the heart commenced in the distal LV regions near the apex and then spread 
towards the base in patients with advanced disease 247. 
 
Uncoupling proteins - Mitochondrial uncoupling is a process which was first described in 
brown fat 212. Long chain fatty acids and lipid peroxides 74 are exported across the 
mitochondrial membrane in exchange for protons via specific proteins known as UCP, 
resulting in dissipation of the mitochondrial electro chemical gradient. The physiological role 
of uncoupling has been the subject of much debate 225 but it has been proposed that its 
primary role is to export excess long chain fatty acids and toxic lipid peroxides. Uncoupling 
protein expression is upregulated by fatty acids via the PPAR α receptor 168;240. The activity of 
UCP is increased by intra-mitochondrial fatty acid concentrations 228 and by ROS and lipid 
peroxides 74. Since the early description of uncoupling in brown fat 84 it has been shown that 
UCP are also expressed in other cell types. UCP2 is  ubiquitous, including expression in the 
heart, whereas UCP3 expression is mainly found in glycolytic rather than oxidative skeletal 
muscle 8;26. Theoretically diabetes should be associated with increased uncoupling because 
increased cardiac and skeletal myocyte cytosolic fatty acids should upregulate UCP 
expression 154;218;240. Increased intra-mitochondrial FFAs, ROS generation and lipid 
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peroxidation via ROS should also increase the activity of UCP 74;228. However, unexpectedly 
(and requiring confirmation) one group reported that uncoupling protein expression was 
reduced in skeletal muscle in diabetes patients 224;227, but in streptozocin-induced diabetic 
mice cardiac UCP expression was upregulated 168. Whatever the level of uncoupling protein 
expression, the activity of UCPs may be markedly increased in diabetes patients for the 
reasons noted above and this may be more important than UCP expression levels in 
determining uncoupling. 
 
Structural changes in the heart associated with diabetes 
Although there is increasing evidence for the presence of diabetic cardiomyopathy as a 
separate entity, detection of early changes in the myocardium is challenging in patients with 
diabetes. Various imaging modalities have been used to detect these changes. 
 
Echocardiography: LVH is one of the commonest structural abnormalities demonstrated in 
diabetes. Previous studies with 2 dimensional (2D) and tissue doppler echocardiography have 
demonstrated abnormalities in various diastolic parameters prior to the onset of overt systolic 
dysfunction. The trans-mitral pulsed wave doppler demonstrates abnormalities in mitral 
inflow velocity and deceleration time (DecT), isovolumetric relaxation time (IVRT) and 
filling patterns 196. However these measurements are load-dependent and can alter depending 
on left atrial (LA) pressures. Tissue doppler imaging (TDI) is a relatively load independent 
method of deriving mitral annular velocities. Previous studies in subjects with both T1DM 
and T2DM have demonstrated a reduction in long axis function indicated by reduced S and E’ 
wave velocity in the presence of normal EF 61;275. The E/E’ is a good measure of LV end 
diastolic pressure and increased E/E’ is associated with diastolic heart failure. 
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Computed Tomography: Electron beam tomography is able to measure coronary artery 
calcium which is one of the early markers of atherosclerosis. Coronary artery calcium scoring  
is highly sensitive in predicting the presence of coronary atherosclerosis32;34. However, it 
lacks specificity for predicting obstructive coronary artery disease32;33. Coronary artery 
calcium also has prognostic value and predicts future cardiovascular events 54. Previous 
studies in young patients with T1DM have demonstrated significantly increased prevalence of 
coronary artery calcium indicating early onset of CAD in these individuals 245. In another 
study invoving patients with T2DM Wolfe et al demonstrated increased coronary artery 
calcium scoring in patients with diabetes as compared with patients without diabetes even 
when matched for other risk factors 283. Hence computed tomography can be utilised to detect 
patients with high risk of developing cardiovascular complications. 
 
Magnetic Resonance Imaging (MRI) and Spectroscopy: MRI provides improved 
resolution in imaging the myocardium. In particular, tagged MRI allows measurement of 
myocardial velocities and LV torsion. In streptozotocin-induced type 1 diabetic mice, high 
resolution MRI demonstrated increase LV wall volume indicating LVH and also features 
suggestive of increased stiffness due to fibrosis 138. A tagged MRI study in T1DM patients has 
shown increased LV torsion and torsion rate in the presence of tight glycaemic control 42. 
 
Conclusions 
The development of heart failure in diabetes is multi-factorial. Diabetes is a metabolic 
disorder associated with metabolic alterations in the myocardium.  Insulin resistance and/or 
deficiency results in increased FFA utilisation and decreased glucose utilisation. This 
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potentially contributes significantly to the development of cardiomyopathy. Studying 
myocardial metabolism provides insights into the patho-physiology of heart failure in diabetes. 
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Aims and hypotheses of all the studies 
MRS feasibility and reproducibility at 3T 
Traditionally cardiac MRS is done at 1.5T. 3T offers increased signal to noise ratio (SNR). 
The increased sensitivity can be traded for either increased spatial resolution or improved 
quantification precision and hence might improve specificity of cardiac MRS as a diagnostic 
tool. The aims of this study were – 
1) To develop a robust, practical and reproducible protocol for cardiac MRS studies at 3T. 
2) To test the feasibility and reproducibility of performing cardiac MRS at 3T. 
 
Perhexiline studies 
Perhexiline was being used on a named patient basis at University Hospital Birmingham NHS 
Trust and Cardiff and Vale NHS Trust for patients with refractory angina and/or refractory 
CHF. Patients were on maximal tolerated medical therapy and were deemed not amenable for 
revascularisation. We aimed to test the feasibility of administering Perxiline in this clinical 
setting. We sought to study the effect of Perhexiline on glucose and fat metabolism in these 
patients. Previous animal studies have demonstrated a concentration-dependent differential 
inhibition of CPT-1 by Perhexiline in the liver or muscle 115. This can result in variable effects 
on glucose and fat metabolism. Studying these effects of Perhexiline will throw more light on 
the CPT-1 inhibition patterns in humans. The aims of the Perhexiline studies were as follows– 
1) To measure the impact of Perhexiline on insulin sensitivity as measured by the HOMA 
method. 
2) To assess the impact of Perhexiline on plasma FFA, ketones, triglycerides and glycerol. 
3) To assess the feasibility of safely administering Perhexiline in a clinical setting with 
adequate monitoring of drugs levels and side effects.  
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Hypotheses 
1) By inhibiting beta-oxidation of FFA and enhancing glucose utilisation Perhexiline 
improves insulin sensitivity. 
2) Inhibition of betaoxidation of FFA results in accumulation of FFA in the plasma. 
3) Perhexiline can be safely administered with regular monitoring of drug levels.  
 
Studies in diabetes patients 
We conducted all our studies in patients with type 1 diabetes. We chose a cohort of young 
patients with no history of hypertension, primary hyperlipidemia, renal failure, coronary 
artery disease or heart failure. In order to tease out the pathophysiological effects of diabetes 
on the heart we divided the patients into two subgroups; newly diagnosed diabetes (diagnosis 
in the last 5 years) and long term diabetes (diagnosed more than 10 years ago). The aims of 
the studies were as follows- 
1) To confirm the presence of cardiac energetic impairment in these patients. 
2) To study the pathophysiological mechanisms responsible for the development of cardiac 
energetic impairment, in particular the role of coronary microvascular dysfunction and 
metabolic effects of diabetes.  
3) To assess the early changes in LV torsion in diabetes and its relationship to coronary 
microvascular dysfunction. 
4) To assess LV untwisting patterns in diabetes and its relation to diastolic function and LV 
filling.  
5) To assess LA contribution to LV filling in the early stages of diabetic cardiomyopathy 
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Hypotheses  
1) Cardiac energetic impairment occurs early in diabetes and is primarily due to metabolic 
effects of diabetes. 
2) Coronary microvascular disease plays little role in the development of cardiac energetic 
impairment. 
3) Study of changes in LV torsion will provide insights into the early changes in systolic 
function in diabetes. 
4) Study of LV untwisting patterns and LV filling will provide insights into early changes in 
diastolic function in diabetes.  
 
Power calculations 
Aims 1 and 2; 10 subjects would be required in each group (newly diagnosed diabetes 
patients, long term diabetes patients and healthy controls) to identify a difference of 25% in 
PCr/ATP ratio with a power of 90% and a significance (P value) of <0.05. The estimated 
standard deviation was 0.4 from previous studies in patients with type 2 diabetes mellitus221. 
We aimed to recruit a higher number of subjects in the long term diabetes group (15 subjects). 
This was to ensure that adequate number of these patients would have coronary microvascular 
dysfunction and hence allow us to assess its role in pathophysiology of cardiac energetic 
impairment. We also aimed to recruit age and sex matched controls for both sub groups of 
diabetes patients. Hence a total of 26 healthy volunteers were recruited. 
Aims 3 and 4; 30 subjects were required in each group (diabetes patients and healthy controls) 
to identify a difference of 25% in LV rotation measurements with a power of 90% and 
significance (P value) of <0.05. The estimated standard deviation was 3.3 from previous 
studies of speckle tracking in healthy controls85 . 
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This chapter describes the different techniques used in the project.  
 
 
Storage of serum samples 
 
The blood samples were collected in lithium heparin, EDTA and sodium fluoride blood tubes. 
The blood tubes were centrifuged for 15 minutes at 1500 revolutions per second at 4oC. The 
serum was pipetted into plain tubes and stored at -80oC. The samples were defrosted before 
analysis. 
 
Insulin assay 
Frozen serum samples were used to perform insulin assay using Mercodia insulin ELIZA kit. 
A 96 well micro plate coated with mouse monoclonal anti-insulin antibody was used. 25 µl of 
calibrator or samples was pipetted into each well. 100 µl of enzyme conjugate solution 
(peroxidise conjugated anti-insulin antibodies) was added to this and incubated on a plate 
shaker at room temperature for 1 hour. Following this the micro plate was washed with wash 
buffer six times to remove any excessive unbound enzyme conjugate. Then 200 µl of 
substrate 3,3’,5,5’ tetra-methyl-benzidine was added to each well and incubated at room 
temperature for 15 minutes. At the end of 15 minutes 50 µl of stop solution (0.5 M H2SO4) 
was added and the plate read at 450 nm on a colorimetric spectrophotometer. A calibrator 
curve was plotted using the absorbance of the different calibrators. The concentration of 
insulin in the samples was determined from the calibrator curve. 
 
Ketone assay 
Frozen serum samples were used to perform the ketone assay using the Ranbut ketone 
analysis kit. This kit measures D-3-hydroxybutarate based on its oxidation to acetoacetate by 
the enzyme 3-hydroxybutarate dehydrogenase. Concomitant to this reaction NAD+ is reduced 
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to NADH which alters the absorbance that is directly correlated with the 3-hydroxybutarate 
concentration. A 96 well micro plate was used and 25µl of calibrator or the serum was added 
to each well. 25 µl of distilled water and 1ml of reagent were added to this. The contents were 
mixed and then read at 340nm in a spectrometer at 370C following incubation for 60 sec. The 
3-hydroxybutarate concentration was calculated as follows: 
 
 3-hydroxybutarate   =       ΔAsample          x           standard concentration 
                                                     ΔAstandard                                  
 
 
 
Echocardiography 
 
 
Echocardiography was performed with participants in the left lateral decubitus position with a 
Vivid 7 (GE Vingmed) echocardiographic machine and a 2.5-MHz transducer (Figure 2.1).  
Standard echocardiographic views were obtained from parasternal (short axis grey scale 
images at mitral, papillary and apical levels) and apical (4 and 2 chamber views) windows. An 
average of three cycles was stored for each view. Trans-mitral flow profiles and tissue doppler 
measurements of mitral annular velocities were performed.  The EF was calculated with 
Simpson’s rule79. The grey scale images obtained both in the parasternal short axis and apical 
view were used to compute LV strain, strain rate and rotation using commercially available 
speckle tracking software on Echopac. 
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Figure 2.1 
 
Vivid 7 echocardiographic machine 
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Speckle Tracking Echocardiography (STE) 
Myocardial deformation was measured using a commercially available speckle tracking 
system in an ECHOPAC (version 4.2.0) workstation. In this system, the displacements of 
speckles of myocardium in each spot were analyzed and tracked from frame to frame 
(Figure2.2).  We selected the best-quality digital two-dimensional image and the LV 
endocardium was traced at end-systole.  The region of interest width was adjusted as required 
to fit the wall thickness.  The software package then automatically tracked the motion through 
the rest of the cardiac cycle.  The onset of QRS complex was taken as the beginning of systole. 
Adequate tracking was verified in real time.  The global longitudinal and transverse strain and 
strain rates were derived from an average of the 12 segments from the 4 and 2 chamber views 
(6 segments in each view). Similarly an 18 segment model was computed from the short axis 
views at mitral, papillary and apical levels. The average of measurements from each of the 
segments was used to derive global circumferential and radial strain and strain rates. In 
addition, LV rotation was computed using speckle tracking. Counter-clockwise rotation was 
marked as a positive value and clockwise rotation as a negative value when viewed from the 
apex. In order to calculate LV torsion, torsion rate and untwist rates, the rotation traces of the 
basal and apical LV cross-sections were exported into DPlot graph software (Version 2.2.1.4, 
HydeSoft Computing, LLC, Vicksburg, USA). The LV twist curve was generated by 
calculating the difference between apical and basal rotations at each corresponding time point. 
LV twist rates were derived from the first derivative of the LV twist curve. Peak LV torsion 
was derived from LV twist divided by LV diastolic longitudinal length. Rotational 
deformation delay was also determined and defined as the magnitude of the time difference 
between time to peak basal rotation and time to peak apical rotation. In order to adjust for the 
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differences in heart rate between individuals the RR interval was normalised to 100% for 
calculation of time intervals. 
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Figure 2.2: Examples of radial (bottom figure) and longitudinal (top figure) 
strain determined using speckle tracking echocardiography. The 
myocardium is divided into six equal segments and strain in each segment 
represented by different coloured line. 
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Metabolic Exercise Testing 
Subjects underwent symptom-limited erect treadmill exercise testing using a standard ramp 
protocol with simultaneous respiratory gas analysis on a Schiller CS-200 Ergo-Spiro exercise 
machine. Sampling of expired gases was performed continuously, and data were expressed as 
30-second means.  Minute ventilation, oxygen consumption, carbon dioxide production, and 
respiratory exchange ratio (RER) were obtained.  Peak oxygen consumption (V02max) was 
defined as the highest value of oxygen consumption measured during the exercise period. 
Blood pressure and ECG were monitored throughout.  Subjects were encouraged to exercise 
to exhaustion with a minimal requirement of RER > 1. 
 
31 P cardiac MRS 
31P cardiac MRS was performed using a Phillips Achieva 3T scanner (Figure 2.3) and a 
linearly polarized transmit and receive 31P coil with a diameter of 14 cm. Localization was 
achieved by ISIS 184 volume selection. The participants were positioned supine with the coil 
directly over the precordium. The coil was secured in place by straps wrapped around the 
upper body of the subject and the coil. The participants were then positioned inside the 
magnet with the center of the coil at the isocenter of the magnet. Survey images were obtained 
to check the position of the coil (Figure 2.4). The subjects and/or the coil were repositioned if 
required to ensure that the distance between coil and septum and apex of the heart was 
minimized. 
 
The standard phosphorus spectroscopy sequence provided by the manufacturer was used. It 
was based on hyperbolic secant pulses for slice selective inversion and adiabatic half passage 
RF pulse for non-selective excitation. In contrast to the standard procedure manual fine 
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adjustment of F0 was performed if the automatic F0 determination was not correct in order to 
ensure the correct voxel position. In contrast to the default iterative or FASTERMAP based 
shimming algorithm, which was based on the selected spectroscopy VOI, an image guided 
shim volume was selected that included the entire myocardium. A short axis cine scan was 
acquired to calculate the trigger delay (TD) for ECG triggering and check quality of 
shimming and F0 determination. The TD was calculated such that the spectra were acquired in 
the diastolic period. The 3-D voxel of acquisition was planned to include most of the septum 
and apex of the heart. Care was taken to minimize blood contamination from the right 
ventricle as much as possible. The voxel size was kept constant at 89.54ml (44x55x37mm3) 
so that comparisons could be made between different subjects and scans. Initially, 1H spectra 
were acquired from the same voxel without water suppression and repetition time (TR) of 
2000 ms (total scan time of 16 sec). This helped to ensure adequate shim quality and correct 
F0 determination. F0 could be manually adjusted if necessary. Following this the 
31P spectrum 
was acquired with a TR of 10000 ms, 136 averages and 512 samples. A TR of 10000 ms was 
found to be optimal to adequately reduce saturation effects without increasing the scan time 
greatly. The spectral acquisition was ECG gated and the TD was set to acquire spectra mainly 
in diastole. The TD was measured by subtracting 250-300 from the total length of the cardiac 
cycle which allowed 250-300 msec of the cardiac cycle left for spectral acquisition 
(acquisition time is 170 msec). The total scan time was 23 minutes.  
 
Increased chemical shift artefacts are present at 3T. In order to minimise this, slice selective 
inversion for ISIS encoding was based on adiabatic hyperbolic secant pulses, which achieved 
a pulse bandwidth between 1300 Hz (at a distance of 9 cm from the surface coil) to 2000 Hz 
(at a distance of 3 cm from the surface coil). This corresponds to a chemical shift 
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displacement of 6-10% for the investigated metabolites PCr and gamma-ATP for volumes of 
interest that were between 3 and 9 cm away from the coil. When subjects where scanned the 
distance from the coil to the ROI averaged about 7.5cm and no subjects were beyond 9.0 cm. 
Therefore all subjects would have a chemical shift displacement less than 10% which is 
acceptable. 
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Figure 2.3 
 
Phillips Acheiva 3T MRI scanner which was used for magnetic resonance spectroscopy 
and magnetic resonance imaging (including stress MRI) 
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Figure 2.4  
 
 
 
Survey images (in transverse, coronal and saggital planes) showing the position of voxel 
of acquisition (yellow box) and centre of the 31P coil. The voxel is positioned such that it 
remains completely within the myocardium and as close as possible to the center of 31P 
coil. 
  
Voxel of acquisition 
Centre of the 31P coil 
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MRS 
The spectra were analysed and quantified on jMRUI software using AMARES a time domain 
fitting program 271. Post-processing was performed with 15Hz Gaussian line broadening and 
Fourier transformation. Phase correction was performed with the PCr peak as the reference 
peak. Quantification was performed with AMARES using a prior knowledge file to preselect 
the peaks. The concentrations of PCr, ATP and 2,3-Diphosphoglycerate (2,3-DPG) were 
calculated as the area under the peaks. PCr/ATP ratio was determined after correcting the 
ATP peak for blood contamination as described previously46. 
 
Cardiac MRI 
Cardiac MRI was performed on a 3 T Phillips Achieva MRI scanner (Figure 2.3). The 
standard protocol provided by the manufacturer was used. The subjects were positioned 
supine with a dedicated cardiac sense coil wrapped around the chest. The subjects were 
positioned in the scanner with their heart at the isocenter of the magnet. Survey images were 
obtained and the short axis images were planned from this. The LV was divided into slices of 
8mm with a gap of 2mm. A total of 12 slices ensured complete coverage of the LV from apex 
to base. Short axis cine images were acquired at breath hold using sense cine sequences. LV 
volumes were computed from the short axis cine MRI images. The images were analyzed on 
the Viewforum software version 5.0. The endocardial and epicardial borders were traced at 
end diastole in each slice and propagated through the rest of the cardiac cycle. The software 
generated LV volumes at each phase of the cardiac cycle incorporating all the slices. The LV 
volume time curves were exported to graphical software Dplot. The first derivative of the LV 
volume curve was computed to represents the rate of LV volume changes. SV is defined as 
the difference between end-diastolic volume (EDV) and end-systolic volume (EDS). Early 
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and late peak filling rates (PFR) were defined as the first and second positive peaks of the first 
derivative curve during diastole. The early and late (atrial) components of LV filling were 
measured from the corresponding LV volume segments and were expressed as percentage of 
SV. 
Stress MRI 
Cardiac MRI was performed on a 3 T Phillips Achieva MRI scanner (Figure 2.3). The 
standard protocol provided by the German Heart Institute was used for the assessment of 
myocardial perfusion during adenosine mediated vasodilation (Perfusion cook book - 
http://www.cmr-academy.com/). The subjects were positioned supine with a dedicated cardiac 
sense coil wrapped around the chest. The subjects were positioned in the scanner with their 
heart at the isocenter of the magnet. Survey images were obtained which was followed by first 
pass images after Gadolinium contrast injection (0.1ml/kg body weight). For perfusion images, 
a single shot Turbo Field Echo SENSE pulse sequence was used with three slices per heart 
beat. Slice thickness was 8mm with a gap of 12mm between the slices. The field of view was 
400mm with a matrix of 152x109. The TR was 3.5ms with an echo time of 1.05ms. LV was 
imaged in the short axis at three levels tracking the entry of contrast first into the right 
ventricle, and then the LV cavity followed by the illumination of the LV myocardium as the 
contrast passed through the coronary arterial tree (Figure 2.5). After a gap of twenty minutes 
which allowed the contrast to be eliminated completely from the myocardium, adenosine 
infusion was started at a rate of 140mcg/kg/min. At three minutes of infusion stress first pass 
images were obtained following injection of further Gadolinium contrast (0.1ml/kg) in a 
similar fashion and at the same short axis levels. ECG was continuously monitored and blood 
pressure was recorded every minute during the stress scan. 
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Figure 2.5  
 
 
 
 
 
Short axis images of the heart depicting the passage of Gadolinium contrast through the 
right ventricle, then the LV cavity followed by illumination of the LV myocardium. 
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MPRI 
Myocardial perfusion reserve index (MPRI) which is a measure of coronary microvascular 
function was computed from the stress MRI images. The images were analyzed on the 
Viewforum software version 5.0. Initially image alignment was done to reduce the motion of 
the heart in different cardiac cycles. Following this the endocardial and epicardial borders 
were traced and propagated throughout all the images. A sample volume was placed in the LV 
cavity as comparison for signal intensity of blood. Signal intensity curves were obtained from 
the software and the peak upslope of the LV myocardial illumination was computed in 
relation to the LV cavity illumination. A similar analysis was done on all three short axis 
images at rest and peak stress. The MPRI was obtained from the ratio of LV relative peak 
upslope at stress compared to rest. 
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CHAPTER THREE 
 
31 P MAGNETIC RESONANCE SPECTROSCOPY OF THE HUMAN 
MYOCARDIUM AT 3 TESLA – TEST OF FEASIBILITY AND 
REPRODUCIBILITY 
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Cardiac Energetics in Normal Myocardium and Hypertrophic Cardiomyopathy:  Experiences at 3 Tesla. 
European Journal of Radiology. 2010;73:255-259. 
 
 
 
The following work was done in conjunction with two other PhD students, Dr Thanh Phan and Dr Khalid 
Abozguia. We equally contributed to this work. 
Dr Roger Beadle has provided the data on further validation testing in our department on twelve healthy 
volunteers.  
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Abstract 
 
Background: 31P MRS allows measurement of in vivo high energy phosphate kinetics in the 
myocardium. Whilst traditionally 31P cardiac spectroscopy is performed at 1.5 Tesla, Cardiac 
MRS at higher field strength can theoretically increase SNR and spectral resolution therefore 
improving sensitivity and specificity of the cardiac spectra. The reproducibility and feasibility 
of performing cardiac spectroscopy at 3 Tesla is presented here in this study in healthy 
volunteers and patients with HCM. 
Methods: Cardiac spectroscopy was performed using a Phillips 3T Achieva scanner in 37 
healthy volunteers and 26 patients with HCM to test the feasibility of the protocol. To test the 
reproducibility a single volunteer was scanned eight times on separate occasions. A single 
voxel 31P MRS was performed using Image Selected Invivo Spectroscopy (ISIS) volume 
localisation.  
Results: The mean PCr/ATP ratio of the eight measurements performed on one individual 
was 2.11±0.25. Bland Altman plots showed a variance of 12% in the measurement of 
PCr/ATP ratios. The PCr/ATP ratio was significantly reduced in HCM patients compared to 
controls, 1.42±0.51 and 2.11±0.57, respectively, P<0.0001. (All results are expressed as mean 
± standard deviation) 
Conclusions: Here we demonstrate that cardiac 31P MRS at 3T is a reliable method of 
measuring in vivo high energy phosphate kinetics in the myocardium for clinical studies and 
diagnostics. Based on our data an impairment of cardiac energetic state in patients with HCM 
is indisputable.   
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Background 
Phosphorus MRS is a non-invasive method of studying cardiac in vivo high energy phosphate 
kinetics 27. It allows for determination of PCr, ATP, ADP and inorganic phosphate (Pi) 
concentrations in the myocardium. The concentrations of these substances and the ratio of 
PCr/ATP are measures of the cardiac energetic status.  PCr is an important short-term reserve 
energy source that maintains a high phosphorylation potential under conditions of increased 
energy demand like exercise and ischaemia. The conversion of ADP to ATP by transfer of a 
phosphoryl group from PCr is catalysed by CK. This reaction occurs 10 times faster than ATP 
production via oxidative phosphorylation 22. In patients with mild to moderate CHF, cardiac 
ATP flux mediated by CK is reduced by approximately 50% 280. Animal and human studies 
have demonstrated that a progressive reduction of the creatine pool is directly related to the 
severity of heart failure 171. This is largely due to a decrease in the number of creatine 
transporters at sites of energy production and utilisation 51. In normal myocardium, two thirds 
of the creatine pool is phosphorylated via CK reaction to form PCr 5 and the expression and 
activity of this enzyme is reduced in heart failure 238;286. Therefore in heart failure the 
available PCr is markedly diminished. The depletion of PCr is greater than the depletion of 
ATP resulting in reduced PCr/ATP ratio in heart failure as measured by MRS 45. A reduced 
PCr/ATP ratio is associated with increased mortality in heart failure patients 176. 31P cardiac 
spectroscopy can also be used to monitor disease progress in heart failure patients. It has been 
used as an objective marker to show benefits of various treatments such as metabolic 
modulators 68.  
 
Reduced PCr/ATP ratio is also seen in other conditions including ischaemic heart disease 279, 
LVH secondary to hypertension 150, valvular heart disease (mitral regurgitation and aortic 
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valve disease) 46;176, diabetes 221 and HCM 50;107;216. Interestingly, patients with genotypic 
HCM who do not yet have hypertrophy have a similar degree of impairment of cardiac 
PCr/ATP ratio as do patients with marked hypertrophy, implying that the disturbance may be 
an early feature of the disease and is not simply due to the hypertrophy 47. 
 
Traditionally cardiac spectroscopy in humans has been performed using 1.5 Tesla magnets.  
However, previous studies in animals 131 and humans demonstrated that higher field strength 
such as 3T 269 or 4.7T offer higher signal to noise ratio (SNR). The increased sensitivity can 
be traded for either increased spatial resolution or improved quantification precision and 
hence might improve specificity of 31P cardiac MRS as a diagnostic tool. Hence it would 
seem desirable to perform cardiac MRS at 3T MR scanners. However, higher field strength 
also result in inhomogeneities of the transmit and receive B1 field along with restrictions of 
the maximum achievable B1 field strength that result in larger chemical shift displacements. 
Furthermore susceptibility differences between adjacent tissues have a greater effect on B0 
homogeneity 41, which results in line broadening. Hence the methods available to perform 
spectroscopy in 1.5 Tesla magnets cannot be reproduced in 3 Tesla magnets. We therefore 
conducted experiments to adapt the spectroscopy methods to suit 3 Tesla magnets. This study 
represents the development of a suitable method to perform cardiac spectroscopy at 3 Tesla. 
Data on feasibility and reliability of 31P cardiac spectroscopy at 3 Tesla is presented.  
 
Methods 
Our initial aim was to develop a robust, practical and reproducible protocol for cardiac 
spectroscopy which could be used in all research studies. I worked along with two other PhD 
students on this task (Dr Khalid Abozguia and Dr Thanh Trung Phan). 9 Healthy volunteers 
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who provided written informed consent participated in this study.  A total number of 35 scans 
were carried out.  We performed spectroscopy using the standard pulse sequences provided by 
the manufacturer and initially studied the effects of various parameters like subject 
positioning, localisation and coil positioning, shimming, decoupling, Nuclear Overhauser 
Enhancement (NOE), TD and TR. 
 
Subject positioning 
The prone position potentially has several advantages such as minimising chest movements, 
short distance between the coil and the heart, and stability of the coil.  However, most subjects 
cannot tolerate this position for the entire duration of the scan. We performed repeated scans 
in the prone and supine positions. The Cramer Rao lower bounds for prone and supine 
postions were 9% and 12% (PCr peak) and 13% and 22% (gamma ATP peak) respectively. 
Hence the spectral quality was of good quality and comparable in the two and we decided to 
always scan in the supine position.  
 
Localisation and Coil position 
We found the best results by positioning the centre of the 14 cm 31 P coil directly over the 
apex and septal region of the myocardium. Placing the coil in any other position would not 
allow the entire voxel of acquisition to lie adjacent to the coil. Survey images were taken to 
locate the position of the coil with respect to the apex of the heart. The coil was repositioned 
if necessary such that the voxel of acquisition would be at the shortest distance from the coil.  
We were able to acquire good cardiac 31 P spectra with distances up to 10 cm from the centre 
of the coil to the centre of voxel of acquisition. This method of coil positioning resulted in an 
average distance of about 7.5cm between the coil and centre of voxel of acquisition. 
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Shimming 
Shimming is a process of minimising the infield inhomogenities in the region of interest. We 
tried various shim routines such as first and higher order shimmimg available on the scanner 
for spectroscopy. However none of these routine shimming methods provided spectral quality 
good enough for quantification. Specifically, the SNR was significantly reduced and it was 
not possible to accurately detect and quantify the ATP peaks (Figure 3.1). Shimming in 
imaging mode provided the best quality and was superior to first and second order shimming 
in spectroscopy mode. A short axis cine image was planned and acquired on breath hold.  The 
short axis image provided a guide to the quality of shimming and also determined RR interval 
to calculate the TD. A check proton spectroscopy scan was performed to ensure good quality 
shim and correct F0 determination. A line width of less than 200Hz with a single peak for 
water signal was required to ensure good shim quality. If the water peak was not present at 
zero frequency, the F0 could be manually altered. The cine image acquisition would be 
repeated if the quality of shimming was found to be not optimal on proton spectroscopy. 
 
Trigger delay 
It is ideal to acquire the spectra when the heart is moving the least. This occurs during diastole 
and hence it is desirable to set the TD such that the spectra are acquired during diastole. The 
TD was measured by subtracting 250-300 from the total length of the cardiac cycle which 
allowed 250-300 msec of the cardiac cycle left for spectral acquisition (acquisition time is 170 
msec for each spectrum). 
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Figure 3.1 
 
 
Cardiac spectra using the routine spectroscopic shim method (figure on left) as 
compared to shim in imaging mode (figure on right) 
 
PCr- Phosphocreatine; 2,3-DPG- 2,3 Diphosphoglycerate;  ATP - Adenosine triphosphate. 
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Repetition Time 
 TR is the time gap between acquisition of two consecutive spectra. Short TR increases the 
saturation effect and reduces the signal as the phosphorus molecules are not completely 
relaxed before the next radio frequency pulse hits them. Long TR however increases the total 
acquisition time. Scans were performed at TR of 5000 msec and 10000 msec. The Cramer 
Rao lower bounds for TR of 5000 msec and 10000 msec were 9% and 10% (PCr peak) and 
26% and 22% (gamma ATP peak) respectively. This demonstrated that the spectral quality 
was adequate at TR of both 5000 and 10000 msec. We chose a TR of 10000 msec to achieve a 
significant reduction in saturation effect without increasing the total scan time considerably 
(total scan time of 23 minutes). 
 
Decoupling and NOE mode 
We found no significant advantages to the quality of spectra acquisition by enabling the 
Decoupling mode. NOE increases the SNR but the net effect is variable on different 
molecules like ATP and PCr. We did not use NOE as it would interfere with quantification of 
the various peaks in the spectra. 
 
Multi-rest Band 
The multi rest band is used to reduce contamination from skeletal muscle and liver. Provided 
we positioned the voxel in a way that excluded the chest skeletal muscle and the liver, we 
found no significant advantages to the quality of spectra acquired with multi-rest band. Hence 
this was not used in our experiments. 
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Summary of the 31 P cardiac MRS protocol 
31P cardiac MRS was performed using a Phillips Achieva 3T scanner and a linearly polarized 
transmit and receive 31P coil with a diameter of 14 cm. Localization was achieved by ISIS 184 
volume selection. The participants were positioned supine with the coil directly over the 
precordium. The coil was secured in place by straps wrapped around the upper body of the 
subject and the coil. The participants were then positioned inside the magnet with the centre 
of the coil at the isocentre of the magnet. Survey images were obtained to check the position 
of the coil (figure 3.2). The subjects and/or the coil were repositioned if required to ensure 
that the distance between coil and septum and apex of the heart was minimized. 
 
The standard phosphorus spectroscopy sequence provided by the manufacturer was used. It 
was based on hyperbolic secant pulses for slice selective inversion and adiabatic half passage 
RF pulse for non-selective excitation. In contrast to the standard procedure, manual fine 
adjustment of F0 was performed if the automatic F0 determination was not correct in order to 
ensure the correct voxel position. In contrast to the default, iterative or FASTERMAP-based 
shimming algorithm, which was based on the selected spectroscopy VOI, an image guided 
shim volume was selected that included the entire myocardium. A short axis cine scan was 
acquired to calculate the TD for ECG triggering and check quality of shimming and F0 
determination. The TD was calculated such that the spectra were acquired in the diastolic 
period. The 3-D voxel of acquisition was planned to include most of the septum and apex of 
the heart. Care was taken to minimize blood contamination from the right ventricle as much 
as possible. The voxel size was kept constant at 89.54ml (44x55x37mm3) so that comparisons 
could be made between different subjects and scans. Initially, 1H spectra were acquired from 
the same voxel without water suppression at a TR of 2000 ms (total scan time of 16 sec). This 
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helped to ensure adequate shim quality and correct F0 determination. F0 could be manually 
adjusted if necessary. Following this the 31 P spectrum was acquired with a TR of 10000 ms, 
136 averages and 512 samples. A TR of 10000 ms was found to be optimal to adequately 
reduce saturation effects without increasing the scan time greatly. The spectral acquisition 
was ECG-gated and the TD was set to acquire spectra mainly in diastole. The TD was 
measured by subtracting 250-300 from the total length of the cardiac cycle which allowed 
250-300 msec of the cardiac cycle left for spectral acquisition (acquisition time is 170 msec). 
The total scan time was 23 minutes.  
 
Increased chemical shift artefacts are present at 3T. In order to minimise this, slice selective 
inversion for ISIS encoding was based on adiabatic hyperbolic secant pulses, which achieved 
a pulse bandwidth between 1300 Hz (at a distance of 9 cm from the surface coil) to 2000 Hz 
(at a distance of 3 cm from the surface coil). This corresponds to a chemical shift 
displacement of 6-10% for the investigated metabolites PCr and gamma-ATP for volumes of 
interest that were between 3 and 9 cm away from the coil. When subjects were scanned the 
distance from the coil to the ROI averaged about 7.5cm and no subject was beyond 9.0 cm. 
Therefore all subjects would have a chemical shift displacement less than 10% which is 
acceptable. 
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Figure 3.2  
 
 
 
Survey images (in transverse, coronal and saggital planes) showing the position of voxel 
of acquisition and centre of the 31P coil. The voxel is positioned such that it remains 
completely within the myocardium and as close as possible to the center of 31P coil. 
 
 
 
 
 
 
Voxel of acquisition 
Centre of the 31P coil 
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Feasibility and reproducibility testing  
37 Controls (22-males) and 26 HCM patients (21-males) with symptomatic non-obstructive 
cardiomyopathy who provided written informed consent, were included in the study.  The 
experiment was approved by the Regional Ethics Committee at Birmingham, UK.  All healthy 
volunteers were screened with history, echocardiography and metabolic exercise testing to 
rule out any structural heart diseases. All patients were recruited from cardiomyopathy clinics 
and had clinically proven diagnosis of non-obstructive HCM. The subject characteristics are 
presented in table 3.1. The mean age of the healthy volunteers was 48 ± 16 years and that of 
HCM patients was 55±13 (P=ns).  The mean EF on echocardiography was 64±6% in controls 
and 64±9% (P=ns) in HCM patients. None of the healthy volunteers had any structural heart 
disease or ECG abnormalities. 31P cardiac spectroscopy was performed eight times in one 
participant both - on the same and on different days - to test the reproducibility and coefficient 
of variation of the test. As a further test of reproducibility and validation in our department 
MRS was repeated twice in twelve healthy volunteers (Mean age 28±10 years).  
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Table 3.1:  Baseline characteristics in controls as compared with HCM patients. Results 
expressed as mean ± standard deviation 
Parameter Controls 
(N=37) 
HCM 
(N=26) 
P Value* 
Age 48 ± 16 55 ± 13 ns 
Male sex –no (%) 22 (59) 21 (81) ns 
EF (%) 64 ± 6 64 ± 9 ns 
VO2 max 39 ± 8 24 ± 6 <0.0001 
RER 1.2 ± 0.2 1.1 ± 0.1 ns 
Heart rate 79.5 ± 11.7 67.5 ± 12.5 <0.01 
QTc interval 421.8 ± 16.0 455.9 ± 35.0 <0.01 
Systolic Blood Pressure 127.0 ± 20.4 126.1 ± 20.1 ns 
Diastolic Blood Pressure  79.5 ± 9.6 75.6 ± 10.7 ns 
 
* P <0.05 considered as statistically significant. 
EF- Ejection Fraction, VO2 max- Maximal oxygen consumption at peak exercise, RER – 
Respiratory exchange ratio, QTc- Corrected QT interval. 
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Analysis 
The spectra were analysed and quantified on jMRUI software using AMARES a time domain 
fitting program 271. Post-processing was performed with 15Hz Gaussian line broadening and 
Fourier transformation. Phase correction was performed with PCr peak as the reference peak. 
Quantification was performed with AMARES using a prior knowledge file to preselect the 
peaks. The concentrations of PCr, ATP and 2,3-DPG were calculated as the area under the 
peaks. Cramer Rao lower bounds 36 were then calculated. PCr/ATP ratio was determined after 
correcting the ATP peak for blood contamination as described previously 46.  
 
Results 
A typical cardiac spectrum in a healthy volunteer as compared to a patient with HCM is 
shown in Figure 3.3.  The PCr/ATP ratio was significantly lower in HCM (1.42 ± 0.51) as 
compared to HC (2.11 ± 0.57, P<0.0001) (Figure 3.4). The mean PCr/ATP ratio for the one 
participant with eight measurements was 2.11 ± 0.25 (Table 3.2). Bland Altman plots were 
used as a test of reproducibility. The distribution of all the data points showed good 
reproducibility with a variance of 12% in the measurement of PCr/ATP ratios which is within 
limits of agreement of repeated measurements. We also measured the line width of PCr peaks 
in the one participant who had 8 repeated scans. The mean line width was 1.36 + 0.07 ppm 
(Figure 3.5). The standard deviation of the line width was low which again confirmed the fact 
that the spectra were of good reproducible quality. As a further measure of the quality of 
spectra we calculated the Cramer Rao lower bounds 36, which was 6 ± 1% for the PCr peak 
and 10 ± 1% for the gamma ATP peak. Cramer Rao lower bounds were calculated for the 
whole group, which was 12 ± 6% for the PCr peak and 17 ± 9% for the gamma ATP peak 
(Table 3.4). 
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The MRS was repeated twice in twelve heathy volunteers to further test the variability of 
PCr/ATP ratio. Bland Altman plots demonstrated a variability of 0.13±0.52 (bias ± 1.96SD) 
with mean PCr/ATP ratio of 1.7±0.3 and 1.6±0.3. Cramer Rao lower bounds were calculated 
at 6 ± 3% for the PCr peak and 10 ± 3% for the gamma ATP peak. Due to an increase of 
susceptibility differences between heart muscle tissue, blood and air in the lungs at high field 
strength shim quality was slightly decreased at 3T in comparison to values reported for 1.5T 
cardiac spectroscopy. Hence multiplet splitting of the ATP resonances due to J-coupling is 
hardly visible. 
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Table 3.2: Table depicting the concentrations of 2,3-DPG, ATP and PCr and the calculated 
PCr/ATP ratios from these measurements in the subject with eight measurements. 
 
Subject No 
2,3 DPG 
sum 
PCr Gamma 
ATP 
Gamma 
ATP (C) 
PCr/Ga
mma 
ATP 
Ratio 
PCr/Gamm
a ATP 
Ratio (C) 
Subject 1A 6.72E-04 4.90E-04 3.57E-04 2.45 E-04 1.37 2.00 
Subject 1B 4.27E-04 4.32E-04 3.21E-04 2.5 E-04 1.34 1.72 
Subject 1C 7.32E-04 6.53E-04 4.77E-04 3.55 E-04 1.36 1.83 
Subject 1D 1.00E-03 8.52E-04 5.12E-04 3.45 E-04 1.66 2.47 
Subject 1E 9.39E-04 5.53E-04 3.86E-04 2.3 E-04 1.43 2.40 
Subject 1F 8.29E-04 6.34E-04 4.26E-04 2.88 E-04 1.48 2.20 
Subject 1G 8.66E-04 5.36E-04 3.90E-04 2.46 E-04 1.37 2.18 
Subject 1H 8.32E-04 5.55E-04 4.05E-04 2.66 E-04 1.37 2.08 
 
PCr- Phosphocreatine; 2,3-DPG- 2,3 Diphosphoglycerate; ATP- Adenosine triphosphate; (C)- 
Corrected for blood contamination 
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Table 3.3: Table depicting the concentrations of 2,3-DPG, ATP and PCr and the 
calculated PCr/ATP ratios from these measurements in controls and HCM patients. 
Results expressed as mean ± strandard deviation 
 
 Controls HCM 
2,3 DPG sum 9.20E-04 ± 3.40E-04 5.40E-04 ± 1.70E-04 
PCr 6.80E-04 ± 4.80E-04 6.00E-04 ± 2.20E-04 
Gamma ATP 4.80E-04 ± 1.80E-04 5.40E-04 ± 1.50E-04 
Gamma ATP (C) 3.23E-04 ± 1.40E-04 4.20E-04 ± 1.40E-04 
PCr/Gamma ATP Ratio 1.30 ± 0.30 1.1 ± 0.32 
PCr/Gamma ATP Ratio (C) 2.11 ± 0.57 1.42 ± 0.51 
 
PCr- Phosphocreatine; 2,3-DPG- 2,3 Diphosphoglycerate; ATP- Adenosine triphosphate; (C)- 
Corrected for blood contamination 
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Table 3.4:  Cramer Rao Lower bounds measured to test the quality of spectra 
 PCr peak Gamma ATP Peak 
Healthy control (8 Measurements) 6% ± 1 10% ± 1 
Whole group( Controls + HCM) 12% ± 6 17% ± 9 
Controls 11% ± 5 16% ± 8 
HCM 12% ± 6 17% ± 9 
 
PCr- Phosphocreatine; ATP- Adenosine triphosphate 
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Figure 3.3 
 
Typical cardiac spectra in a control and a patient with HCM 
 
PCr- Phosphocreatine; 2,3-DPG- 2,3 Diphosphoglycerate;  PDE - Phosphodiesters; ATP - 
Adenosine triphosphate. 
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Figure 3.4 
 
 
Figure 3.3: Box-plots of PCr/ATP ratios in con 
Box-plots of PCr/ATP ratios in controls and HCM patients  
 
 
 
 
 
 
 
P<0.0001 
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Figure 3.5   
 
 
 
Line width of PCr peaks from the healthy volunteer who had 8 repeated scans expressed 
as parts per million (ppm) 
 
 
 
 
 
 
 
 
 
 
 
Line width: 1.3625+ 0.072 ppm (Mean + SEM) 
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Discussion 
Here we demonstrate that in-vivo cardiac 31P MRS at 3T is a reliable method of measuring 
high energy phosphate kinetics in the myocardium. We also show reduced PCr/ATP ratio in 
HCM patients known to have impaired cardiac energetics as measured in 1.5T systems 47;107. 
The spectra show good reproducibility indicating that 31P cardiac MR spectroscopy is feasible 
on a clinical 3T MR system. The standard deviation for the PCr/ATP ratio for the whole 
group was low and comparable to previous published data on cardiac spectroscopy at 1.5 
Tesla 159. This basic method of acquiring 31P spectra at 3T using pre-implemented methods 
such as ISIS volume localisation and iterative shimming promises to be an important 
diagnostic and research tool. Possible applications are the comparison of PCr/ATP ratios in 
conditions like heart failure, ischaemic heart disease and valvular heart disease. It might also 
be used to monitor disease progression and study effects of medications like metabolic 
modulators in heart disease.  
 
Cardiac spectroscopy at 3T continues to face some challenges which are present at 1.5T as 
well, but some of them are even more pronounced at high field strength. One major drawback 
of cardiac spectroscopy is the effect of respiratory motion and movement of the heart itself. 
This can result in contamination from liver and skeletal muscle of the chest wall. Careful 
localization of the voxel ensures minimal contamination. We particularly paid attention to this 
aspect while planning our voxel of acquisition. Provided the voxel is positioned carefully, no 
significant advantages to the quality of spectra acquired with multiple outer volume 
suppression bands was observed.  None of our spectra show any significant contamination 
with skeletal muscle or liver. It is also important to ensure that the spectral acquisition is done 
when the heart motion is at its minimum. This is during diastole and we set the TD such that 
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all of the spectral acquisition happened during diastole. One other problem is the respiratory 
motion. This could be partially negated by acquiring the spectra with respiratory gating as 
well as cardiac gating (double triggered) and volume tracking 127;219. Further developments in 
these techniques should improve quality of cardiac spectra and reduce the contamination from 
surrounding structures. 
 
Higher field strength of 3T offers better spatial resolution and SNR. These effects have been 
particularly noted in proton spectroscopy of the human brain 17. However, increasing 
susceptibility differences between muscle tissue, blood and air in the lungs cause increased B0 
field inhomogeneities and hence problems with shim convergence. Various shimming 
techniques like iterative and FASTMAP based 78 higher order shimming were compared. 
Localized iterative 1st order shimming based on a volume including the entire heart offered 
the best and most reproducible shim quality. However, there is definitely scope for further 
improvement in shimming techniques. One possibility might be localized shimming based on 
cardiac triggered B0-mapping as reported earlier for cardiac imaging at 3T 
220. Another 
problem is the shortened transverse relaxation times (T2) at 3T in comparison to 1.5T. This 
causes an additional increase in line width of the various peaks. 
 
No significant advantages to the quality of spectral acquisition using proton decoupling or 
NOE were found. Therefore these techniques were not used. Although NOE can increase the 
SNR by up to 40%, this is not useful for experiments in which quantification is required. NOE 
in particular imparts different amounts of energy to phosphates in ATP and PCr which can 
result in altered PCr/ATP ratio. This is particularly important as the effect of NOE is different 
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for distinct molecules and depends on conditions as the pH which might be changed in the 
diseased myocardium.  
 
Due to a decrease of the maximum achievable B1 field strength at 3T together with an 
increase in spectral separation compared to 1.5T, the bandwidth of the excitation pulse was 
limited and hardly sufficient to excite the entire frequency range of interest. Using a simple 
surface coil this is especially a problem in large penetration depth. In addition, the excitation 
profile was not homogeneous. Hence different flip angles were applied to spins with different 
offset frequencies. This resulted in a frequency-dependent weighting of peak intensities. 
Hence, the intensity of the beta ATP peak, which has a large frequency offset compared to 
PCr, was always significantly decreased (Figure 3.3) or even lost in obese subjects, where the 
distance between coil and VOI is large. However the determined PCr/ γ ATP ratios were not 
affected, because the frequency difference between the two resonances is small and the pulse 
frequency offset was chosen to be between the two.  
 
Conclusions 
31P MRS of the myocardium at 3T is feasible and allows reliable determination of high energy 
phosphate kinetics. Our reproducibility data suggests that the suggested method is robust and 
might be used for clinical diagnostic studies as well as for clinical experimental studies. 
However, to take full advantage of increased SNR and spectral separation at 3T, advances in 
shimming, coil and RF pulse design are necessary.  
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CHAPTER FOUR 
 
 
THE RELATIONSHIP BETWEEN CORONARY MICROVASCULAR 
DYSFUNCTION AND CARDIAC ENERGETIC IMPAIRMENT IN 
TYPE 1 DIABETES 
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Abstract 
Background: Asymptomatic subjects with diabetes have impaired cardiac energetic status 
that may play a significant role in development of heart failure. In this study we assessed the 
role of microvascular dysfunction in the development of impaired cardiac energetics in 
subjects with T1DM. 
Methods: 25 asymptomatic subjects with T1DM (mean ± SD, age 33 ± 8 yr) and 26 age, sex 
and body mass index matched HC (age 32 ± 8 yr) were recruited into the study. The T1DM 
subjects were divided into two age matched groups: newly (<5 yr) diagnosed and longer 
duration (>10 yr) diabetes to assess the impact of microvascular disease. All subjects 
underwent echocardiogram and exercise ECG followed by MRS and stress MRI.  
Results: The PCr/ γ ATP ratio was significantly reduced as compared to HC in both longer 
term (2.1±0.5 vs 1.5±0.4, P<0.001) and newly diagnosed subjects (2.1±0.5 vs 1.6±0.2, 
P<0.001). The PCr/ γ ATP ratio was similar in newly diagnosed diabetes subjects as 
compared to longer term (1.6±0.2 vs.1.5±0.4 P=0.44). The mean MPRI assessed by stress 
MRI in the longer term T1DM subjects was significantly lower than in HC (1.7±0.6 vs 
2.3±0.4, P<0.05). On univariate analysis, there was no significant correlation of PCr/ γATP 
ratio with MPRI (r=0.21, P=0.26). 
Conclusions: We demonstrate that young subjects with uncomplicated T1DM have impaired 
myocardial energetics irrespective of duration of diabetes and that the impaired cardiac 
energetics is independent of coronary microvascular function. We postulate that impairment 
of cardiac energetics in these subjects primarily results from metabolic dysfunction rather 
than microvascular impairment.  
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Background  
Diabetes is a metabolic disorder characterized by hyperglycaemia and dyslipidaemia. The 
prevalence of diabetes is rapidly increasing throughout the western world 59;266;282. Heart 
failure occurs more frequently in diabetes 109 and is commonly due to epicardial CAD and/or 
hypertension 101;126;250. There is a markedly increased mortality associated with CAD and 
heart failure in patients with T1DM 264. However in some patients, LV dysfunction occurs in 
the absence of significant epicardial CAD or hypertension 214. This indicates that diabetes 
may have a direct effect on the heart, which can contribute to the development of LV 
dysfunction. The impact of diabetes on the heart could occur via various mechanisms 
including unrecognized hypertension, large vessel and microvascular disease, energetic 
impairment, autonomic neuropathy and oxidant stress. Asymptomatic subjects with T2DM 
have impaired cardiac energetic status as reflected in a reduced PCr/ γ ATP ratio on cardiac 
MRS 221. Impairment of cardiac energetic status has the potential to play a significant role in 
the development of contractile dysfunction. Whilst microvascular ischaemia may potentially 
be contributory to energetic impairment, a primary disturbance of energetic status that is 
unrelated to ischaemia and due to the metabolic effects of diabetes, is also likely. 
 
 Thus, the primary aim of the study was to confirm the presence of cardiac energetic 
impairment in uncomplicated T1DM and to establish its relationship to coronary 
microvascular dysfunction. For this we recruited a cohort of young healthy T1DM subjects 
with no history of hypertension, primary hyperlipidemia, renal disease or coronary heart 
disease. In order to tease out the potential patho-physiological mechanisms in the 
development of cardiac energetic impairment we studied two age matched groups of T1DM 
subjects. The first group (newly diagnosed T1DM) were diagnosed for less than 5 years and 
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hence unlikely to have microvascular disease; the second group (longer term) was diagnosed 
for more than 10 years and were thus likely to have a certain degree of microvascular 
dysfunction. We used MRS to determine cardiac energetic status and used stress MRI to 
compute MPRI which is a measure of coronary microvascular function. 
 
Methods  
51 subjects who met the inclusion criteria and provided informed consent were recruited from 
the Heart of England NHS Foundation Trust and University Hospital Birmingham NHS Trust, 
Birmingham, UK. HC were recruited by general advertisements in the University of 
Birmingham and in blood banks. All the investigations were undertaken in the University of 
Birmingham and the project was approved by Multicenter Regional Ethics Committee in 
Birmingham. 
 
Subjects 
We recruited 25 subjects with T1DM (WHO definition) without a history of chest pain or 
breathlessness. All patients had no evidence of coronary heart disease or heart failure based 
on history, 12 lead ECG, a normal EF on echocardiography and metabolic exercise testing.  
Subjects were divided into predefined subgroups (age matched) based on duration of their 
diabetes as defined above: Newly diagnosed (10 subjects, age 32±10y) and longer term (15 
subjects, age 33±6y). 
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Healthy Controls 
26 age, sex and body mass index matched controls with no cardiac history or diabetes mellitus 
were recruited. All HC had a normal 12 lead ECG, echocardiogram and metabolic exercise 
test. 
 
Subjects fasted overnight and blood samples were taken on the morning of the study. After 
this, a light breakfast was given and patients were allowed to take their morning dose of 
insulin. Following this, subjects underwent cardiac stress MRI, cardiac MRS, 
echocardiography and metabolic exercise testing as described in the chapter 2 (Methods). 
Stress MRI was done only in a subgroup of HC (8 subjects). 
 
Analysis 
 
MRS 
The spectra were analysed and quantified on jMRUI software using AMARES a time domain 
fitting program 271. Post-processing was performed with 15Hz Gaussian line broadening and 
Fourier transformation. Phase correction was performed with PCr peak as the reference peak. 
Quantification was performed with AMARES using a prior knowledge file to preselect the 
peaks. The concentrations of PCr, ATP and 2,3-DPG were calculated as the area under the 
peaks. PCr/ γATP ratio was determined after correcting the ATP peak for blood 
contamination as described previously 46. We have previously published the reproducibility 
data in HC 236. The MRS was repeated twice in five diabetes patients to test the variability of 
PCr/ γATP ratio. Bland Altman plots demonstrated a variability of 0.13±0.28 (bias ± 1.96SD) 
with mean PCr/ATP ratio of 1.6 and 1.5.   The quality (SNR) of spectra in all subjects were 
further assessed by Cramer Rao lower bounds and were 8±4% for PCr peak and 11±4% for 
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the γATP peak in the control population and 8±2% for PCr peak and 11±3 for γATP peak in 
the patient population. These figures indicate that the spectra are of good quality and suggest 
good reproducibility of PCr/ γATP ratios in both HC and patients in our current study. 
 
MPRI 
MPRI which is a measure of coronary microvascular function was computed from the stress 
MRI images. The images were analyzed on the Viewforum software version 5.0. Initially 
image alignment was done to reduce the motion of the heart in different cardiac cycles. 
Following this the endocardial and epicardial borders were traced and propagated throughout 
all the images. A sample volume was placed in the LV cavity as comparison for signal 
intensity of blood. Signal intensity curves were obtained from the software and the peak 
upslope of the LV myocardial illumination was computed in relation to the LV cavity 
illumination. A similar analysis was done on all three short axis images at rest and peak stress. 
The MPRI was obtained from the ratio of LV relative peak upslope at stress compared to rest. 
 
Statistics 
All continuous variables are expressed as mean ± SD. Comparison between means was 
performed using unpaired Student T-tests. Categorical variables were compared with Pearson 
Chi-Square test. For comparison of variables when the diabetes patients were subdivided, one 
way ANOVA was used. A P value of <0.05 was considered to indicate statistical significance. 
Variances of data sets were determined using F-test. Pearson correlation coefficient (r) was 
used to describe the relationship between variables. SPSS (v15.0) was used to perform the 
statistical operations.  
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Results  
The baseline characteristics and results are summarized in Table 4.1. The LVEF was 61.4±5% 
in HC, 60±2% in the longer term diabetes subjects and 62±6% in the newly diagnosed 
subjects, with no significant difference between the three groups. In the HC the E/A ratio was 
1.7±0.6, the IVRT was 73±12 msec and the E/E’ was 4.9±1.3. The corresponding values in 
longer term T1DM subjects were 1.3±0.3, 69±9 msec and 5.3±1.2 and in the newly diagnosed 
subjects were 1.7±0.7, 76±15 msec and 5.5±1. All of these diastolic parameters were within 
the normal range with no statistical difference between the subject groups. 
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Table 4.1  
Variable Newly diagnosed 
T1DM 
Longer term 
T1DM 
HC  
Number 10 15 26 
Age, years 32±10 33±6 32±8 
Male Gender (%) 8 (80) 10 (66) 18(69) 
Duration of diabetes 3.5±3 18±7 - 
HbA1C, % 7.4±0.8† 8.3±1 - 
BMI, Kg/m2 23±2 26±3 25±3 
Total cholesterol, mmol/L 4.3±1.2 4.4±0.7 4.9±0.9 
HDL, mmol/L 1.5±0.3 1.7±0.5 1.7±0.6 
Triglycerides, mmol/L 1.3±1.2 1.1±0.8 1±0.5 
Free fatty acids, mmol/L 0.32±0.22 0.28±0.13 0.23±0.1 
VO2 max, ml/kg/min 42.6±10.2 35.6±8.4* 44.1±7.2 
PCr/γATP ratio 1.6±0.2 * 1.5±0.4* 2.1±0.5 
MPRI 2.1±0.2 1.7±0.6* 2.3±0.4 
Microalbuminuria, % 0 4(27) - 
Retinopathy, % 3(30) †  10(66) - 
 
Baseline characteristics and results in both groups of T1DM patients as compared with 
HC 
 
* Significant difference as compared with HC 
†Significant difference as compared to longer term diabetes subjects 
 
BMI; Body mass index, VO2 max; Peak oxygen consumption, PCr/γATP ratio; 
Phosphocreatine/ gamma adenosine triphosphate, MPRI; Myocardial perfusion reserve index 
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MRS 
Typical cardiac spectra in T1DM and HC are shown in figure 4.1. The PCr/ γATP ratio was 
significantly reduced as compared to HC in both longer term (2.1±0.5 vs 1.5±0.4, P<0.001) 
and newly diagnosed diabetes (2.1±0.5 vs 1.6±0.2, P<0.001). The PCr/ γATP ratio was 
similar in newly diagnosed diabetes as compared to long term diabetes subjects (1.6±0.2 vs 
1.5±0.4, P=0.44). When the subject groups were divided by retinopathy status (obtained using 
retinal photography) the subjects with retinopathy (9-background retinopathy, 2-proliferative 
retinopathy and 2-maculopathy) had similar PCr/ γATP ratio as compared with those without 
retinopathy (1.4±0.4 vs 1.6±0.4, P=0.62) (Table 4.2).  
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 Table 4.2  
 
 
Cardiac energetics in subgroups of subjects with various complications (retinopathy and 
coronary microvascular disease). 
 
* Significant difference as compared with HC 
 
PCr/γATP ratio; Phosphocreatine/ gamma adenosine triphosphate, MPRI; Myocardial 
perfusion reserve index 
 
 
 
 
 
 
Variable Complications 
absent 
Complications 
present 
HC 
Retinopathy 
PCr/γATP ratio  1.6±0.4* 1.4±0.4* 2.1±0.5 
MPRI 
PCr/γATP ratio 1.6±0.4* 1.4±0.2* 2.1±0.5 
  
88 
 
Figure 4.1  
 
 
 
 
 
 
Typical spectra in T1DM and HC.  
 
2,3 DPG: 2,3 Diphospho-glycerate, PCr: Phosphocreatine, ATP: Adenosine triphosphate 
 
PCr 
ATP 2, 3 DPG 
ATP 
PCr 
2, 3 DPG 
Typical spectra in HC Typical spectra in T1DM 
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MPRI 
The mean MPRI in the longer term T1DM group was significantly lower than in HC (1.7±0.6 
vs 2.3±0.4, P<0.05). The MPRI in newly diagnosed T1DM was not significantly different 
than in longer term (1.7±0.6 vs 2.1±0.2, P=0.13) or HC. When the subject groups were 
divided into those with and without coronary microvascular dysfunction (MPRI of 1.5 was 
considered to be the lower limit of normal - 2 standard deviations below the mean for HC), 
the patients with and without coronary microvascular dysfunction had similar PCr/ γATP ratio 
(1.4±0.2 vs 1.6±0.4, P=0.64) (Table 4.2). However, those with coronary microvascular 
dysfunction (1.4±0.2 vs 2.1±0.5, P<0.01) and without coronary microvascular dysfunction 
(1.6±0.4 vs 2.1±0.5, P<0.01) had significantly lower PCr/ γATP ratio as compared to HC.  
 
Correlation 
On univariate analysis there was no significant correlation of the PCr/ γATP ratio with MPRI 
(r=0.21, P=0.26), the HbA1c (r=-0.27, P<0.05), FFA (r=-0.11, P=0.45) or triglycerides 
(r=0.09, P=0.54). 
 
Discussion  
In this study we have shown that cardiac energetics as determined by PCr/ γATP ratio is 
reduced in uncomplicated young T1DM subjects in the absence of ischaemic heart disease, 
irrespective of the duration of diabetes or presence of coronary microvascular dysfunction or 
other microvascular disease (retinopathy or nephropathy). As cardiac energetics did not 
correlate with coronary microvascular dysfunction, this suggests a primary metabolic role in 
the development of impaired energetics in these individuals. 
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Previous studies have demonstrated altered cardiac energetics in asymptomatic T1DM 160 and 
T2DM patients 57;221. Our findings confirm their results. However in this study we have 
extended their findings by exploring the potential pathophysiology of this deficit. Subjects 
were characterized for the presence of macro and microvascular disease by exercise testing 
and stress MRI (and by history of nephropathy/retinopathy). This is important as CAD is, in 
itself, a cause of impaired cardiac energetic status 284 and diabetes patients in particular have a 
high incidence of asymptomatic CAD 175. 
 
It has been demonstrated previously that impaired cardiac energetics play a key 
pathophysiological role in the development of heart failure and that the energetic abnormality 
usually precedes the onset of contractile dysfunction 7;234. But, the key underlying 
mechanisms for this energetic impairment are not well known. Diabetes is associated with 
decreased glucose transport, glycolysis and oxidation 141. The reduced uptake of glucose via 
GLUT4 receptors decreases the availability of glucose in the myocardium 243. In normal 
hearts, 60-90% of the energy is derived from fatty acid oxidation. In diabetes this can increase 
to 90-100% 140. The increased utilization of FFA to generate energy is demonstrated in PET 
studies 88. Increased FFA usage has a greater oxygen cost, which is in part attributable to 
stoichiometry but also possibly due to increased mitochondrial uncoupling 225 and wasteful 
cycling of FFAs through intramyocardial lipolysis and esterification 91;209. In type1 diabetes, a 
recent PET study demonstrated reduced cardiac glucose uptake and utilisation and markedly 
increased FFA uptake and utilisation 88. In our study there was a nonsignificant trend towards 
increased plasma FFA in the diabetes subjects (0.3±0.18 vs 0.23±0.11, P=0.07). This 
increased FFA in the plasma coupled with increased FFA uptake could be an important factor 
resulting in impairment of cardiac energetics.  
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Increased FFA uptake results in lipid accumulation in spite of the increased FFA oxidation 29. 
Lipid accumulation can worsen the myocardial insulin resistance which in turn worsens 
glucose uptake 188. Also increased FFA oxidation produces more ROS which can oxidize 
lipids and proteins resulting in cell damage. ROS impairs mitochondrial coupling resulting in 
decrease in ATP production 86. 
 
Myocardial energetic impairment might also occur secondary to ischaemia caused by 
microvascular disease. It is well known that development of microvascular disease is directly 
related to diabetes duration and glycaemic control in T1DM. Indeed the longer term T1DM 
subjects in our study had a lower MPRI as compared to HC. However, the study was not 
powered to detect significant difference in MPRI between longer term T1DM and newly 
diagnosed T1DM subjects. MPRI is a good indicator of coronary microvascular function. Our 
study demonstrates a lack of association between coronary microvascular dysfunction and 
energetic impairment. Moreover, cardiac energetic impairment was present even in the newly 
diagnosed diabetes patients (although to a slightly lesser degree) implicating metabolic 
impairment as the probable important mechanism.  Hence microvascular disease does not 
appear to account for the development of cardiac energetic impairment in diabetes. 
 
Previous studies in T2DM have demonstrated that impaired cardiac energetics may contribute 
to the development of diastolic dysfunction in these subjects 57. In our study we demonstrate 
that impaired cardiac energetics is present even in the newly diagnosed diabetes patients. This 
substantiates the fact that energetic impairment precedes onset of contractile dysfunction as 
shown in previous animal studies 234.  
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Interestingly, we found that there was a significantly lower VO2 max in the longer term 
T1DM as compared to newly diagnosed T1DM and HC (Table 4.1). Previous studies have 
shown that reduced exercise capacity in T2DM is related to subclinical LV dysfunction, 
diabetes control and heart rate recovery 62. In our study most of the T1DM subjects had 
impaired cardiac energetics. But the myocardial perfusion was impaired only in the longer 
term subjects. It is therefore tempting to speculate that a combination of energetic and 
perfusion abnormalities could result in reduced VO2 max in the longer term T1DM subjects. 
Skeletal muscle perfusion abnormalities could also contribute to the reduced exercise capacity, 
although this was not measured in the current study. 
 
Clinical implications 
Development of heart failure in diabetes is a complex process and is affected by many 
secondary factors like hypertension, CAD renal disease and hyperlipidemia. In this study we 
have demonstrated cardiac energetic impairment in uncomplicated diabetes indicating that 
diabetes has a direct effect on the myocardium. This impairment occurs early in the disease 
process and intervention at this stage to improve the myocardial energetic status may be an 
important method of reducing cardiovascular complications.  Metabolic modulation has 
assumed importance recently in the management of patients with CAD and heart failure 5;6. 
Since subjects with diabetes have a metabolic profile similar to these patients, metabolic 
agents could potentially be used to prevent heart failure in diabetes. However, large scale 
studies are required to substantiate this. Alternatively, intensive metabolic control early in 
T1DM may be able to achieve long term benefits in reducing cardiovascular complications 174.  
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Study Limitations 
The principal limitation of the study was the small sample size of the study population. 
Additionally, this was a cross-sectional study which therefore gives no information on the 
ultimate outcome of these subclinical deficits. 
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CHAPTER FIVE 
 
 
INCREASED LEFT VENTRICULAR TORSION IN 
UNCOMPLICATED TYPE 1 DIABETES: THE ROLE OF 
CORONARY MICROVASCULAR FUNCTION AND ROTATIONAL 
DEFORMATION DELAY 
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Abstract 
Background: Heart failure is a common cause of morbidity and mortality in diabetes. The 
early manifestations of diabetic cardiomyopathy are however not well established. LV torsion 
followed by untwisting during diastole is an important component that affects LV filling. We 
used STE to study the early changes in LV torsion in patients with uncomplicated T1DM and 
used stress MRI to assess its interrelationships with coronary microangiopathy. 
Methods: 33 asymptomatic subjects with T1DM and 32 age-matched HC were recruited into 
the study. The T1DM subjects were divided into two age matched groups: newly diagnosed 
and longer duration diabetes to assess the impact of microvascular disease. All subjects 
underwent echocardiogram and metabolic exercise testing. Stress MRI was performed in 28 
subjects (6 HC) to compute MPRI, a measure of coronary microvascular function. LV rotation 
measurements were made using a speckle tracking system.  
Results: Peak LV torsion was significantly increased in the T1DM as compared to HC 
(1.9±0.6 vs 1.4±0.7, P<0.01). The mean MPRI in T1DM was 1.9±0.5 significantly lower than 
in HC (2.3±0.4, P<0.05). On multivariate regression analysis, rotational deformation delay 
(r=-0.48, P<0.05) and MPRI (r=-0.44, P<0.05) were independent predictors of LV torsion. 
Conclusion: We demonstrate for the first time using speckle tracking that LV torsion is 
increased in young patients with uncomplicated T1DM. This may represent a myocardial 
compensatory mechanism to maintain EF during the early stages of diabetic cardiomyopathy. 
MPRI predicted LV torsion in T1DM subjects implicating a role for microvascular disease in 
the development of increased torsion in these individuals.   
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Background 
Diabetes is a metabolic disorder associated with increased incidence of heart failure. There is 
a high incidence of mortality associated with CAD and heart failure in patients with T1DM 264. 
However in some patients, LV dysfunction occurs in the absence of significant epicardial 
CAD or hypertension 214 indicating that diabetes contributes towards the development of LV 
dysfunction. Microvascular disease occurs frequently in subjects with both T1DM as well as 
T2DM  and is related to duration of diabetes and to antecedent glycaemic control 1;122;173;206. It 
results in both ischaemia and increased capillary permeability, both of which may be involved 
in the pathogenesis of diabetic heart failure 149. Previous studies have demonstrated a reduced 
coronary flow reserve in asymptomatic T1DM and T2DM as compared to HC 55, which is a 
measure of microvascular function in the heart (in the absence of epicardial CAD). Presence 
of microvascular disease in the form of nephropathy or retinopathy is associated with high 
mortality in diabetic heart disease 264. 
Although there is increasing evidence for the presence of diabetic cardiomyopathy as a 
separate entity, detection of early changes in the myocardium is challenging in patients with 
diabetes. Previous studies with 2D and tissue doppler echocardiography have demonstrated 
abnormalities in various diastolic parameters prior to the onset of overt systolic dysfunction. 
The trans-mitral pulsed wave doppler demonstrates abnormalities in mitral inflow velocity, 
DecT, IVRT and filling patterns 196. However these measurements are load dependent and can 
alter depending on LA pressures. TDI is a relatively load independent method of deriving 
mitral annular velocities. Previous studies in subjects with both T1DM and T2DM have 
demonstrated a reduction in long axis function indicated by reduced S and E’ wave velocity in 
the presence of normal EF 61;275. However tissue doppler is not without limitations including 
its angle dependency. It relies on aligning the probe in line with the motion of the 
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myocardium.  STE is a novel angle independent method of measuring LV strain and strain 
rates 58. The added advantage is that we are now able to measure LV rotation for the first time 
with grey scale 2D images 85. In order to assess early changes in the diabetic myocardium, we 
used speckle tracking to measure LV torsion, strain and strain rates in young patients with 
uncomplicated T1DM and compared it with age and sex matched controls.  
 
In order to assess the impact of hyperglycaemia per se on the myocardium we chose cohorts 
of young subjects with T1DM and healthy non-diabetic controls without a history of 
hypertension, primary hyperlipidemia, peripheral vascular disease, CAD, cerebrovascular 
disease or renal disease. In order to assess the impact of coronary microvascular dysfunction 
on the development of LV dysfunction we recruited two predefined subgroups of T1DM 
subjects. The first group (newly diagnosed T1DM) was diagnosed for less than 5 years and 
hence unlikely to have microvascular disease; the second group (long term) was diagnosed 
more than 10 years previously and were thus likely to have a certain degree of microvascular 
dysfunction. These two diabetic groups were age matched. We used stress MRI to compute 
MPRI which is a measure of coronary microvascular function.  
 
Methods  
65 subjects who met the inclusion criteria and provided informed consent were recruited from 
the Heart of England NHS Foundation Trust and University Hospital Birmingham NHS Trust, 
Birmingham, UK. HC were recruited by general adverts in the University of Birmingham and 
blood banks. All the investigations were undertaken in the University of Birmingham and the 
project was approved by Multicenter Regional Ethics Committee in Birmingham. 
 
  
99 
 
Patients 
We recruited 33 subjects with T1DM (WHO definition) without a history of chest pain or 
breathlessness. All patients had no evidence of CAD or heart failure based on history, 12 lead 
ECG, a normal EF on echocardiography and metabolic exercise testing.  Subjects were 
divided into predefined subgroups (age matched) based on duration of their diabetes as 
defined above: Newly diagnosed (13 patients [10 male], age 31±10y) and long term (20 
patients [12 male], age 34±6y). The mean HbA1c and duration of diabetes was 7.4±0.8% and 
3.2±2.6y in the newly diagnosed and it was 8.3±1% (P<0.05) and 18.4±6.9y correspondingly 
in the long term diabetes patients. 
 
Healthy Controls 
32 age and sex matched controls with no cardiac history or diabetes mellitus were recruited. 
All HC had a normal 12 lead ECG, echocardiogram and metabolic exercise test. 
 
The subjects underwent echocardiography, metabolic exercise testing and stress MRI as 
described in chapter 2 (Methods)  
 
Analysis 
Speckle Tracking Echocardiography 
Myocardial deformation was measured using a commercially available speckle tracking 
system in an ECHOPAC (version 4.2.0) workstation. In this system, the displacement of 
speckles of myocardium in each spot were analyzed and tracked from frame to frame.  We 
selected the best-quality digital two-dimensional image and the LV endocardium was traced 
at end-systole.  The region of interest width was adjusted as required to fit the wall thickness.  
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The software package then automatically tracked the motion through the rest of the cardiac 
cycle.  The onset of QRS complex was taken as the beginning of systole. Adequate tracking 
was verified in real time.  The global longitudinal and transverse strain and strain rates were 
derived from an average of the 12 segments from the 4 and 2 chamber views (6 segments in 
each view). Similarly an 18 segment model was computed from the short axis views at mitral, 
papillary and apical levels. The average of measurements from each of the segments was used 
to derive global circumferential and radial strain and strain rates. In addition, LV rotation was 
computed using speckle tracking. Counter-clockwise rotation was marked as a positive value 
and clockwise rotation as a negative value when viewed from the apex. In order to calculate 
LV torsion, torsion rate and untwist rates, the rotation traces of the basal and apical LV cross-
sections were exported into DPlot graph software (Version 2.2.1.4, HydeSoft Computing, 
LLC, Vicksburg, USA). The LV twist curve was generated by calculating the difference 
between apical and basal rotations at each corresponding time point (Figure 5.1). LV twist 
rates were derived from the first derivative of the LV twist curve. Peak LV torsion was 
derived from LV twist divided by LV diastolic longitudinal length. Rotational deformation 
delay was also determined and defined as the magnitude of the time difference between time 
to peak basal rotation and time to peak apical rotation. Of the 65 subjects in the study, 61 
(94%) subjects had both adequate LV basal and apical images for speckle tracking allowing 
complete analysis of all LV rotational parameters.  
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Figure 5.1  
 
 
 
Typical torsion curves in HC and T1DM. 
HC- healthy control, T1DM – type 1 diabetes mellitus 
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Reproducibility of STE 
 
Reproducibility of STE was determined within our department using a randomly selected 
group of 10 controls. Inter-observer measurement variability was determined by two 
independent observers who measured LV torsion in the 10 controls. To obtain the intra-
observer variability, the first observer performed the analysis on two separate occasions 1 
month apart.  We performed Bland-Altman plots to assess variability of measurement. Our 
results showed that for LV torsion, intra-observer reproducibility was 0.24 ± 0.58 (bias ± 1.96 
standard deviation of the difference (SD)) and inter-observer reproducibility was 0.15 ± 0.69 
(bias ± 1.96 SD), which are acceptable. 
 
MPRI 
MPRI which is a measure of coronary microvascular function was computed from the stress 
MRI images. The images were analyzed on the Viewforum software version 5.0. Initially 
image alignment was done to reduce the motion of the heart in different cardiac cycles. 
Following this the endocardial and epicardial borders were traced and propagated throughout 
all the images. A sample volume was placed in the LV cavity as comparison for signal 
intensity of blood. Signal intensity curves were obtained from the software and the peak 
upslope of the LV myocardial illumination was computed in relation to the LV cavity 
illumination. A similar analysis was done on all three short axis images at rest and peak stress. 
The MPRI was obtained from the ratio of LV relative peak upslope at stress compared to rest. 
 
Statistics 
Continuous variables are expressed as mean ± standard deviation. Comparison between 
means was performed using unpaired Student T-tests. Categorical variables were compared 
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with Pearson Chi-Square test. For comparison of variables when the diabetes population was 
subdivided one way ANOVA was used. A P value of <0.05 was considered to indicate 
statistical significance. Variances of data sets were determined using F-test. Pearson 
correlation coefficient (r) was used to describe the relationship between variables. Variables 
of interest that were found to correlate with the dependent variable on univariate analysis 
were included in a stepwise linear regression analysis to identify independent predictors. 
SPSS (v15.0) was used to perform the statistical analysis. Bland Altman plot was used to 
assess data reproducibility using MedCalc (v9.2.1.0). 
 
Results  
The baseline characteristics are summarized in table 5.1. LVEF was 60.7±5% in the T1DM 
subjects and VO2 max was 38.5±9.9 ml/kg/min. In the HC, the corresponding values were 
61.4±5% (P=0.29 vs T1DM) and 44.1±7.2 ml/kg/min (p<0.01 vs T1DM), respectively. The 
mean HBA1c in the diabetic patients was 8±1%. The trans-mitral pulsed wave and tissue 
doppler results are summarized in table 5.2. 
 
LV torsion 
Peak LV torsion was significantly increased in the T1DM as compared to HC (1.9±0.6 vs 
1.4±0.7, P<0.01). Peak LV torsion rate and peak untwisting rate were increased in T1DM but 
the differences did not reach statistical significance. There were significant increases in LV 
apical rotation, LV twist and LV twist rate in T1DM compared with HC (Table 5.3). When 
the patient group was subdivided based on duration of diabetes and comparisons made 
between the three groups (newly diagnosed vs long term vs HC) with one way ANOVA there 
was a statistically significant difference in LV torsion and torsion rate (P<0.05). Post hoc 
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Tukey tests comparing the three groups between each other revealed a significant increase in 
LV torsion (2±0.7 vs 1.4±0.7, P<0.05) and torsion rate (14.5±5.1 vs 10.9±4.8, P<0.05) in 
patients with long term diabetes as compared to HC. The LV torsion in newly diagnosed 
T1DM (1.7±0.4) was midway between that of long term T1DM and HC (Figure 5.2). LV 
torsion rates (10.4±4.3) was however very similar in newly diagnosed and HC. 
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Table 5.1  
Variable T1DM HC P value 
Number 33 32 ns 
Female gender (%) 11 (33) 10(31) ns 
Age,years 33±9 30±8 0.13 
BMI, Kg/m2 24±3 25±3 0.25 
Resting heart rate, beats/min 82±16 77±11 0.09 
Systolic blood pressure, mmHg 119±13 112±10 <0.05 
Diastolic blood pressure, mmHg 75±10 70±10 0.06 
VO2 max, ml/kg/min 38.5±9.9 44.1±7.2 <0.01 
VO2 max, percentage predicted 98.6±16 112.2±16 <0.001 
RER 1.2 1.2 0.12 
Ejection fraction, % 60.7±5  61.4±5  0.29 
HBA1C, % 8±1 - - 
Fasting plasma glucose, mmol/L 8.6±3.3 4.5±0.4 <0.000 
Total cholesterol, mmol/L 4.4±0.9 4.9±0.9 <0.05 
HDL, mmol/L 1.6±0.4 1.7±0.6 0.44 
 
Baseline characteristics and results in T1DM patients as compared with HC. The results 
are expressed as mean ± standard deviation. 
 
P < 0.05 was considered as statistically significant  
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Table 5.2  
Variable T1DM HC P value 
Ejection fraction, % 60.7±5 61.4±5 0.29 
MV E velocity, cm/sec 79.7±13 77.4±15 0.26 
MV A velocity, cm/sec 58.4±15 49.1±10 <0.01 
E/A ratio 1.4±0.5 1.6±0.5 0.06 
Dec time, ms 252±57 248±66 0.38 
IVRT, ms 72±11 72±12 0.47 
TDI Peak S, cm/sec (inferior septal) 8.9±2 9.4±2 0.19 
TDI Peak E', cm/sec (inferior septal) 10.6±2 12.2±2 <0.01 
TDI Peak A', cm/sec (inferior septal) 8.6±2 7.8±2 0.05 
E/E' (inferior septal) 7.7±1 6.4±2 <0.001 
E/E' (anterior lateral) 5.3±1 4.9±1 0.06 
E'/A' (inferior septal) 1.3±0.5 1.6±0.5 <0.05 
E'/A' (anterior lateral) 1.8±0.6 2.1±0.8 <0.05 
 
Mitral and tissue doppler measurements in T1DM patients as compared with HC. The 
results are expressed as mean ± standard deviation. 
 
P < 0.05 was considered as statistically significant 
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Table 5.3  
 
 
Variables T1DM HC P 
    
Peak apical rotation, ° 11.3±4.4 8.5±4 <0.01 
peak basal rotation, ° -5.8±2.6 -4.9±2.5 0.09 
Rotational deformation delay, sec  0.13±0.1 0.16±0.1 0.15 
Peak LV twist, ° 15.3±4.4 11.3±6 <0.01 
Peak LV torsion, °/cm 1.9±0.6 1.4±0.7 <0.01 
Peak twist rate S, °/sec 12.7±5.1 10.9±4.8 0.08 
Peak untwist rate E, °/sec -11.9±4.6 -11.3±4.7 0.29 
Peak untwist rate A, °/sec -6.2±3 -4.9±3.9 <0.05 
 
LV torsion and untwist measurements in T1DM patients as compared with HC. The 
results are expressed as mean ± standard deviation. 
 
P < 0.05 was considered as statistically significant 
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Figure 5.2   
 
 
 
LV torsion measurements (expressed in degree/cm) in the HC and subgroups of patients 
with T1DM  
 
HC- Healthy control, T1DM-L – Long term diabetes patient group, T1DM-N – Newly 
diagnosed type 1 diabetes patient group. 
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Rotational deformation delay  
This is defined by the difference in time between the apical rotation and basal rotation 
achieving its peak value. The mean rotational deformation delay was greater in HC compared 
to T1DM (0.16± 0.1 vs 0.13±0.1, P=0.15) but the difference did not reach statistical 
significance. 
 
Strain and strain rates 
Global transverse and circumferential strain was significantly increased in T1DM compared 
to HC. Also the global circumferential and radial strain rates (S, E and A) were higher in 
T1DM. There was no significant difference in the global longitudinal and radial strain, 
although the longitudinal strain was non-significantly reduced in T1DM (table 5.4). 
 
MPRI 
The mean MPRI in T1DM was 1.9±0.5 significantly lower than in HC (2.3±0.4, P<0.05). 
When comparison was made between the three subgroups (new vs long term vs HC) using 
one way ANOVA, there was a significant difference in MPRI (P<0.05). Post hoc Tukey test 
revealed a significant difference in MPRI between long term T1DM and HC (1.7±0.6 vs 
2.3±0.4, P<0.05). The MPRI in new T1DM tended to be higher than in long term (2.1±0.2, 
P=0.13), but this difference did not reach statistical significance (Figure 5.3). 
 
Correlation and linear regression 
On univariate analysis, LV torsion negatively correlated with MPRI (r=-0.40, P<0.05), VO2 
max (r=-0.26, P=0.05), global circumferential strain (r=-0.35, P<0.05), circumferential strain 
rate S(r=-0.39, P<0.01), anterior-lateral E’/A’ (r=-0.37, P<0.01) and rotational deformation 
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delay (r=-0.46, P<0.001). LV torsion correlated positively with fasting plasma glucose 
(r=0.40, P<0.01), global transverse strain (r=0.34, P<0.05) and circumferential strain rate E 
(r=0.37, P<0.01) and A (r=0.39, P<0.01) (table 5.5). On multivariate regression analysis only 
rotational deformation delay (r=-0.48, P<0.05: Figure 5.4) and MPRI (r=-0.44, P<0.05: Figure 
5.5) were independent predictors of LV torsion. 
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Table 5.4  
 
 
Variables T1D HC P 
Global Longitudinal Strain, % -17.6±2.5 -18.4±2.8 0.14 
Global Longitudinal Strain Rate peak S, 1/sec -1.2±0.2 -1.2±0.2 0.22 
Global Longitudinal Strain Rate peak E, 1/sec 1.5±0.3 1.5±0.3 0.14 
Global Longitudinal Strain Rate peak A, 1/sec 0.8±0.2 0.8±0.3 0.46 
Global Transverse Strain, % 32.6±11 26.6±10.3 <0.05 
Global Radial Strain, % 30.5±8.5 28.3±12.2 0.21 
Global Radial Strain Rate Peak S, 1/sec 1.6±0.3 1.3±0.4 <0.01 
Global Radial Strain Rate Peak E, 1/sec -1.7±0.5 -1.3±0.5 <0.01 
Global Radial Strain Rate Peak A, 1/sec -0.8±0.2 -0.6±0.2 <0.001 
Global Circumferential Strain, % -20.8±3 -16.8±4 <0.000 
Global Circumferential Strain Rate Peak S, 1/sec -1.7±0.3 -1.4±0.3 <0.000 
Global Circumferential Strain Rate Peak E, 1/sec 2±0.5 1.6±0.4 <0.001 
Global Circumferential Strain Rate Peak A, 1/sec 0.9±0.2 0.7±0.2 <0.001 
 
Global longitudinal, radial and circumferential strain in T1DM patients as compared 
with HC. The results are expressed as mean ± standard deviation. 
 
P < 0.05 was considered as statistically significant 
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Table 5.5  
  
Variable R P  
MPRI -0.40969 <0.05 
Glucose 0.407503 <0.01 
VO2 max -0.25894 0.05 
Rotational deformation delay -0.45651 <0.001 
Global Transverse Strain 0.337503 <0.05 
Global Circumferential Strain -0.3475 <0.05 
Global Circumferential Strain Rate Peak S -0.38668 <0.01 
Global Circumferential Strain Rate Peak E 0.366952 <0.01 
Global Circumferential Strain Rate Peak A 0.387069 <0.01 
Anterior lateral E'/A' -0.36961 <0.01 
 
 
Correlation of variables with LV torsion in the whole group of subjects (includes HC 
and T1DM patients). Only the significant correlations are presented. 
 
P < 0.05 was considered as statistically significant 
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Figure 5.3  
 
 
 
 
Comparison of LV torsion (expressed in degrees) and MPRI (expressed as ratio) in HC 
and subgroups of T1DM 
 
HC- Healthy control, T1DM-N – Newly diagnosed type 1 diabetes patient group, T1DM-L – 
Long term diabetes patient group. 
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Figure 5.4  
 
 
 
Figure depicting the significant correlation between rotational deformation delay 
(expressed in seconds) and LV torsion (expressed in degree/cm) in the whole subject 
group. 
 
 
 
 
 
r= - 0.48 
P<0.05 
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Figure 5.5  
 
 
 
 
Figure depicting the significant correlation between MPRI (expressed as a ratio) and LV 
torsion (expressed in degree/cm) in the whole subject group. 
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Discussion  
The principal findings in this study are: a) LV torsion is increased in young patients with 
uncomplicated diabetes with normal EF. b) Global transverse and circumferential strain and 
strain rates are increased in these patients with mild abnormalities in long axis function. c) 
Rotational deformation delay and coronary microvascular function may play key roles in 
determining LV torsion.  
 
LV torsion is the net result of counter-clockwise rotation of the base with respect to clockwise 
rotation of the apex along the long axis of the LV. Normally  LV torsion contributes 
significantly to an energy-efficient ejection during systole 14;20. LV untwisting which follows 
LV twist is a key determinant of LV filling. It helps to generate the intra-ventricular pressure 
gradient during isovolumetric relaxation thus creating a suction effect to allow early diastolic 
filling to occur once the mitral valve opens 200.  In this study, we found LV torsion is 
increased in young T1DM. There are different plausible explanations for this. In a previous 
study with 53 diabetic patients with no LV hypertrophy, normal EF and no ischaemia on 
dobutamine echocardiography, radial contractility was increased and appeared to compensate 
for reduced longitudinal contractility 290. Longitudinal (long-axis) contraction of the left 
ventricle is dependent on the integrity of longitudinal subendocardial myocardial fibers, 
whereas radial (short-axis) contraction depends on integrity of the circumferential fibers. The 
former is more susceptible to ischaemia and fibrosis 145;254 which may result in a relative 
increase in short-axis function compared with a decrease in long-axis function due to 
compensatory ventricular remodeling. Hence the increased torsion and circumferential strain 
may be a compensatory mechanism for a subclinical reduction in long axis function. Previous 
studies have shown increased LV torsion in aging 270, aortic stenosis 52 and HCM 287. During 
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contraction the sub-endocardial fibres partially counteract the rotational motion of the sup-
epicardial fibers. Contractile dysfunction of the sub-endocardial fibers due to ischaemia, 
fibrosis or remodeling results in a net increase in LV torsion secondary to unopposed action of 
the sub-epicardial fibres. Thus increased torsion may indicate sub-endocardial contractile 
dysfunction. Studies using tagged MRI in uncomplicated T1DM patients have previously 
shown increased torsion 42. The clinical characteristics of these patients were similar to our 
own study population. However we have extended these findings by exploring potential 
mechanisms responsible for the increase in LV torsion. We noted in our study that the 
rotational deformation delay was higher in the controls although the difference did not reach 
clinical significance. This means that the apical rotation reaches its peak at a different time 
compared to the mitral peak. Hence the net twist would be lower as a direct consequence of 
rotational deformation delay. We speculate that this reduction in rotational delay at least 
partially explains the increase in torsion in T1DM patients. In agreement with this construct, 
rotational deformation delay was an independent predictor of LV torsion on multivariate 
regression analysis. A previous study assessing the impact of aging on LV twist concluded 
that reduced rotational deformation delay contributed to the increase in LV twist associated 
with aging 270. 
 
In this study, we found that LV torsion was negatively correlated with MPRI and positively 
correlated with fasting plasma glucose. There was no significant correlation of LV torsion 
with HbA1c indicating that atleast in the medium term blood glucose control had no bearing 
on development of increased LV torsion. In fact MPRI was an independent predictor of LV 
torsion. In the subgroup analysis we found that the long term T1DM had the highest LV 
torsion followed by the newly diagnosed T1DM patients. The LV torsion in HC was the 
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lowest in the three subgroups. Owing to the fact that our patients had no other co-morbidities 
like hypertension, primary hyperlipidaemia or ischaemic heart disease, the increased torsion 
may be a direct consequence of the effect of hyperglycaemia on the heart which worsens with 
duration of diabetes. It is well known that development of microvascular disease is directly 
related to duration and glycaemic control in T1DM patients. Indeed the long term T1DM 
patients in our study had a lower MPRI as compared to HC. The study was not powered to 
detect significant differences in MPRI between longer term T1DM and newly diagnosed 
T1DM subjects. MPRI is a good indicator of coronary microvascular function. In our study 
MPRI was an independent predictor of LV torsion. This implies that coronary microvascular 
disease may play a key pathophysiological role in the development of increased torsion in 
these patients. Previous studies in T1DM and T2DM have suggested a role of coronary 
microvascular disease in the development of diabetic cardiomyopathy. Normotensive diabetic 
patients without large vessel CAD were found to have reduced coronary reserve flow 
associated with diastolic dysfunction 251;252. Furthermore, previous studies by our group have 
demonstrated that CAN is associated with impaired myocardial blood flow by using PET 
197;246. The sympathetic dysinnervation of the heart commenced in the distal LV regions near 
the apex and then spread towards the base in patients with advanced disease 247. Thus, 
dysinnervation of the apex in uncomplicated T1DM may have a role in increasing apical 
rotation. This will need confirmation with studies targeting this hypothesis. 
 
Interestingly, we found that circumferential strain and strain rates were increased in the 
patient cohort. However, there was no significant difference in the longitudinal strain or tissue 
doppler mitral annular peak S, although there was a trend towards lower strain and Peak S in 
the diabetes patients. However, tissue doppler derived E’ (inferior-septal) was significantly 
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lower in T1DM (10.6±2 vs 12.2±2, P<0.01). The E/E’ (inferior-septal) was significantly 
higher in T1DM (7.7±1 vs 6.4±1, P<0.001), but still within the normal range. The tissue 
doppler derived E’/A’ which is another marker of diastolic dysfunction was significantly 
reduced in T1DM (table-5.2) consistent with our previous studies 197. There was a significant 
negative correlation between LV torsion and anterior lateral E’/A’, implying that the 
increased torsion was a compensatory mechanism for the early relaxation abnormality. The 
increased torsion would provide the potential energy for untwisting in diastole and indeed 
untwisting rate was preserved in the patients’ cohort in our study. A recent study looking at 
LV torsion in different stages of diastolic dysfunction demonstrated that LV torsion is 
increased in mild diastolic dysfunction but returned to normal in patients with higher grades 
of diastolic dysfunction 187. Subjects in this study had diastolic dysfunction secondary to 
hypertension, HCM or amyloidosis. Although the reason for diastolic dysfunction in this 
study was different to our study population, the results are comparable in that mild diastolic 
dysfunction was associated with increased LV torsion. The increased LV torsion may be 
either a compensatory mechanism to abnormal relaxation or as a direct consequence of the 
abnormal relaxation. The absence of markedly reduced longitudinal function in our subjects 
indicates that increased torsion probably occurs before this and is one of the first stages of 
diabetic cardiomyopathy.   
 
Clinical implications  
Development of heart failure in diabetes is a complex mechanism and is affected by many 
secondary factors like hypertension, CAD, renal disease and hyperlipidemia. We have shown 
in our study that diabetes per se and microvascular disease has a major impact on the 
myocardium. Increased torsion may be one of the earliest features of diabetic cardiomyopathy 
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and it is tempting to speculate that this may herald ultimate progression to heart failure. If 
confirmed in large scale prospective studies it could form the basis of a screening tool for the 
identification of patients at risk for the development of heart failure. It could also form the 
basis of targeted therapy to reduce incidence of heart failure in diabetes patients. 
 
Study Limitations 
One of the main drawbacks of the study was the small sample size of the study population. 
Also patients were studied at one point in time and hence there is no indication as to 
progression to heart failure. The mean HbA1c in our study population was 8±1%. It will be 
important to elucidate the effect of glycaemic control on LV torsion. The subjects were not 
studied in a metabolically standardized environment which reflected the practical difficulties 
of infusing insulin and glucose during the MRI when adenosine and Gadolinium contrast also 
had to be infused. Our study was in a cohort of uncomplicated T1DM. However T2DM is also 
a major health problem with high incidence of CAD and heart failure 101;109.  Previous studies 
have demonstrated diastolic dysfunction as early changes in these patients 30. There have been 
no studies looking at LV torsion as early manifestation of cardiomyopathy in T2DM. We 
expect the LV torsion to be similarly increased in uncomplicated T2DM. But T2DM is 
associated more often with hypertension and CAD which may have a major bearing on LV 
torsion. 
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CHAPTER SIX 
 
 
LEFT ATRIAL FUNCTION AND ITS CONTRIBUTION TO LEFT 
VENTRICULAR FILLING IN PATIENTS WITH TYPE 1 DIABETES 
AND NORMAL EJECTION FRACTION 
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Abstract 
Background: In diabetes mellitus, cardiomyopathy is characterized by the development of 
left ventricular diastolic and then systolic function. In this study we evaluated young patients 
with T1DM who had normal LVEF in order to evaluate subtle preclinical changes in cardiac 
function. We used STE to assess changes in LV untwisting and its relation to diastolic 
parameters. We used cardiac MRI to assess the LA contribution to left ventricular filling. 
Methods: We recruited 33 T1DM patients and 32 age-matched HC into the study. Study 
participants underwent echocardiogram, cardiac MRI and metabolic exercise testing. LV 
rotation measurements were made using a commercially available speckle tracking system. In 
order to adjust for the differences in heart rate between individuals the RR interval was 
normalised to 100%. LV volume measurements were made using the Viewforum software 
from cardiac MRI images. 
Results: LVEF was not different in T1DM subjects and HC (60.7±5% vs 61.4±5%, p=0.29). 
The early peak LV untwisting rate (E) was similar in T1DM and HC (-11.9±4.6 0/cm/sec vs -
11.3±4.7 0/cm/sec, P=0.29) but the late peak LV untwisting rate (A) was significantly 
increased in T1DM (-6.2±3 0/cm/sec vs -4.9±3.9 0/cm/sec, P<0.05). The time to early peak 
untwisting rate was not different (50.9±9.6% vs 48.4±7.3%, P=0.12) but the time to late peak 
untwisting rate was significantly delayed in T1DM patients (80.4±12.5% vs 72.7±14.6%, 
P<0.05). Tissue doppler analysis demonstrated a reduction in E’ (10.6±2 cm/sec vs 12.2±2, 
P<0.01) and E’/A’ (1.3±0.5 vs 1.6±0.5, P<0.05) with an increase in E/E’ (7.7±1 vs 6.4±2, 
P<0.001) indicating an early relaxation abnormality in T1DM subjects. Also there was 
increase in trans-mitral A wave velocity (58.4±15 cm/sec vs 49.1±10 cm/sec, P<0.01) and 
mitral annular A’ (8.6±2 cm/sec vs 7.8±2 cm/sec, P<0.05). The LV filling patterns 
demonstrated a significantly increased LA contribution to LV filling in T1DM. On linear 
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regression peak late filling rate (r=0.60, P<0.000), trans mitral A wave (r=0.25, P<0.05) and 
A’ (r=0.30, P<0.01) were predictors of LA contribution to LV filling. 
 
Conclusion: We demonstrate for the first time using speckle tracking that LV untwisting rate 
E is preserved and untwisting rate A is increased and delayed in young patients with 
uncomplicated T1DM. This is associated with early relaxation abnormalities in the LV. The 
LA contribution to LV filling is increased in these patients and is directly related to increases 
in other indices of LA function like peak late filling rate, trans-mitral A wave and A’. 
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Background  
Heart failure occurs more frequently in diabetes 109 and although frequently due to CAD 
and/or hypertension, may occur in the absence of these, when it is termed  diabetic 
cardiomyopathy. Although there is increasing evidence for the presence of diabetic 
cardiomyopathy as a separate entity, detection of early changes in the myocardium is 
challenging in patients with diabetes. Previous studies with 2D and tissue doppler 
echocardiography have demonstrated abnormalities in various diastolic parameters prior to 
the onset of overt systolic dysfunction. Echocardiographic trans-mitral pulsed wave doppler  
demonstrates abnormalities in mitral inflow velocity, DecT, IVRT and filling patterns 196. In 
healthy young subjects the majority of LV filling is accomplished in the early filling phase 
and the LA contributes the remainder. In heart failure the early phase of filling is hampered by 
the stiff ventricle 123;272. In this situation the LA contributes significantly more to LV filling. 
Similarly there is increased reliance on the LA for LV filling in the presence of diastolic 
dysfunction. We demonstrated recently that increased LA filling compensates for impaired 
early relaxation during exercise in patients with heart failure with preserved EF 194. LA 
function may be an important factor in maintaining EF in the early stages of diabetic 
cardiomyopathy. Loss of atrial function with the onset of atrial fibrillation may precipitate 
worsening heart failure in any of the above situations. 
 
In this study we investigated various aspects of LA function in young T1DM subjects with no 
underlying heart failure or CAD. STE has recently been used to measure LV torsion and 
untwisting. LV untwisting, which follows LV torsion contributes significantly to LV filling. 
We studied the untwisting patterns in patients with T1DM and its relation to diastolic function 
and LV filling. The early untwist corresponds to the early phase of filling and late untwisting 
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corresponds to the LA filling phase. We used cardiac MRI to directly measure LV volumes 
during the cardiac cycle and hence LV filling patterns in these subjects. 
 
Methods  
65 subjects who met the inclusion criteria and provided informed consent were recruited from 
the Heart of England NHS Foundation Trust and University Hospital Birmingham NHS Trust, 
Birmingham, UK (The recruited subjects are the same as those in the previous chapter/study). 
HC were recruited by general adverts in the University of Birmingham and blood banks. All 
the investigations were undertaken in the University of Birmingham and the project was 
approved by Multicenter Regional Ethics Committee in Birmingham. 
 
Patients 
We recruited 33 subjects with T1DM (WHO definition) without a history of chest pain or 
breathlessness. All patients had no evidence of CAD or heart failure based on history, 12 lead 
ECG, a normal EF on echocardiography and metabolic exercise testing.   
 
Healthy Controls 
32 age and sex matched controls with no cardiac history or diabetes mellitus were recruited. 
All HC had a normal 12 lead ECG, echocardiogram and metabolic exercise test. 
 
Subjects underwent echocardiography, metabolic exercise testing and cardiac MRI as 
described in the methods chapter (chapter 2) 
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Analysis 
Speckle Tracking Echocardiography 
Myocardial deformation was measured using a commercially available speckle tracking 
system on  an ECHOPAC (version 4.2.0) workstation. In this system, the displacement of 
speckles of myocardium in each spot were analyzed and tracked from frame to frame.  We 
selected the best-quality digital two-dimensional image and the LV endocardium was traced 
at end-systole.  The region of interest width was adjusted as required to fit the wall thickness.  
The software package then automatically tracked the motion through the rest of the cardiac 
cycle.  The onset of the QRS complex was taken as the beginning of systole. Adequate 
tracking was verified in real time.  Counter-clockwise rotation was marked as a positive value 
and clockwise rotation as a negative value when viewed from the apex. In order to calculate 
LV torsion, torsion rate and untwist rates, the rotation traces of the basal and apical LV cross-
sections were exported into DPlot graph software (Version 2.2.1.4, HydeSoft Computing, 
LLC, Vicksburg, USA). The LV twist curve was generated by calculating the difference 
between apical and basal rotations at each corresponding time point. LV twist rates were 
derived from the first derivative of the LV twist curve (figure 6.1). Peak LV torsion was 
derived from LV twist divided by LV diastolic longitudinal length. In order to adjust for the 
differences in heart rate between individuals the RR interval was normalised to 100%. Of the 
65 subjects in the study, 61 (94%) subjects had both adequate LV basal and apical images for 
speckle tracking to complete analysis of all LV rotational parameters.  
 
LV volumes 
LV volumes were computed from the short axis cine MRI images. The images were analyzed 
on  Viewforum software version 5.0. The endocardial and epicardial borders were traced at 
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end diastole in each slice and propagated through the rest of the cardiac cycle. The software 
generated LV volumes at each phase of the cardiac cycle incorporating all the slices. The LV 
volume time curves (figure 6.2) were exported to graphical software Dplot. The first 
derivative of the LV volume curve was computed to represents the rate of LV volume changes. 
SV was defined as the difference between end-diastolic volume (EDV) and end-systolic 
volume (ESV). Early and late PFR were defined as the first and second positive peaks of the 
first derivative curve during diastole. The early and late (atrial) components of LV filling 
were measured from the corresponding LV volume segments and were expressed as 
percentage of SV. 
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Figure 6.1  
 
 
 
A typical twist and untwist curve in HC as compared to T1DM. 
HC- healthy control, T1DM – type 1 diabetes mellitus patient. 
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Figure 6.2  
 
 
 
 
Typical left ventricular filling curves in a healthy control (top figure) as compared with 
type 1 diabetes patient (bottom figure). 
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Statistics 
Continuous variables are expressed as mean ± standard deviation. Comparison between 
means was performed using unpaired student T-tests. Categorical variables were compared 
with Pearson Chi-Square test. For comparison of variables when the diabetes population was 
subdivided one way ANOVA was used. A P value of <0.05 was considered to indicate 
statistical significance. Variances of data sets were determined using F-test. Pearson 
correlation coefficient (r) was used to describe the relationship between variables. Variables 
of interest that were found to correlate with the dependent variable on univariate analysis 
were included in a stepwise linear regression analysis to identify independent predictors. 
SPSS (v15.0) was used to perform the statistical operations.  
 
Results  
The baseline characteristics are summarized in Table 5.1. LVEF was 60.7±5% in the T1DM 
subjects and VO2 max was 38.5±9.9 ml/kg/min. In the HC, the corresponding values were 
61.4±5% (P=0.29 vs T1DM) and 44.1±7.2 ml/kg/min (p<0.01 vs T1DM), respectively. The 
mean HBA1c in the diabetic patients was 8±1%. The trans-mitral pulsed wave and tissue 
doppler results are summarized in Table 5.2. Tissue doppler analysis demonstrated a 
statistically significant reduction in E’ and E’/A’ with an increase in E/E’ indicating early 
relaxation abnormality.  There were also statistically significant increases in trans-mitral A 
wave velocity and mitral annular A’. The LA volume index was significantly increased in 
T1DM as compared to HC. 
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LV torsion and untwist 
Peak LV torsion was significantly increased in the T1DM as compared to HC (1.9±0.6 vs 
1.4±0.7, P<0.01). We noted significant increases in LV apical rotation, LV twist and LV twist 
rate in T1DM compared with HC (Table 6.1). The early peak LV untwisting rate was similar 
in T1DM and HC (-11.9±4.6 0/cm/sec vs -11.3±4.7 0/cm/sec, P=0.29). The late peak LV 
untwisting rate was significantly increased in T1DM (-6.2±3 0/cm/sec vs -4.9±3.9 0/cm/sec, 
P<0.05). The time to early peak untwisting rate was not different (50.9±9.6% vs 48.4±7.3%, 
P=0.12) but the late peak untwisting rate was significantly delayed in T1DM patients 
(80.4±12.5% vs 72.7±14.6%, P<0.05). 
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Table 6.1  
 
 
 
Variables T1DM HC P 
    
Peak apical rotation, ° 11.3±4.4 8.5±4 <0.01 
peak basal rotation, ° -5.8±2.6 -4.9±2.5 0.09 
Peak LV twist, ° 15.3±4.4 11.3±6 <0.01 
Peak LV torsion, °/cm 1.9±0.6 1.4±0.7 <0.01 
Peak twist rate S, °/sec 12.7±5.1 10.9±4.8 0.08 
Peak untwist rate E, °/sec -11.9±4.6 -11.3±4.7 0.29 
Peak untwist rate A, °/sec -6.2±3 -5±3.9 <0.05 
Time to untwist rate E, %* 50.9±9.6 48.4±7.3 0.12 
Time to untwist rate A, %* 80.4±12.5 72.7±14.6 <0.05 
 
 
LV rotation measurements in T1DM (whole group) as compared with HC expressed as 
mean ± standard deviation. 
 
P<0.05 was considered as significant 
* Expressed as % of RR interval. 
LV – left ventricle, T1DM – type 1 diabetes mellitus, HC- healthy control. 
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LV volumes 
The results from the cardiac MRI are summarized in Table 6.2. The LVEF and SV were 
similar in T1DM and HC. The early PFR was slightly but not significantly higher where as 
the late PFR was significantly higher in the T1DM as compared to HC. The LV filling 
patterns demonstrated a significantly increased LA contribution to LV filling in T1DM. 
Although the total diastolic period (as a percentage of the RR interval) was similar, T1DM 
patients spent significantly less time in early filling and significantly longer  time in atrial 
filling. 
 
Correlation and linear regression 
LA contribution to LV filling correlated positively with LV torsion (r=0.39, P<0.05), trans 
mitral A wave(r=0.58, P<0.00), A’ (r=0.56, P<0.00), E/E’ (r=0.32, P<0.05), and peak late 
filling rate (r=0.80, P<0.000) and negatively with E’/A’ (r=-0.54, P<0.000) and E’ (r=-0.40, 
P<0.01). On linear regression peak late filling rate (r=0.60, P<0.000), trans-mitral A wave 
(r=0.25, P<0.05) and A’ (r=0.30, P<0.01) were predictors of LA contribution to LV filling. 
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Table 6.2  
 
 
Variables T1DM HC P 
Peak emptying rate, ml/msec 0.35±0.1 0.31±0.1 0.08 
Time to peak emptying rate, msec 148±30 166±0.2 <0.05 
Peak early filling rate, ml/msec 0.44±0.14 0.40±0.10 0.19 
Peak late filling rate, ml/msec 0.19±0.07 0.15±0.05 <0.05 
Early filling contribution, % 75.6±8.9 80.7±7.1 <0.05 
Late filling contribution, % 24.4±8.9 19.3±7.1 <0.05 
Total systolic time, % 37.5±5.1 37.5±5.5 0.48 
Total diastolic time, % 62.5±5.1 62.5±5.5 0.48 
Total early filling time, % of diastole 71.6±7.2 76.9±4.8 <0.01 
Total late filling time, % of diastole 28.4±7.2 23.1±4.8 <0.01 
Ejection fraction, % 60.3±6.7 59.7±4 0.14 
End diastolic volume, ml 117.1±29 113±20 0.30 
End systolic volume, ml 47.4±17.1 45.9±10.9 0.36 
Stroke volume, ml 69.6±14.6 67.1±11.4 0.26 
Cardiac output, l/min 4.5±1.3 4.1±0.69 0.07 
LV mass 98.2±27.2 95.3±22 0.33 
 
LV volume results in T1DM (whole group) as compared with HC expressed as mean ± 
standard deviation. 
 
P<0.05 was considered as significant 
LV – left ventricle, T1DM – type 1 diabetes mellitus, HC- healthy control. 
 
 
 
 
  
135 
 
Discussion  
The principal findings in this study are: a) LV untwist rate A and time to LV untwist rate A 
were increased in young patients with T1DM as well as other indices of left atrial function 
(trans mitral A wave and A’). b) Left atrial contribution to LV filling was increased in T1DM 
patients  c) peak late filling rate, trans-mitral A wave and A’ were predictors of the left atrial 
contribution to LV filling. 
LV torsion is the net result of counter-clockwise rotation of the base with respect to clockwise 
rotation of the apex along the long axis of the LV. Normally  LV torsion contributes 
significantly to an energy-efficient ejection during systole 14;20. LV untwisting which follows 
LV twist is a key determinant of LV filling. It helps to generate the intra-ventricular pressure 
gradient during isovolumetric relaxation thus creating a suction effect to allow early diastolic 
filling to occur once the mitral valve opens 200.  In this study, we found that early LV untwist 
was preserved. This might be as a direct result of increased LV torsion which creates the 
potential energy for early untwisting. The late LV untwist was increased indicating 
augmented atrial contraction.    In a previous study in diabetes patients the trans-mitral A 
wave was increased in subjects associated with impaired relaxation 196. This is similar to our 
findings of increased indices of atrial function like increased trans-mitral A wave and A’. 
Also a recent study in T1DM patients demonstrated changes in LA transport function 
suggesting increased reliance on LA for LV filling 193.   
 
Our study has demonstrated abnormalities in early diastolic filling. This is suggested by a 
reduced E’ and E’/A’ and an increased E/E’ on tissue doppler analysis.  Previously various 
studies have demonstrated early relaxation abnormalities as the precursors of heart failure in 
diabetes 61;196;275. A recent study has demonstrated that E/E’ is a predictor of mortality in 
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diabetic patients without heart failure who were followed up for more than 10 years 70. The 
early relaxation abnormalities results in impaired early LV filling and probably represents one 
of the earliest functional changes in the left ventricle.  
To the best of our knowledge this is the first study that investigates the LV filling patterns in 
T1DM patients with normal EF using LV volumes measured by cardiac MRI. The EF, SV, 
end-diastolic and end systolic volume were all similar in both T1DM patients and HC. 
However the late PFR was significantly increased in T1DM patients suggesting increased 
trans-mitral gradient produced by augmented LA contraction. This resulted in increased LA 
contribution to LV filling. This increased contribution of LA to LV filling helps to maintain 
adequate LV filling and hence generate appropriate SV. Hence the EF is maintained at this 
time despite abnormal early filling. The augmented LA function appears to be the key 
compensatory mechanism at this point. The early relaxation abnormality is likely to worsen 
on exercise and hence the reliance on LA for LV filling will only increase. The increase in LA 
function is noticed in early stages of heart failure. However, with worsening LV dysfunction 
LA dilates and this compensation is lost worsening the situation 123. 
 
Clinical implications 
Development of heart failure in diabetes is a complex process and is affected by many 
secondary factors like hypertension, CAD, renal disease and hyperlipidemia. We have shown 
in our study that LA plays a key functional role in compensating early relaxation 
abnormalities in patients who still have normal EF. Therefore assessment of LA function is an 
important step in evaluating these patients. Loss of atrial function may predict the onset of 
overt heart failure. 
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Study Limitations 
One of the main drawbacks of the study was the small sample size of the study population. 
Also patients were studied at rest. It will be interesting to study LA function on exercise.  
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CHAPTER SEVEN 
 
 
IMPACT OF PERHEXILINE ON GLUCOSE AND FAT 
METABOLISM IN PATIENTS WITH REFRACTORY ANGINA 
AND/OR REFRACTORY HEART FAILURE 
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Background 
Perhexiline was a frequently prescribed anti-anginal agent in the 1970s and is effective at 
relieving symptoms of angina 95;277;281, improving exercise tolerance, and increasing workload 
needed to induce ischaemia 44.  Perhexiline use declined dramatically in the late 1970s and 
early 1980s following reports of hepatotoxicity 192;208 and peripheral neuropathy 28.  This was 
later demonstrated to occur in patients who are `slow hydroxylators` with a genetic variant of 
a cytochrome P-450 enzyme which metabolises the drug, resulting in drug accumulation, in 
turn leading to accumulation of phospholipids in liver and nerves 163.  Horowitz et al 96 
demonstrated that the risk of toxicity could be virtually eliminated by maintaining plasma 
concentrations between 150 to 600 ng/ml without compromising efficacy of the drug and this 
was subsequently confirmed by Cole et al 44. This has led to resurgence in the use of 
Perhexiline in some parts of the world, particularly Australia, for the treatment of refractory 
angina. At therapeutic plasma levels, Perhexiline is not negatively inotropic and does not alter 
systemic vascular resistance 121;190;191.  In studies funded by a BHF Project Grant we 
demonstrated salutary effects of Perhexiline in maximally treated heart failure patients of both 
ischaemic and non-ischaemic etiologies 132. There was a large increase in the primary end 
point, VO2max (almost 3ml/kg/min), additionally LVEF increased by approximately 10 
percentage points, and there was a substantial improvement in symptomatic status as assessed 
by the Minnesota Living with Heart Failure Questionnaire (all pre-defined secondary end 
points). 
 
Perhexiline is currently used clinically in the treatment of refractory angina 95;277;281 and heart 
failure 132 in patients on maximum tolerated medical therapy. Perhexiline  inhibits of CPT-1 
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and CPT-2, key enzymes in mitochondrial free fatty acid uptake 114;115, leading to increased 
myocardial glucose substrate utilization 182.   
 
Previous animal studies have demonstrated that concentration-dependent inhibition of CPT-1 
by Perhexiline in the liver or muscle 114. This can produce variable effects on plasma glucose, 
insulin, triglycerides, FFA, glycerol and ketones depending on the site of action. The aim of 
the study was to assess the impact of Perhexiline on ketone body synthesis and fatty acid and 
glucose metabolism and assess whether this would throw light on CPT-1 inhibition patterns in 
humans. Plasma levels of glucose, insulin, ketone bodies, FFA, glycerol and triglycerides 
were measured at baseline and 1 and 4 weeks after commencement of Perhexiline.  
 
Methods   
30 patients who met the entry criteria indicated below and provided written informed consent 
were recruited to the study. Patients were recruited from cardiomyopathy clinics in 
Birmingham. Before commencement of Perhexiline patients underwent history, physical 
examination and filled in the Minnesotta Living with Heart Failure questionnaire. Following 
this, fasting blood samples were collected and patients were started on Perhexiline.  After one 
week Perhexiline levels were taken and dosage adjusted to achieve therapeutic concentrations. 
At 4 weeks repeat fasting blood samples were collected and this completed the study. Patients 
continued on Perhexiline as this was commenced on a clinical basis.  
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Patient inclusion criteria  
1. Patients with angina or heart failure 
2. Being commenced on Perhexilene for clinical reasons i.e. refractory angina or heart 
failure. 
3. Age > 18 years 
4. Provide informed consent 
 
Exclusion criteria 
1. Patients < 18 years or who cannot provide informed consent 
2. Women of child bearing age who are not using effective contraception (or if 
pregnancy test positive) 
3. Abnormal liver function tests (LFT) 
4. Clinically apparent peripheral neuropathy 
5. Severe chronic renal failure (creatinine >250) or diabetic nephropathy 
6. Concomitant use of Amiodarone, Quinidine, Haloperidol or Selective serotonin (5HT) 
uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 
enzyme 
 
Insulin and ketone assay  
Insulin and ketone assay was performed as described in detail in the methods chapter (chapter 
2). 
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Results 
27 patients completed the study. The other patients stopped taking Perhexiline due to side 
effects or did not have the second set of blood tests.  Patients characteristic and treatments are 
shown in table 7.1. The patients were divided into those with and without diabetes before the 
analysis. The results were analysed on SPSS version 15.0. Paired students T test was used as 
test of significance. Spearmans rho rank tests were used as tests of correlation. The results are 
summarised in table 7.2. 
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Table 7.1 
 
Parameter 
 
 
Results 
Parameter  
Results 
    Age (years) 60.4 + 13 Diuretics  
18 
 
Number (Male) 24 (16)  Aldosterone 
antagonist 
 
10 
 
MLHF score 
 
 
63 ± 18.7 
 
 
B-Blockers 
 
17 
 
EF% 
 
 
31.35 + 2.08 
 
ACE inhibitors 
 
16 
Weight (kg) 
 
 
96  ± 6.26 
 
 
ARB 7 
Diabetics  
11 
 
 
Anticoagulants 
 
12 
Ischaemic Heart 
Disease 
 
15 
 
Antiplatelet 13 
Dilated 
Cardiomyopathy 
 
9 Nitrates 7 
 
Baseline characteristics and treatment regimen of patients in refractory angina and/or 
refractory heart failure. 
 
The results are expressed as mean ± standard deviation 
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Table 7.2  
 
Variable Baseline (no-
diabetes) 
Post (no-Diabetes) Baseline 
(Diabetes) 
Post ( Diabetes) 
Glucose, mmol/L 5.1±0.5 5±0.6 8.4±2.4 6.7±2* 
Insulin, µIU/ml 13±15.2 19.9±23.7* 41.4±37.4 23.1±16.4* 
IS, % 187.5±178.4 112.2±125* 30.1±29.1 54.7±52.2* 
IR 1±0.9 1.5±1.2* 5±4.6 3±2.3* 
%B 85.2±56 124.9±84.4* 114.5±95.2 128.9±83.1 
FFA, µmol/L 279±112 250±105 316±131 387±174* 
Triglycerides, µmol/L 1184±655 1475±766 2025±552 2477±1496 
Glycerol, µmol/L 99±44 99±22 99±40 90±50 
Ketones, mmol/L 0.8±0.3 1.2±0.6* 1.4±0.7 1.6±0.8 
 
The results at baseline and at 4 weeks following Perhexiline therapy. The patients are 
divided into those with diabetes and without diabetes. The results are expressed as mean 
± standard deviation. 
 
IS – insulin sensitivity, IR – insulin resistance, %B – percentage of beta cell activity, FFA – 
free fatty acids 
*- Statistically significant as compared to baseline 
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Patients with diabetes (11 subjects) 
There was a significant fall in fasting plasma glucose and insulin following Perhexiline 
therapy. There was a significant increase in insulin sensitivity as measured by HOMA (Figure 
7.1). HOMA calculations also revealed that Perhexiline resulted in increased beta-cell 
function within the pancreas. The FFA concentration in the plasma significantly increased 
with a non significant increase in triglyceride concentration post Perhexiline therapy. Fasting 
plasma ketones increased non-significantly following Perhexiline therapy (Table 7.2). 
 
Patients without diabetes (16 subjects) 
There was no change in fasting plasma glucose and a significant increase in plasma insulin 
following Perhexiline therapy. The HOMA calculated insulin sensitivity fell significantly. 
Interestingly HOMA also demonstrated that the beta cell function increased significantly as in 
the diabetic population. Perhexiline had no effect on plasma FFA and non-significantly 
increased the triglyceride levels. Interestingly there was a statistically significant increase in 
fasting plasma ketones post Perhexiline. 
 
All subjects 
There was a significant increase in plasma fasting triglyceride concentrations following 
Perhexiline therapy (1577±691 vs 1891±1151, P<0.05). Concurrently, there was a significant 
increase in plasma fasting ketone body levels (1.0±0.3 vs 1.4±0.7, P<0.01). Perhexiline 
caused a non-significant fall in fasting plasma FFA (303±131 vs 299±146) and glycerol 
(101±55 vs 87±39) (Table 7.3).  
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Figure 7.1 
 
 
 
Changes in insulin sensitivity at baseline and following Perhexiline therapy (for 4 weeks). 
 
NDM – patients without diabetes mellitus, DM – patients with diabetes mellitus. 
P<0.05 was considered as statistically significant.  
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Table 7.3 
 
 
 Baseline Post-Perhexiline P Value 
Triglycerides, µmol/L 1577±691 1891±1151 <0.05 
Ketones, mmol/L 1.0±0.3 1.4±0.7 <0.01 
Free Fatty Acids, µmol/L 303±131 299±146 ns 
Glycerol, µmol/L 101±55 87±39 ns 
 
The results of fasting plasma levels at baseline and post Perhexiline therapy (4 weeks) in 
the whole patient group. The results are expressed as mean ± standard deviation. 
 
P<0.05 considered as statistically significant. 
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Spearmans rho Correlation 
Perhexiline therapy resulted in increase of both fasting plasma ketones and triglycerides. In 
order to look for an association between the two, we conducted Spearmans Rank correlation 
tests. A significant positive correlation was noted between the increase in plasma ketones and 
triglycerides(r=0.62, P<0.01) (Figure 7.2). The increase in ketones (r=0.62, P<0.01) and in 
triglycerides (r=0.45, P<0.01) both correlated positively with the plasma level of Perhexiline 
at 5 weeks. Interestingly, at Perhexiline levels of <0.50 mg/dl plasma ketones and 
triglycerides increased. Whereas at Perhexiline levels of >0.5 mg/dl there was only a modest 
increase in ketones with fall in triglyceride levels (Figure 7.3).  
 
Post-Perhexiline levels of ketones correlated significantly with triglycerides (r=0.66, P<0.01) 
and FFA (r=0.54, P<0.05). But there was no association with either Perhexiline levels or 
plasma glycerol. Interestingly post perhexiline levels of FFA correlated with glycerol (r=0.54, 
P<0.05). However, no correlation was found between post-perhexiline triglycerides and either 
FFA or glycerol.      
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Figure 7.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter plot of increase in plasma triglyceride concentration against increase in ketones 
in the whole patient group. The blue line indicates the linear trend line. 
 
Plasma triglycerides are measured in µmol/L and plasma ketones in mmol/L 
P<0.05 considered as statistically significant. 
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Figure 7.3 
 
 
 
 
Changes in plasma triglyceride and ketone concentration at different Perhexiline levels 
(<0.5 and >0.5). Perhexiline is measured in mg/L. 
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Discussion  
In this study we have demonstrated a divergent response of Perhexiline on insulin sensitivity 
in patients with and without diabetes. Perhexiline inhibits the enzymes CPT-1 and CPT-2 
preventing the entry of free fatty acids into the mitochondria and hence reducing fatty acid 
metabolism. This causes an increase in glucose utilisation. We expected Perhexiline to 
improve insulin sensitivity by driving glucose utilisation within the muscle in all subjects. 
However, unexpectedly and interestingly Perhexiline increased insulin sensitivity in diabetes 
patients whereas in non-diabetics it worsened the insulin sensitivity. There could be several 
explanations for these findings.  
In diabetes patients insulin sensitivity is impaired as a part of disease process. Perhexiline 
improves glucose utilization within the muscles in these subjects improving the insulin 
sensitivity. However, the insulin sensitivity is normal to begin with in the patients without 
diabetes and increased glucose utilisation should not have any impact on the insulin 
sensitivity. Moreover, by preventing the entry of FFA into mitochondria Perhexiline may lead 
to accumulation of triglycerides and diacyl-glycerol in the cytosol resulting in increased 
insulin resistance at the cellular level. This effect may be overshadowed by the increased 
glucose utilization in patients with diabetes. 
Although, there was a significant worsening of insulin sensitivity in the patients without 
diabetes following Perhexiline therapy, the fasting plasma glucose did not alter. The 
percentage of beta cell function increased resulting in higher levels of plasma insulin. The 
beta cell activity increased as a counter regulatory mechanism to worsening insulin sensitivity.  
 
In this study, we also demonstrate that Perhexiline increases plasma levels of both 
triglycerides and ketones which is directly related to its plasma concentration. Previously, it 
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has been demonstrated that Perhexiline inhibits CPT-1 in rat liver and heart 115. This 
inhibition is concentration-dependent with cardiac CPT-1 being inhibited at concentrations 
lower than that needed for inhibition of liver CPT-1. This leads to the possibility that 
inhibition of cardiac CPT-1 is related to its therapeutic action and that of liver CPT-1 may 
explain its hepato-toxicity at higher concentrations. However, no studies have been 
undertaken in humans to confirm this. This is the first study done to look at this possibility.  
Under normal conditions, FFA generated from the adipose tissue is utilised by the liver for 
either beta-oxidation or synthesis of triglycerides. Acetyl Co-A generated from beta-oxidation 
of FFA either enters the Krebs cycle or is used to synthesise ketone bodies. In fasting 
conditions ketone synthesis and utilisation is increased due to lack of availability of glucose. 
We hypothesise that at therapeutic levels Perhexiline only inhibits skeletal and heart muscle 
CPT-1. This decreases FFA utilisation and hence more is available for the liver to generate 
ketones and triglycerides. However at supra-therapeutic levels Perhexiline also inhibits liver 
CPT-1. This prevents the uptake of FFA by the liver and hence we see only modest changes 
in the plasma ketone and triglyceride levels at higher plasma levels of Perhexiline. 
 
Interestingly, previous studies in animal models (rats) have shown that the concentration of 
Perhexiline is 20 fold in the heart 3 hours after oral administration 115. Hence, the plasma 
concentrations may not reflect the concentrations achieved in the tissue. The theurapeutic 
benefit of Perhexiline will be achieved only if it reaches adequate levels in the myocardium. 
This may be difficult to predict based only on the plasma concentration of Perhexiline, which 
does not necessarily predict tissue concentration. This is also important from the point of view 
of side effects. We cannot be sure that Perhexiline achieves high concentrations in the liver 
only at supra-therapeutic plasma levels. However, clinical studies previously have 
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demonstrated that Perhexiline can be used safely without producing hepatotoxic effects as 
long as the plasma concentration is maintained between 150-600 ng/ml 44. 
 
Further studies measuring tissue concentrations and correlating this with plasma 
concentrations may help settle this issue. However, these studies would be extremely difficult 
to perform in humans. Animal studies will help to work out the underlying pathophysiological 
mechanisms as we are able to sample various tissues including liver, skeletal muscle and 
myocardium. 
 
Conclusions 
Perhexiline increases ketone and triglyceride synthesis which is concentration-dependent. A 
differential action on muscle and liver CPT-1 is a plausible explanation for this. Interestingly, 
Perhexiline increased the insulin sensitivity in patients with diabetes and decreased it in 
patients without diabetes. 
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CHAPTER EIGHT 
 
 
MULTI-CENTRE EXPERIENCE ON THE USE OF PERHEXILINE 
IN CHRONIC HEART FAILURE AND REFRACTORY ANGINA: 
OLD DRUG, NEW HOPE 
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Introduction 
The prevalence of CHF is increasing and it is a leading cause of morbidity and mortality in 
developed countries and an emerging one in the developing world. The mortality of CHF at 
five years remains about 50%, which is similar to the prognosis for many cancers and is worse 
than this in more severe CHF 248. Despite considerable advances in neuro-humoral modulation 
therapy 105, the limits of this approach have already been encountered 157. Thus there is an 
urgent need for novel therapeutic approaches. Ironically, our search for a future therapy has 
led us to look to the past. An old drug, a metabolic modulator called perhexiline was first 
introduced into Europe nearly 30 years ago for the adjunctive treatment of angina 37.   
 
Perhexiline was first introduced in the 1970s as an anti-anginal agent effective at relieving 
symptoms of angina, improving exercise tolerance, and increasing workload needed to induce 
ischemia. The drug works in part by modifying myocardial substrate utilisation from fatty 
acids to carbohydrates, which is energetically more efficient for the heart to metabolise 7.  By 
the early 1980s there were reports of hepatotoxicity 208 and peripheral neuropathy 28 with 
perhexiline use. These effects were later shown to occur in patients who were `slow 
hydroxylators` secondary to a polymorphic variant of the cytochrome P-450 enzyme 
(CYP2D6) which metabolises the drug 163. However, this toxicity can be completely avoided 
by maintaining drug plasma concentration between 0.15-0.60 mg/L 96. Perhexiline has acute 
(< 2 weeks) and chronic (> 3 months) potential toxicity as well as predictable effect on 
lowering blood glucose levels which, in diabetics, can potentially induce the development of 
hypoglycaemia. Both acute and chronic toxicity are essentially plasma-level related, but they 
are not confined to ‘slow hydroxylators’ only 94.  
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In the UK, perhexiline is available off licence, on a named patient and named consultant 
cardiologist basis. In some parts of the world, particularly Australia, perhexiline is quite 
widely used in the treatment of refractory angina and unstable angina, with excellent results 
197. In addition, recently, our group have demonstrated the beneficial short-term effects of 
perhexiline in patients with CHF (of both ischaemic and non-ischaemic aetiology) in a phase 
2 double-blind, randomized, placebo-controlled trial 79. This has led to our centres using 
perhexiline therapy in highly symptomatic otherwise optimally-treated patients with CHF 
and/or refractory angina. To date there is however very limited published long-term clinical 
data on the use of perhexiline in patients with CHF and/or refractory angina. In this study we 
aim to report on our five-years collective experience on the use of perhexiline in patients with 
CHF and/or refractory angina, with a focus on ‘real-life’ drug side effects and toxicity, 
therapeutic drug level monitoring, five-year mortality outcomes and predictors of response to 
perhexiline therapy. 
 
Methods 
Study patients and outcome measures 
The study population consisted of patients with CHF and/or refractory angina who were 
referred by specialist cardiologists from coronary care unit or outpatient cardiology practice at 
University Hospital of Birmingham and University Hospital of Wales. CHF was defined as 
LVEF <40% on echocardiography, on current optimal medical therapy with NYHA class IIB 
or worse symptoms. All refractory angina patients had evidence of significant CAD at 
coronary angiography and/or a documented history of acute myocardial infarction. 
Additionally, all patients had recurrent episodes of typical chest pain despite being on optimal 
medical therapy in the opinion of the treating cardiologist. Patients with refractory angina also 
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had coronary anatomy that rendered them unsuitable candidates for initial or repeat coronary 
artery bypass graft surgery or percutaneous transluminal coronary angioplasty.  
 
A total of 151 patients were followed-up during the period Feb 2003 – Dec 2008. Data were 
retrospectively collated from two centralized perhexiline databases at the University Hospital 
of Birmingham (UK) and University Hospital of Wales (UK). Variables of interest such as 
patients’ clinical characteristics, drug levels, side effects, response to therapy and mortality 
were analysed. All patients were followed-up until December 2008 for all-cause mortality 
analysis. Symptomatic responses to perhexiline therapy were assessed by our heart failure 
specialist nurse as well as cardiologist during follow-up outpatient consultations. Heart failure 
‘responders’ would be typically those who self report improved exercise tolerance, reduced 
shortness of breath on activity of daily living, improved orthopnoea and paroxysmal nocturnal 
dyspnoea symptoms. Refractory angina ‘responders’ would be typically those who self report 
reduction in frequency and /or severity of angina and requiring less nitroglyerin use.  
Abnormal aspartate aminotransferase (AST), alkaline phosphatase (ALP) and bilirubin were 
defined as being twice the upper limit of the local laboratory reference range (AST (5-43 
(U/L), ALP (70-330 (U/L) and bilirubin (1-22 µmol/L)). In addition, patients with renal 
impairment were defined as patients with urea and creatinine above the upper limit of local 
laboratory reference range (3.4-8.0 mmol/L and 60-126 mmol/L, respectively). 
 
Therapeutic drug level monitoring 
The two databases were maintained by specialist heart failure nurses with specialist heart 
failure cardiologist support. Patients were initially given 100mg of perhexiline twice daily 
after initial medical assessments for co-administered medication, peripheral neuropathy and 
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liver function testing. Serum perhexiline levels are assayed at approx. 1, 4 and 12 weeks after 
initiating perhexiline. Drug levels between 0.15-0.60 mg/L were considered to be therapeutic, 
sub-therapeutic levels were <0.15 mg/L and supra-therapeutic levels were >0.60 mg/L. 
Perhexiline level assays were performed at the Therapeutic and Toxicology Laboratory, 
University of Cardiff (UK) with blood samples sent either by hospital laboratory or by 
community general practice. Results are subsequently delivered to the cardiologist and the 
nurse to up-date the centralised databases. Patients were subsequently contacted by phone to 
be advised on any dose adjustment. After every dose adjustment the patients were scheduled 
to have a repeat perhexiline level testing. Table 8.1 outlines our perhexiline dose adjustment 
protocols with respect to corresponding serum perhexiline levels. 
 
Statistics 
Continuous variables were expressed as means ± standard deviation. P value of <0.05 was 
considered to indicate statistical significance. Comparisons between groups were performed 
with one-way ANOVA if the data were normally distributed. Variables of interest such as 
patients’ age, gender, medical history, medications and presence of abnormal LFTs were 
included as independent variables in the multivariate analysis. Binary logistic regression was 
used to identify independent predictors of response to therapy. Survival curves were 
constructed by the Kaplan-Meier method and statistical differences between curves were 
assessed by the Tarone-Ware. Cox regression was used to assess significance of cumulative 
survival curves adjusted for age and gender. SPSS (v15.0) was used to perform the statistical 
operations. 
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Table 8.1: Perhexiline dosing schedule 
Time of  
blood sampling 
Perhexiline 
concentration (mg/L) 
Recommended new daily 
dose (mgs) 
Dose planning based on Perhexiline 
assays result on day 7 
0.00-0.05 300 
 0.05-0.15 250 
 0.15-1.00 200 
 1.00-1.50 100 
 1.50-2.00 50 
 >2.00 Cease for 1 week then 50 mg 
on alternative days 
   
Dose planning based on Perhexiline 
assays result at ≥ 4 weeks on 
therapy 
 
  
 <0.15 Double the daily dose 
 0.15-0.60 No change 
 0.60-0.90 Reduced dose by 25% 
 0.90-1.20 Halve the daily dose 
 >1.20 Cease for 1 week then reduce 
the daily dose to 25% of the 
previous dose 
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Results 
Study population 
Data on 151 patients on perhexiline therapy were analysed.  Their mean age was 67±12 years 
with males making up 69.5% of the cohort. The average period of initial follow-up was 
20±14 months. The indications for perhexiline therapy was refractory angina (54.3%), CHF 
(33.1%) or both (12.6%). In total, 41.6% had undergone coronary artery bypass grafting 
(CABG), 4.7% PCI, and 4.0% had both treatments. 62% of patients with CHF had NYHA 
class III symptoms and 52% of patients with refractory angina had Canadian Cardiovascular 
Society (CCS) 35 class II symptoms. Amongst patients with refractory angina, 69.5% were on 
a beta blocker, 50.0% on a calcium channel blocker, 66.7% on nitrates, 51.3% on nicorandil, 
81.7% on a statin and 88.5% were on anti-platelet therapy. Amongst patients with CHF, 
70.0% were on a beta blocker, 71.4% on an angiotensin converting enzyme inhibitor (ACEi), 
26.5% on an angiotensin II receptor blocker (ARB) and 57.1% on an aldosterone antagonist. 
Table 8.2 provides a summary of patients’ baseline clinical characteristics. 
 
Perhexiline monitoring 
The first drug level check was on average at 10±9 days with 44.8% within the therapeutic 
range and 20.3% above the therapeutic range.  The time of the third level check was on 
average at 16±6 weeks with 68.8% of patients within the therapeutic range and 20.8% above 
the therapeutic range. At 3-4 months the mean dosage for patients was 189±84 mg/day 
(range of 19 -400 mg per day). For patients with CHF, refractory angina or both, the mean 
dosage were 194±98 mg/day, 179±72 mg/day and 236±90 mg/day, respectively (p=0.097). 
Figure 8.1 indicates the spectrum of dosages after 3-4 months on perhexiline therapy 
indicating the diversity of metabolizers within our cohort of patients. At the end of the long-
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term mortality follow-up period which was on average 37±24 months, the percentage of 
patients achieving therapeutic range and those above the therapeutic level were 82.2% and 
6.2%, respectively. (See table 8.3)  
 
Side effects 
The proportion of patients who developed abnormal AST, ALP and bilirubin were 4.6%, 
4.0% and 3.3%, respectively. 23.8% of patients had transient side effects such as anorexia, 
weight loss and lethargy. Four patients (2.6%) had their perhexiline discontinued due to side 
effects such as nightmares and insomnia, and in one case due to peripheral neuropathy. 
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Table 8.2: Baseline clinical characteristics of patients 
 All patients 
N 151 
Male 105 (69.5) 
Age, yrs 67±12 
Male, No. (%) 105 (69.5) 
Refractory Angina, No. (%) 82 (54.3) 
CHF, No. (%) 51 (33.1) 
CHF and refractory angina, No. (%) 18 (12.6) 
NYHA classification, No. (%)  
IIb 20 (34.5) 
III 36 (62.1) 
IV 2 (3.4) 
CCS classification, No. (%)  
I 17 (19.5) 
II 45 (51.7) 
III 16 (18.4) 
IV 9 (10.3) 
Diabetes, No. (%) 51 (33.8) 
Renal Impairment, No. (%) 57 (37.7) 
Revascularization, No. (%)  
Coronary artery bypass grafting  62 (41.6) 
Percutaneous coronary intervention  7 (4.7) 
Both 6 (4.0) 
None 74 (49.7) 
Liver function tests  
Aspartate aminotransferase, U/L  30±53 
Alkaline phosphatase, U/L  130±114 
Bilirubin μmol/L 12±8 
Urea & Electrolytes    
Urea mmol/L 10±5 
Creatinine mmol/L  144±53 
Medications, No. (%)  
Beta Blockers 104 (68.9) 
Calcium Channel Blocker 49 (32.5) 
Angiotensin converting enzyme inhibitor  60 (39.7) 
Angiotensin II receptor blocker 21 (13.9) 
Aldosterone antagonists 43 (28.5) 
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Nitrates 65 (43) 
Nicorandil 47 (31.1) 
Statins 81 (53.6) 
Anti-platelets 85 (56.3) 
Diuretics 97 (64.2) 
 
Data are presented as mean ± standard deviation or number (%) of patients.  
 
CCS – Canadian Cardiovascular Society functional classification of angina, NYHA – New 
York Heart Association functional classification. 
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Table 8.3: Drug level safety monitoring  
 All patients 
Time to first drug level assay – day 10±9 
First drug level -  mg/l 0.32±0.31 
Sub-therapeutic – No. (%)  50 (35.0) 
Therapeutic– No. (%) 64 (44.8) 
Supra-therapeutic– No. (%)   29 (20.3) 
Time to second drug level assay (Weeks) 7±4 
Second drug level (mg/l) 0.53±0.37 
Sub-therapeutic – No. (%)  18 (13.2) 
Therapeutic– No. (%) 71 (52.2) 
Supra-therapeutic– No. (%)   47 (34.6) 
Time to third drug level assay (Weeks) 16±6 
Third drug level (mg/l) 0.43±0.32 
Sub-therapeutic – No. (%)  13 (10.4) 
Therapeutic– No. (%) 86 (68.8) 
Supra-therapeutic– No. (%)   26 (20.8) 
Time to most recent drug level assay (months) 37±24 
Most recent drug level (mg/l) 0.34±.22 
Sub-therapeutic – No. (%)  17 (11.6) 
Therapeutic– No. (%) 120 (82.2) 
Supra-therapeutic– No. (%)   9 (6.2) 
 
Data are presented as mean ± standard deviation or number (%) of patients. 
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Figure 8.1  
 
 
 
A histogram demonstrating the distribution of dosage amongst all patients at 3-4 
months. 
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Response to perhexiline therapy 
58.9% of patients reported to have felt better on the perhexiline (responders). Amongst 
patients with only refractory angina 64.6% had a symptomatic response and amongst patients 
with only heart failure 48.0% had a symptomatic response. Amongst patients who had both 
heart failure and angina 61.1% had symptomatic response. Multivariate analysis (with logistic 
regression) was used to examine independent predictors of response to perhexiline therapy, 
with responders to perhexiline as the dependent variable, we found that the presence of 
refractory angina (OR 2.84, 95% CI 1.28-6.32, P=0.01) was an independent predictor of 
response to perhexiline therapy. 
 
Mortality outcomes 
Long term mortality data were collected for all 151 patients. The mean duration of follow-up 
for mortality data was 37±24 months. The all-cause five-year mortality was 27.7%. Amongst 
patients with refractory angina, CHF or both, the five-year mortality was non-significantly 
different at 20.5%, 31.0% and  38.4%, respectively (p=0.20  Cox regression, adjusted for age 
and gender). Amongst patients classified as responders or non-responders, the five-year 
mortality was similar at 26.1% and 32.2%, respectively (p=0.94 by Cox regression, adjusted 
for age and gender). The proportion of patients who had their perhexiline stopped was 19.2%.  
 
Discussion 
In this study we have demonstrated the efficacy and safety of perhexiline therapy which is the 
only metabolic agent currently in clinical use in the UK for CHF and refractory angina. This 
study, to date, represents the longest reported follow-up ever of patients with CHF and/or 
refractory angina treated with perhexiline. The principal findings are: a) a majority of patients 
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experienced symptom relief with perhexiline therapy, b) the use of perhexiline in patients was 
safe and only a small minority developed any side-effects or abnormal LFTs, c) an 
independent predictor of response to perhexiline is the presence of refractory angina, d) five-
year mortality was non-significantly different in patients with CHF, refractory angina , or both, 
and were similar in responders and non-responders.  
 
It has long been established that CAD is associated with impaired cardiac energetics 284, 
which has been reviewed elsewhere 7. More recently however, there is a growing body of 
evidence to suggest that an impairment of cardiac energetic status may also play an important 
role in the pathophysiology of heart failure even in the absence of CAD. The hypothesis that 
heart failure is due to energy-starvation has been around for decades. Analysis of human 
biopsy specimens has shown a 25-30% reduction in ATP levels in the failing human heart 172. 
This has been confirmed by cardiac MRS studies, which have shown that the reduction in PCr 
is greater in magnitude than the reduction in ATP. In the canine rapid pacing heart failure 
model a reduction in high energy phosphate status precedes objective evidence of impairment 
of LV systolic function 234.  In CHF there is strong evidence demonstrating deranged substrate 
metabolism and insulin resistance 202, 203. Furthermore, there is a generalised down regulation 
of metabolism that contributes to the observed myocardial energetic deficiency 99. There is 
also evidence to suggest oxygen wastage relating to insulin resistance and increased 
catecholamine secretion in failing hearts 15. These observations provided the theoretical 
platform for the use of metabolic modulators such as perhexiline in CHF and CAD 79, 205. 
Perhexiline works by modifying myocardial substrate utilisation from FFAs to carbohydrates 
104. Perhexiline inhibits both CPT-1 and CPT-2, which are involved in mitochondrial uptake 
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of long chain fatty acids. This results in a reduction in myocardial fatty acid β-oxidation, and 
an increase in glucose utilization at a reduced oxygen cost for energy production 7.  
 
Studies have shown that in the presence of high plasma FFA the heart becomes  less 
mechanically efficient (≈30%) than when carbohydrate metabolism predominates 124, the 
reason being that FFAs requires substantially more oxygen to produce a unit of ATP than 
carbohydrates (a theoretical difference of approximately 10%). In practice the increased 
oxygen requirement compared with glucose appears to be substantially greater (approximately 
30%) 208-210, implying an ‘oxygen wasting’ effect. In addition, high levels of FFA can induce 
mitochondrial uncoupling that wastes energy 211.  
 
The use of perhexiline in CAD has been extensively discussed in the literature over the years. 
In a systematic review of 26 randomized, double-blind, controlled trials including about 700 
patients, perhexiline was found to be extremely potent at providing symptom relief as a 
monotherapy or as an adjunct to current best anti-anginal therapy 116. Although all but one of 
the trials was of cross-over design, perhexiline led to 50% reduction in anginal symptoms 
over the use of nitroglycerin 116. In addition to being excellent in chronic stable angina, 
perhexiline is also an effective therapy in acute coronary syndrome. Recently, our group have 
demonstrated the beneficial short-term effects of perhexiline in patients with CHF (ischaemics 
and non-ischaemics) in a double-blind, randomized, placebo-controlled trial 79. Other studies 
have reported beneficial effects of trimetazidine, a metabolic modulator that inhibits FFA beta 
oxidation, in patients with heart failure 213.  
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The main focus of this study was to examine the acute and chronic toxicity of perhexiline, and 
the plausibility and effectiveness of the therapeutic drug level monitoring in a real-life clinical 
setting. In this study patients were started on an initial dose of 200mg which is similar to the 
eventual maintenance dose in many cases (and sometimes lower than the maintenance dose). 
Our incidence of side effects is similar to published data and depending on the manner and 
rate of perhexiline administration, the incidence of adverse events with perhexiline can vary 
between 0% and 60% 116. The common transient side effects (acute toxicity) include 
symptoms such as dizziness, unsteadiness, as well as nausea, vomiting, headache, anorexia 
and weight loss (2 to 4kg). Other less common reported side effects include lethargy, tremor, 
diarrhoea, insomnia, and loss of libido. These side effects usually spontaneously resolve or 
abate with drug dose reduction and do not result in drug discontinuation. Only four patients 
(2.6%) had their perhexiline stopped secondary to nightmares and insomnia, and in one case it 
was due to peripheral neuropathy. 
 
Chronic toxicity usually takes at least 3 months to develop. This includes debilitating 
neuropathy 129, papilloedema, and severe hepatotoxicity 208. In 1983, Shah et al reported 80 
cases of hepatotoxicity and 131 cases of neuropathy associated with perhexiline use in the 
United Kingdom 233. Before drug level monitoring was introduced in 1988, perhexiline 
associated hepatotoxicity constituted between 5-9% of all serious adverse hepatic events in 
New Zealand and France 116. Perhexiline also can lower blood glucose level which, in patients 
with diabetes, can potentially induce hypoglycaemia 49. The mechanisms responsible have not 
been clearly elucidated.  
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In order to prevent these acute and chronic toxicities, perhexiline plasma level should be 
tightly monitored and stay within the therapeutic window (0.15-0.60 mg/L) 96.  Drug level 
monitoring is essential to identify patients who are slow metabolizers, which occurs in about 
7% to 10% of U.S. and European Caucasians who harbour mutations in CYP2D6 60. In 
normal metabolizers, perhexiline's half-life is between 3-12 days, in slow metabolizers this 
half-life could be as long 30 days. In our study population the range of dosage after 3-4 
months indicates the diversity of metabolizers from some ultra-rapid to slow metabolizers, 
which reinforces the necessity for therapeutic drug level monitoring.  
 
In clinical practice drug interaction is also an important aspect to consider. The most obvious 
group of agents are the selective serotonin reuptake inhibitors (SSRIs) e.g., fluoxetine and 
paroxetine which interferes with the P450 CYP2D6 microsomal enzymes. In addition, in 
patients with existing liver impairment due to other causes, perhexiline metabolism may be 
impaired. For all the reasons outlined above it is mandatory for patient's liver function and 
co-administered drugs to be considered carefully.  
 
In terms of responders, patients with refractory angina respond symptomatically better to 
perhexiline than patients with CHF and indeed from multivariate analysis the presence of 
refractory angina was an independent predictor of response to perhexiline therapy. The five-
year mortality was similar in responders and non-responders. This study demonstrates the 
effectiveness of perhexiline in alleviating symptoms. However, the question of whether it also 
has a beneficial effect on mortality remains to be answered in a randomized placebo 
controlled trials. 
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This study has demonstrated promising results with the use of perhexiline in CHF and/or 
refractory angina in terms of both symptomatic relief and drug safety. We show that 
perhexiline can be safely started with 100mg twice daily for the adjunctive treatment of 
highly symptomatic patients with CHF and/or refractory angina. This should be commenced 
after a baseline medical assessment (including LFTs) with attention to co-administered 
medication for possible drug interaction. Therapeutic drug level monitoring should be 
undertaken after the initiation of the drug with subsequent dose adjustment to prevent acute 
and chronic toxicity and to achieve the therapeutic range.  
 
Study limitations 
We acknowledge that our measure of response to therapy is subjective and that it is possible 
that patients with refractory angina had more symptomatic improvement because 
improvements in angina may be more noticeable. Ideally we would have liked to present 
more objective measurements. However in the context of a clinical real-life database, such 
objective measurements such as LVEF or exercise tolerance pre and post perhexiline therapy 
were not completely available. However, the results and findings of this study will contribute 
significantly to the lack of real-life long-term mortality data and drug safety and monitoring 
of perhexiline in CHF and/or refractory angina as well as from a patient perspective some 
subjective measurement of symptomatic improvement such as breathlessness and/or chest 
pain. We would also have liked to define the causes of death in all our patients; unfortunately 
this information was not available. In this real-life analysis the percentage of patients on 
relevant optimal conventional medical therapy was not 100%, which could be due to 
intolerance, side-effects or the presence of contraindications. 
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Conclusion 
Perhexiline therapy provides symptomatic relief in the majority of patients with minimal side 
effects or toxicity. Careful therapeutic level monitoring for dose titration is important to 
prevent acute and chronic toxicity. Patients with refractory angina were more likely to be 
responders. Five-year mortality was non-significantly different in patients with CHF 
compared to patients with refractory angina and was similar in responders and non-responders. 
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CHAPTER NINE 
 
 
 
DISCUSSION 
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The myocardium is a metabolic omnivore and utilises fatty acids, glucose, ketones, amino 
acids and lactate to produce energy. Its main feature is the fact that it is able to alter its 
substrate use based on availability and various situations of stress. Metabolic conditions like 
diabetes result in specific changes in myocardial metabolism. Altered metabolism in itself 
results in cardiac muscle dysfunction and can play a potentially significant role in the 
development of heart failure in diabetes. Metabolic modulators like perhexiline are potentially 
significant new treatments in the management of heart failure and CAD. 
 
In this work I have initially discussed the metabolic alterations in various diseases like heart 
failure, CAD and diabetes. Currently available metabolic modulators and the evidence base 
for their use are discussed. Then I explored the potential mechanisms for the development of 
altered cardiac energy status in diabetes. Using STE we studied the early changes in the 
myocardium in T1DM. In addition using cardiac MRI we explored the role of left atrial 
function in LV filling in these individuals and demonstrated the use of STE to complement 
data on left atrial function. In the study with Perhexiline we demonstrated its effects on 
carbohydrate and fatty acid metabolism in subjects treated with Perhexiline for clinical 
reasons. Finally we looked at clinical experience in using perhexiline for refractory heart 
failure and angina.  
 
Cardiac MRS allows measurement of high energy phosphate kinetics in the myocardium. 
Previous studies in patients with type 1 and type 2 diabetes have demonstrated impaired 
cardiac energetics in asymptomatic patients with diabetes. However, these studies did not 
elucidate the underlying pathophysiological mechanisms. In particular I wanted to 
demonstrate the role of microvascular disease in the development of impaired cardiac 
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energetics. My work has shown that coronary microvascular disease probably plays little role 
in development of impaired cardiac energetics and therefore it is primarily metabolic in 
nature. Cardiac energetic impairment is an important factor in the development of diabetic 
cardiomyopathy. This raises the question as to whether metabolic modulators would be able 
to delay the onset of diabetic cardiomyopathy.  
There have been great advances in cardiac imaging in the last decade. Advanced 
echocardiographic techniques like TDI and speckle tracking have allowed early detection of 
abnormalities in LV function. STE in particular has allowed measurement of LV rotation. I 
used speckle tracking and demonstrated that increased LV torsion occurs even prior to the 
onset of overt diastolic dysfunction. LV torsion and apical rotation could be measured quickly 
from the 2D images and potentially used clinically. If my findings are substantiated by large 
scale population studies LV torsion measurement could be a good screening tool to detect 
early diabetic cardiomyopathy. 
 
Great advances have also been made in cardiac MRI in the last decade. I used cardiac MRI to 
make accurate measurement of LV volumes during the cardiac cycle. From this data I 
obtained accurate measure of LV filling characteristics. I demonstrate the importance of the 
atrial component of LV filling and how this compensates for reduced LV compliance in the 
early stages of diabetic cardiomyopathy. The onset of atrial fibrillation could be detrimental in 
these patients and hasten the development and presentation of heart failure. Therefore 
preventing the development of atrial fibrillation could be a potential way of preventing onset 
of symptomatic diabetic cardiomyopathy. 
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This part of my work raises many important questions and can form the basis for further 
studies to help us understand the pathogenesis of diabetic cardiomyopathy. Ideas for further 
studies are as follows – 
1.  Study of the effect of microvascular disease on cardiac energetic impairment in type 2 
diabetes patients. Patients with type 2 diabetes tend to have higher incidence of 
associated risk factors including hypertension and hypercholesterolemia. Hence it will 
be interesting to study this group of patients. 
2.   Study of LV torsion and untwist patterns in patients with type 2 diabetes prior to 
onset of cardiomyopathy. It will be interesting to study the early changes in the 
myocardium in these subjects. 
3.  The HbA1C range in my subjects was 6 – 9%. In order to study the impact of 
glycemic control on cardiac energetic impairment and LV torsion subjects with different 
HbA1C ranges needs to be studied. These studies will also provide insights into the 
effect of glycemic control on the development of cardiomyopathy in diabetes patients. 
4.  It will be very interesting to conduct larger scale longitudinal studies in diabetes 
patients. Our subjects had early functional and structural abnormalities in the 
myocardium. Following these patients on a regular basis will provide insights into the 
progression of these early structural abnormalities and also provide us clues about the 
specific changes that herald the onset of overt cardiomyopathy. This can provide the 
basis for identifying the best screening tools in patients with diabetes to detect the 
development of cardiovascular complications and targeting specific therapies in these 
patients. 
5.   Perhexiline and other metabolic modulators increase glucose utilisation within the 
myocardium by various mechanisms as elucidated before (Chapter 1). Another 
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interesting study would be to assess the effect of the metabolic modulators on cardiac 
energetic impairment in diabetes patients. If the metabolic modulators are able to 
reverse the energetic impairment, they may have the potential to be used to prevent or 
delay the onset of cardiovascular complications in diabetes patients. 
 
Metabolic modulators are a group of drugs that act by enhancing glucose utilisation within the 
myocardium and hence making it more oxygen efficient. Perhexiline is a metabolic modulator 
that prevents FFA uptake by inhibition of CPT1 and CPT2 resulting in enhanced glucose 
metabolism. I studied the effects of Perhexiline on carbohydrate and lipid metabolism in 
patients with intractable angina and/or heart failure. Perhexiline improved insulin sensitivity 
in patients with diabetes; however it made it worse in patients without diabetes. Also 
Perhexiline increased ketone and triglyceride synthesis which was directly dependent on its 
concentration.  The differential action on muscle and liver CPT-1 is a plausible explanation 
for this. 
 
Perhexiline is used currently for patients with intractable angina and /or heart failure with 
maximal medical therapy on a named patient basis.  We analysed the database of perhexiline 
patients at two centres and reported on side effects, tolerance, mortality and experiences with 
drug level monitoring. Perhexiline therapy provides symptomatic relief in the majority of 
patients with minimal side effects or toxicity. Careful therapeutic level monitoring for dose 
titration is important to prevent acute and chronic toxicity. Patients with refractory angina 
were more likely to be responders. Five-year mortality was non-significantly different in 
patients with CHF compared to patients with refractory angina. 
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Studying myocardial metabolism provides insights into the patho-physiology of heart failure 
in diabetes.  Ideas for further studies are as follows – 
1.  Many small scale studies have demonstrated benefits of metabolic modulators in 
angina and heart failure. There is an urgent need for large scale studies using 
metabolic modulators to confirm or refute their potential importance in providing 
symptomatic improvement in these patients. These large scale studies will also 
provide insights into the effects of these agents on long term morbidity and mortality 
in angina and heart failure.  
2.  My study on the effects of Perhexiline on carbohydrate and fat metabolism have 
provided interesting results and raised many important questions. In order to study the 
underlying pathophysiological mechanisms responsible for these changes animal 
studies can be conducted. Animal studies will provide us the opportunity to sample 
tissues including liver, skeletal muscle and myocardium and hence help to determine 
the tissue concentrations to work out the mechasims involved in the pathogenensis. 
3. Of particular interest in my study was the divergent response of perhexiline on insulin 
sensitivity in patients with and without diabetes.  In order to confirm or refute these 
findings the same study can be conducted by measuring insulin sensitivity via insulin 
clamping method. Insulin clamping provides a more robust and accurate measurement 
of insulin sensitivity as compared to HOMA method.  
 
Limitations of the study 
One of the main limitations of this study is the small sample size.  Although the study 
provides insights into the patho-physiology of myocardial dysfunction in asymptomatic 
patients with T1DM, this has to be proven using large scale studies.  The studies did not 
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collect longitudinal data and hence we cannot comment on the progression of these early 
changes in diabetic myocardium.  All study participants were type I diabetes patients without 
a history of hypertension or hypercholesterolemia. These results cannot therefore be 
extrapolated to type II diabetes patients in whom hypertension and hypercholesterolemia 
frequently co-exist. 
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Information sheet for participants  
                                       (Observational study only) 
 
Study title: Mechanisms responsible for cardiac and skeletal muscle energetic 
impairment in diabetes. 
 
Researchers: Prof M Frenneaux, Prof M Stevens and Dr G Nallur Shivu. 
 
I am writing to invite you to take part in a study we are conducting. Your treatment will not 
be affected in any way if you decide not to take part in this study. 
 
What is the purpose of this study? 
 
We are planning to study the mechanisms involved in development of heart failure in diabetic 
patients. We plan to study the metabolism of heart and skeletal muscle in diabetics and 
compare it with healthy volunteers. 
 
Why have I been chosen? 
 
You have been chosen because you have diabetes which is currently well controlled, and you 
have no diabetic complications.  
 
Who is organising the study? 
 
This study is organised by the University of Birmingham and funded by the British Heart  
Foundation.  Prof Michael Frenneaux (Head of the Department of Cardiovascular Medicine at 
University of Birmingham) is the chief investigator.  
 
What will happen to me if I take part? 
 
Following an overnight fast, you will be asked to arrive at 9:00 a.m. at the Department of 
Cardiovascular Medicine, which is on the site of Queen Elizabeth Hospital, Birmingham.  
You will be examined and asked to provide written informed consent. You will have the 
opportunity to ask questions and clarify any doubts before the start of the study.  
Mechanisms responsible for cardiac and skeletal muscle energetic impairment in 
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Note: If you are a woman of child bearing age then we will ask you if you are using effective 
contraception. We will also do a pregnancy test before the start of the study. You will not be 
included in the study if you are not using effective contraception or if you have a positive 
pregnancy test. 
 
 
 
The study will involve the following tests:  
1.Blood Tests:  Blood samples will be collected to measure your kidney function, 
haemoglobin, liver function, glucose and fat (lipids). This will involve inserting a small 
needle into your vein and drawing blood into various bottles.  
 
2.Metabolic Exercise Test: You will be asked to exercise on a treadmill wearing a mask to 
measure the amount of oxygen you consume.   
 
3.Echocardiography: An echocardiogram (a non-invasive ultrasound scan of the heart) will 
be performed. The above three tests will last a total of one hour.  
 
4.NIRS: We will then conduct NIRS, which is test to determine the oxygen consumption by 
your forearm muscle. For this we will tie a tourniquet around your arm and place the NIRS 
probe on the forearm muscle. The tourniquet will be released after 1-2 minutes. The whole 
test will take about 10 minutes.  
5.MRI: Then you will have the Magnetic Resonance studies carried out in the University of 
Birmingham Imaging Centre (BUIC).  Scanners that are used for the Magnetic Resonance 
tests are shaped like a polo mint and some patients find this scanner slightly claustrophobic.  
The first test (Magnetic Resonance Imaging [MRI] scan of the heart) will measure the heart 
size and function at rest.  For this test, you will lie comfortably on your back, and we will ask 
you to hold your breath for a few seconds during the scan.  This test will involve inserting a 
small needle in your forearm and injecting a contrast agent called Gadolinium. About 15 
minutes after the first scan we will inject a drug called adenosine and repeat the scan. The 
adenosine can make you feel tight in the chest –but this lasts for only a few seconds. The 
whole test will take approximately 40 minutes.   
 
6.Cardiac MRS:  This test (Magnetic Resonance Spectroscopy [MRS] of the heart) will look 
at the metabolism of the heart.  We will ask you to lie on your stomach, and you do not need 
to hold your breath.  This study will last about 45 minutes.  
 
7.Skeletal MRS:  Then you will have a similar scan (MRS) on your forearm and calf muscle. 
For this scan, you will be asked to lie on your back and we will apply a tourniquet around 
your arm for ten minutes.  We will then ask you to exercise your calf muscle until you feel 
tired.  The whole studies on your forearm and calf muscle will take approximately around 60 
minutes.   
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What do I have to do? 
 
Study day 1: Blood tests, exercise test, and echocardiography. Then you will be taken to 
BUIC (Birmingham) for MRI and MRS scan of the heart and MRS scan of calf muscle. We 
will pay your travel and any accommodation expenses. 
 
What are the possible benefits of taking part? 
There are no specific benefits to you by taking part in the study. This study will however help 
us to better understand how diabetic patients develop heart failure. This may allow us to find 
new treatments for heart failure in diabetics in the future. 
 
Who will have access to the data and study results? 
 
Prof M Frenneaux will be ultimately responsible for the data and study results.  University of 
Birmingham and the University of Oxford will have control of the data.  Ethics Committees, 
national and international regulatory authorities, which will review information on the drug 
and study, may also inspect them.  These will be kept in a locked filing cabinet at the 
Department of Cardiovascular Medicine, University of Birmingham.  In addition, information 
about you will be kept confidential, and your medical records will not be made public.  
Furthermore, if the results from this trial should be published, your identity will be kept 
completely confidential. If at the end of the study you would like a copy of the published 
paper, this can be sent to you on request.  
 
 
Are there compensation arrangements if something goes wrong? 
 
If the unlikely event of your health deteriorating in any way as a result of negligence, you 
may submit a claim to the University Hospital of Birmingham NHS Foundation Trust for 
compensation to be considered.  If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated during the course 
of this study, the normal NHS complaints mechanisms should be available to you.  If you are 
covered by Private Medical Insurance you should contact them to determine whether your 
cover would be affected in any way by taking part in this research. 
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What happens if I do not want to participate or I change my mind during the research 
study? 
 
You do not have to participate in this study.  If you decide not to participate or change your 
mind later on; you can withdraw at any time, without affecting your subsequent treatment in 
any way. 
 
 
Are there other ways of treating my condition? 
 
You are being considered for this study in the hope of finding new drug treatments to prevent 
heart failure in diabetics. Studies are underway looking at different drugs. 
 
What if new information becomes available? 
You would be informed by telephone of any new developments. 
 
Will my GP be informed?  
Yes.  Your GP will receive a letter explaining the objectives of the study. 
 
If you have any complaints during the study please do not hesitate to let me know.  
If you are unhappy about our approach, manners, or the way we have dealt with any of your 
requests, please feel free to contact chief investigator Professor M Frenneaux in the 
Department of Cardiovascular medicine, University of Birmingham (Tel: 0121–4146926). 
 
 If you are interested in taking part or if you have more questions or do not understand 
something please contact one of the following members of our research team: 
Dr Ganesh Nallur Shivu                                      
Department of Cardiovascular Medicine      
University of Birmingham                            
Edgbaston, Birmingham                               
B15 2TT                                                        
                                         
 
In cases of emergencies Dr G Nallur Shivu can also be contacted on his mobile phone 
(07789818670). Finally, thank you very much for taking the time to consider taking part in 
this study. 
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Information sheet for participants (Healthy Volunteers)  
 
 
Study title: Mechanisms responsible for Cardiac and Skeletal Muscle Enegetic 
Impairment in Diabetes 
 
Researchers: Prof M Frenneaux, Prof M Stevens and Dr G Nallur Shivu. 
 
 
I am writing to invite you to take part in a study we are conducting.  We intend to assess the 
function and the energy status of the heart and limb muscle. 
 
What is the purpose of this study? 
 
We are planning to study the function and energy status of the heart and limb muscle. We 
would like to initially study healthy volunteers and then compare these results in healthy 
volunteers with results in diabetic patients. This potentially can be a useful tool to assess the 
mechanisms involved in the development of heart failure in diabetics.   
 
Why have I been chosen? 
 
You have been chosen because you are a healthy volunteer with no ongoing medical problems. 
 
Who is organising the study? 
 
This study is organised by the University of Birmingham and funded by a charity called the 
British Heart Foundation.  Prof Michael Frenneaux (Head of the Department of 
Cardiovascular Medicine at University of Birmingham) is the chief investigator.  
 
What will happen to me if I take part? 
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Following an overnight fast, you will be asked to arrive 9:00 a.m. at the Department of 
Cardiovascular Medicine, which is on the site of Queen Elizabeth Hospital, Birmingham.  
You will be examined and asked to provide written informed consent. You will have the 
opportunity to ask questions and clarify any doubts before the start of the study.   
 
Note: If you are a woman of child bearing age then we will ask you if you are using effective 
contraception. We will also do a pregnancy test before the start of the study. You will not be 
included in the study if you are not using effective contraception or if you are pregnant. 
 
 
 
The study will involve the following tests:  
1.Blood Tests:  Blood samples will be collected to measure your kidney function, 
haemoglobin, liver function, glucose and fat (lipids). This will involve inserting a small 
needle into your vein and drawing blood into various bottles.  
 
2.Metabolic Exercise Test: You will be asked to exercise on a treadmill wearing a mask to 
measure the amount of oxygen you consume.   
 
3.Echocardiography: An echocardiogram (a non-invasive ultrasound scan of the heart) will be 
performed. The above three tests will last a total of one hour.  
 
4.NIRS: We will then conduct NIRS, which is test to determine the oxygen consumption by 
your forearm muscle. For this we will tie a tourniquet around your arm and place the NIRS 
probe on the forearm muscle. The tourniquet will be released after 1-2 minutes. The whole 
test will take about 10 minutes.  
5.MRI: Then you will have the Magnetic Resonance studies carried out in the University of 
Birmingham Imaging Centre (BUIC).  Scanners that are used for the Magnetic Resonance 
tests are shaped like a polo mint and some patients find this scanner slightly claustrophobic.  
The first test (Magnetic Resonance Imaging [MRI] scan of the heart) will measure the heart 
size and function at rest.  For this test, you will lie comfortably on your back, and we will ask 
you to hold your breath for a few seconds during the scan. The whole test will take 
approximately 40 minutes.   
 
6.Cardiac MRS:  This test (Magnetic Resonance Spectroscopy [MRS] of the heart) will look 
at the metabolism of the heart.  We will ask you to lie on your stomach, and you do not need 
to hold your breath.  This study will last about 45 minutes.  
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7.Skeletal MRS:  Then you will have a similar scan (MRS) on your forearm and calf muscle. 
For this scan, you will be asked to lie on your back and we will apply a tourniquet around 
your arm for ten minutes.  We will then ask you to exercise your calf muscle until you feel 
tired.  The whole studies on your forearm and calf muscle will take approximately around 60 
minutes.   
 
 
What are the possible benefits of taking part? 
 
There are no specific benefits to you by taking the drug. This study will however help us to 
assess measurement of energetic status in healthy volunteers and to compare with these 
measurements in patients with diabetes. It will also help us to find new and better ways of 
treating heart failure patients and assessing the efficacy of these treatments.    
 
  
 
 
Who will have access to the data and study results? 
 
Prof M Frenneaux will be ultimately responsible for the data and study results.  University of 
Birmingham and Birmingham University Imaging Centre will have control of the data.  Ethics 
Committees, national and international regulatory authorities, which will review information 
on the study, may also inspect them.  These will be kept in a locked filing cabinet at the 
Department of Cardiovascular Medicine, University of Birmingham.  In addition, information 
about you will be kept confidential, and your records will not be made public.  Furthermore, if 
the results from this trial should be published, your identity will be kept completely 
confidential. If at the end of the study you would like a copy of the published paper, this can 
be sent to you on request.  
 
What happens if I do not want to participate or I change my mind during the research 
study? 
 
You do not have to participate in this study.  If you decide not to participate or change your 
mind later on; you can withdraw at any time. 
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What if new information becomes available? 
 
You would be informed by telephone of any new developments. 
 
 
Will my GP be informed?  
 
Yes.  Your GP will receive a letter explaining the objectives of this study. 
 
If you have any complaints during the study please do not hesitate to let us know.  If you are 
unhappy about our approach, manners, or the way we have dealt with any of your requests, 
please feel free to contact chief investigator Professor M Frenneaux in the Department of 
Cardiovascular medicine, University of Birmingham (Tel: 0121–4146926). 
 
 If you are interested in taking part or if you have more questions or do not understand 
something please contact one of the following members of our research team: 
 
Dr Ganesh Nallur Shivu  
Department of Cardiovascular Medicine             
University of Birmingham                            
Edgbaston, Birmingham                               
B15 2TT                                                        
                                         
 
In cases of emergencies Dr G Nallur Shivu can be contacted on Finally, thank 
you very much for taking the time to consider taking part in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanisms responsible for cardiac and skeletal muscle       version 1                   26/07/2006 
energetic impairment in diabetes 
  
190 
 
 
 
 
Patient Identification/Study Number: _____________ 
 
   
                                          CONSENT FORM  
 
Mechanisms responsible for cardiac and skeletal muscle energetic impairment in 
diabetes. 
 
Researchers: Prof M.P. Frenneaux, Prof M Stevens, Dr G Nallur Shivu 
 
PLEASE INITIAL BOX: 
 
1) I confirm that I have read and understand the information sheet    
dated …… (Version ….) for the above study and have had the    
opportunity to ask questions. 
 
2) I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving a reason, and without   
my medical care or legal rights being affected in any way. 
 
3) I understand that sections of any of my medical records may be 
looked at by responsible individuals from the University of 
Birmingham or from regulatory authorities where it is relevant    
to my taking part in research. I give permission for these 
individuals to have access to my records.      
 
4) I agree to my GP being informed of my participation. 
     
 
5) I agree to take part in this study.  
 
 
 
     _____________  
Patient Name   Date   Signature 
 
     _____________  
Researcher Name   Date   Signature 
 
     _____________  
Witness Name   Date   Signature   
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Patient Identification/Study Number: _____________ 
 
   
                                          CONSENT FORM  
(Healthy Volunteers) 
 
Mechanisms responsible for cardiac and skeletal muscle energetic impairment in 
diabetes. 
 
Researchers: Prof M.P. Frenneaux, Prof M Stevens, Dr G Nallur Shivu 
 
PLEASE INITIAL BOX: 
 
6) I confirm that I have read and understand the information sheet    
dated …… (Version ….) for the above study and have had the    
opportunity to ask questions. 
 
7) I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving a reason, and without   
my medical care or legal rights being affected in any way. 
 
8) I understand that sections of any of my medical records may be 
looked at by responsible individuals from the University of 
Birmingham or from regulatory authorities where it is relevant    
to my taking part in research. I give permission for these 
individuals to have access to my records.      
 
9) I agree to my GP being informed of my participation. 
     
 
10) I agree to take part in this study.  
 
 
 
     _____________  
Patient Name   Date   Signature 
 
     _____________  
Researcher Name   Date   Signature 
 
     _____________  
Witness Name   Date   Signature   
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